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Esta tese apresenta o planejamento, a síntese e a avaliação biológica de diferentes 
moléculas inibidoras de enzimas proteína-tirosina fosfatases (PTP), a saber: as 
enzimas proteína tirosina fosfatase 1B (PTP1B) e a fosfatase de baixo peso 
molecular (LMW-PTP). Essas enzimas são superexpressadas em muitos tipos de 
cânceres e estão envolvidas em várias vias importantes de sinalização celular. Estas 
enzimas têm um sítio ativo conservado, o que torna um grande desafio encontrar 
inibidores seletivos para as PTP. Baseado nas informações disponíveis na literatura 
sobre PTP e estudos de docagem, propusemos dez séries de compostos que foram 
avaliadas neste estudo. A modelagem computacional foi utilizada para definir cinco 
séries diferentes de compostos: os ácidos (N-fenilamino)oxoacéticos (série 1), 
ácidos N-fenilsulfônicos (série 2), ácidos isoxazolcarboxílicos (série 3), ácidos 
tioacéticos (série 4); e ácidos N-(2-(1H-benzo[d]imidazol-2-il)tioacetamido)benzóicos 
(série 5) selecionado pela docagem ou por similaridade a medicamentos planejados 
por FBDD (do inglês Fragment-Based Drug Discovery). As cinco séries restantes de 
compostos foram definidas utilizando uma abordagem BIOS (do inglês Biology–
Oriented Synthesis), a saber: os ácidos fosfônicos (série 6), os ácidos sulfônicos 
(séries 7), os ácidos borônicos (série 8), os ácidos carboxílicos (série 9) e os ácidos 
cinâmicos (série 10). No total cento e cinquenta e quatro compostos foram avaliados 
contra PTP1B e LMW-PTP em uma faixa de concentração entre 1 mM e 5 mM de 
inibidor. Estes compostos exibiram valores de IC50 na faixa milimolar (mM) a 
micromolar (µM). Os compostos mais ativos foram selecionados com base nos 
valores de IC50: (MKR-18a (IC50 = 70,2 µM), MK-35 (IC50 = 180 mM), MK-38 (IC50 = 
2,33 µM), KSR-6ab (IC50 = 5,0 µM) e KSR-6f (IC50 = 89,5 µM)) para a PTP1B; e os 
compostos MKR-42a (IC50 = 0,55 mM), MKR-36a (IC50 = 0,39 mM), MK-48 (IC50 = 
0,44 mM), MK-49 (IC50 = 0,39 mM), KAM-12 (IC50 = 160 µM) e KAM-4 (IC50 = 180 
µM) para a LMW-PTP. Os compostos mais ativos foram submetidos a ensaios de 
cocristalização contra a PTP1B e a LMW-PTP. Os dados de cocristalização foram 
coletados e refinados, entretanto, as análises estruturais mostraram que os ligantes 
não apareceram nos mapas de densidade eletrônica. Além disso, sessenta e nove 
compostos foram empregados em estudo de relação quantitativa entre estrutura e 
atividade (QSAR) contra PTP1B, fornecendo um coeficiente de correlação (R2) de 
0,8126 para o modelo predito. As análises preliminares dos estudos de relação 
  
estrutura atividade (SAR) mostraram que os derivados de ácido (N-fenilamino) 
oxoacético são os melhores inibidores de PTP1B e LMW-PTP. 
 
Palavras-chave: Câncer, inibidores de proteína-tirosina fosfatases, screening virtual, 
síntese orientada pela biologia, descoberta de medicamentos baseada em 







































This thesis presents the design, synthesis and biological evaluation of different 
inhibitors to protein tyrosine phosphatase (PTP) enzymes which are overexpressed 
in many types of cancer: protein tyrosine phosphatase 1B (PTP1B) and low 
molecular weight phosphatase (LMW-PTP). PTP1B and LMW-PTP are also involved 
in several important cell signaling pathways. These enzymes have a conserved 
active site, which makes the design of selective PTP inhibitors a challenging task. 
Based on available literature information about PTP and docking studies, we 
proposed ten chemical series of compounds to be assessed in this study. We used 
modeling studies to design five different series of compounds such as (N-
phenylamino)oxoacetic acids (series 1), N-phenylsulfamic acids (series 2), 
isooxazole carboxylic acids (series 3), thioacetic acids (series 4), and N-(2-(1H-
benzo[d]imidazol-2-ylthio)acetamido)benzoic acids (series 5). The remaining five 
series of compounds were designed using a biology-oriented synthesis (BIOS) for the 
compounds of phosphonic acids (series 6), sulfonic acids (series 7), boronic acids 
(series 8), carboxylic acids (series 9), and cinnamic acids (series 10). In total, one 
hundred and fifty-four compounds were assayed against PTP1B and LMW-PTP at a 
1 mM and 5 mM concentration. These compounds showed IC50 values in range 
micromolar (µM) to millimolar (mM). We observed best inhibition activities for MKR-
18a (IC50 = 70.2 µM), MK-35 (IC50 = 180 µM), MK-38 (IC50 = 2.33 µM), KSR-6ab (IC50 
= 5.0 µM) and KSR-6f (IC50 = 89.5 µM) against PTP1B; and MKR-42a (IC50 = 0.55 
mM), MKR-36a (IC50 = 0.39 mM), MK-48 (IC50 = 0.44 mM), MK-49 (IC50 = 0.39 mM), 
KAM-12 (IC50 = 160 µM), and KAM-4 (IC50 = 180 µM) against LMW-PTP. Most active 
compounds were selected for cocrystallization with PTP1B and LMW-PTP. But, 
unfortunately, we were unable to see the ligands in the active site. Furthermore, 
sixty-nine compounds were selected for Quantitative Structure–Activity Relationship 
(QSAR) studies against PTP1B and the predicted model showed a correlation 
coefficient (R2) of 0.8126. Preliminary analysis of Structure Activity Relationship 
(SAR) studies showed that (N-phenylamino)oxoacetic acid derivatives are the best 





Key words: Cancer, Protein Tyrosine Phosphatase Inhibitors, Virtual Screening, 
Biology-Oriented Synthesis, Fragment–Based Drug Discovery, Rational Drug Design, 
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Cancer is one of the most lethal sicknesses, and millions of people are 
suffering worldwide.  According to the World Health Organization (WHO), cancer is 
among the three leading causes of death in developing countries, which are facing a 
heavier cancer burden than developed nations, as both incidence and mortality are 
increasing at alarming rates. By 2020, cancer could kill more than HIV/AIDS, 
tuberculosis, and malaria put together, with 10.3 million deaths estimated worldwide, 
two-thirds of them in newly-industrialized or developing countries. By 2030, 27 million 
new cases of cancer are expected in all countries. Apart from Acquired Immune 
Deficiency Syndrome (AIDS), cancer is one of the worst diseases affecting people 
worldwide. World Health Organization conducts many cancer control programs 
including awareness, prevention, and treatment. According to International Agency 
for Research on Cancer (IARC) statistics, among cancer diseases, lung, prostate, 
breast, stomach, melanoma, kidney, liver, uterine cervix, colorectal cancers are the 
most common all over the world.[1, 2] 
In Brazil, accordingly to Instituto Nacional de Câncer (INCA), up to 2016 
report, approximately 596.070 thousand new cases of cancer are expected, including 
non-melanoma, which reinforces the magnitude of the cancer problem. The non-
melanoma type of skin cancer is the most frequent in the Brazilian population, 
followed by prostate tumors, female breast, colorectal, lung, stomach, and cervix 
uteri. Excluding cases of non-melanoma skin cancer, 420.310 new cases, 205.960 
for men and 214.350 for women, are estimated in Brazil. The most common cancers 
observed in men are prostate, lung, colorectal, stomach and oral cavity. Conversely, 
in women, the most observed cancer cases are breast, colorectal, uterine cervix, 
lung, stomach, corpus uteri, ovary and thyroid gland cancers.[1, 3] 
Cancer arises from a single normal cell after a series of small mutations 
and spread to any part of the body in a multiple stage process to produce a tumor 
cell, multiplied by mitosis and their descendants accumulated several other mutations 
that add up to give rise to cancer cells. Such cells proliferate too much fast, lose their 
adherence capacity, secrete enzymes capable of attacking the extracellular matrix, 





where they produce secondary tumors. This process is known as metastasis, and 
this one is the leading cause of death from cancer.[1, 4] Hanahan and Weinberg,[5] 
Sonnenschein and Soto,[6] and also Luo and co-workers[7] described in more details 
all the hallmarks of cancer. The emergence of cancer commonly takes decades to 
happens, and it is a complex process in which healthy cells progressively get a 
neoplastic phenotype by the accumulation of several mutations. The characteristics 
acquired by incipient neoplastic cells favor tumor growth and thus their malignancy. 
Tumor cells do not develop the disease by themselves; however, they recruit 
corrupted cells of their microenvironment to contribute in the process.[5–7] 
There are three main factors of risk to develop the cancer cells: 
a). Physical Carcinogenicity, such as ultraviolet and ionizing radiation; 
b). Chemical Carcinogenicity, such as asbestos, components of tobacco 
smoke, alcohol, aflatoxin (a contaminant of food), arsenic (a contaminant of drinking 
water) and urban air pollution; 
c). Biological Carcinogenicity, such as infection with certain viruses, 
bacteria or parasites.  
Ageing is also another major factor for cancer development. The incidence 
of the disease increases dramatically with age, probably due to the accumulation of 
taken risks for particular types of cancer which increases with age. The overall risk 
accumulation must be combined with the tendency for cellular repair mechanisms to 
show the actual probability for cancer development as a person ages.[1] 
Sadly, many of these deaths could be prevented if the diagnosis was 
made earlier. Over 30% of cancer cases could be prevented by adopting healthy 
lifestyle or immunization for some infections, for instance: hepatitis B (HBV), hepatitis 
C (HCV) and human papilloma viruses (HPV).[1, 8] Other types could be detected at 
early stages, treated and cured. There are mainly three types of treatments available. 
They can be curable effectively by surgery (laser, electro and cryosurgery), 
radiotherapy or chemotherapy if they are detected early.[1, 9]  
Even patients at a final stage of the disease can have their suffering 
relieved with palliatives. Innovative new anticancer drugs (e.g: rituximab, 
trastuzumab, and bevacizumab) have roles within the treatment regimens 
recommended for certain malignancies.[10] Nevertheless, spending efforts on these 





and their benefits appear to be modest. In the majority of cases treatments and 
anticancer therapies are not entirely adequate. Thus it is paramount to develop new 
therapies or improve the existing ones. Therefore, prevention and treatment of 
cancer acquire immense importance in the current era. 
There are different types of chemotherapeutic agents available for the 
treatment of cancer. Almeida,[11] Cohen,[12] Luo,[7] and Kroemer,[13] described in 
reviews some small molecule inhibitors which are important for cancer therapies 
targeting various hallmarks of cancer. Those therapeutic agents are approved for 
clinical trials to treat multiple cancer targets (such as tyrosine kinases, tumor protein 
p53, succinate dehydrogenase subunits SDHB, C, and D, fumarate hydratase 
(fumarase), glycolysis, fatty acid synthesis, hypoxia-Inducible factor (HIF), proton 
extrusion, B-cell lymphoma-extra large (BCL-XL), B-cell lymphoma 2 (BCL-2), human 
telomerase reverse transcriptase (hTERT) and deoxyribonucleic acid.[7, 12–13] 
According to medicinal research, some specific enzymes that can regulate abnormal 
gene transcription are responsible for cancer. Protein Tyrosine Phosphatases (PTPs) 
are a large family of signaling enzymes and play an essential role in intracellular 
signal transduction. They regulate the cellular level of tyrosine phosphorylation to 
control cell growth, migration, differentiation, metabolism, and gene transcription. 
PTPs were also able to control ion-channel activity, immune response, cell apoptosis, 
and bone development.[14, 15] In recent years, many research groups have been 
involved in various studies with PTPs inhibitors including a mechanistic study of 
inhibitors, structure–activity relationship (SAR), synthetic and pharmacological 
studies.[16, 17] It is still very challenging to discover specific inhibitors towards PTPs 
to utilize them in clinics. The structural homogeneity of active and allosteric binding 
sites in PTPs family highlights the importance of developing drugs against PTPs with 
the capability to differentiate each of them.[18] In particular, the Protein Tyrosine 
Phosphatase 1B (PTP1B) and Low Molecular Weight Phosphatase (LMW-PTP) are 
involved in cell signaling pathways, and they are also overexpressed in many types 
of malignant tumors. Those enzymes have been identified as important targets for 
new anticancer therapies and could afford an ideal strategy for drug discovery. Since 
several PTP families have structural homologies, it is a challenging task to find 
specific inhibitors to each enzyme.[18] 





approach to the family inhibitors, more precisely PTB1B and LMW-PTP for the 
treatment of human diseases, such as diabetes, obesity, and neurodegenerative 
pathologies.[19] 
 
1.2. Protein tyrosine phosphatases 
 
Protein tyrosine phosphatases (PTPs) exert crucial regulatory functions in 
several pathologies, in particular the carcinogenesis process.[20] This group of 
enzymes is an attractive molecular target due to its highly conserved catalytic 
domain, even in different subfamilies. Therefore, a systematic study of the Structure-
Activity Relationship (SAR) of the ligand is fundamental for the design of more 
selective compounds concerning a particular enzyme of this group.[14, 21] A total 
amount of 107 genes which codify enzymes pertaining to the PTPs family were 
identified in human genome.[22] Members of this family show a highly conserved 
catalytic domain characterized for the presence of a common sequence [(Ile/Val)-His-
Cys-X-Ala-Gly-Arg-(Ser/Thr)-Gly], where Ile/Val means isoleucine or valine, His – 
histidine, Cys - cysteine, Ala – alanine, Gly – glycine, Arg - arginine, Ser/Thr - serine 
or threonine and X can be any amino acid residue.[23] 
PTPs are a large family of enzymes responsible for the hydrolysis of 
phosphate bound to tyrosine residues in proteins. All PTPs use the same mechanism 
to cleave the phosphate group, and it is based on a nucleophilic cysteine in the active 
site.[22b] The characteristic sequence in the catalytic site of this family is CX5R 
(CXXXXXR, where C means cysteine, R - arginine, and X - any amino acid), sharing 
a pattern consisting of an arginine and cysteine in the active site, which is essential 
for enzymatic catalysis and involve the formation of a cysteinyl-phosphate catalytic 
intermediate.[24] The cysteine residue in the active site is responsible for the 
common feature of PTPs, which is inhibited by some oxidants. 
Three-dimensional structures of PTPs have helped to understand the 
function of the enzyme at the molecular level by defining the interactions that stabilize 
the structure of the active site and formation of the enzyme-substrate complex. 
Based on the function, structure, and sequence protein tyrosine phosphatases can 
be grouped into three main families: specific tyrosine phosphatases (or classical 
PTPs), dual-specificity protein phosphatases (DSPs), and low molecular weight 





PTPs revealed a common mechanism for chemical reactions catalyzed by these 
enzymes.[14, 25-28] 
The catalytic mechanism of all PTPs is depicted in Scheme 1.The first 
step involves nucleophilic attack of cysteine at the P-loop to the electrophilic 
phosphorus atom bounded to the substrate to form the cysteinyl-phosphate 
intermediate I. In the second step, the cysteinyl-phosphate intermediate (I) is 
attacked by a water molecule, which acts as the nucleophile activated by the 
aspartate residue at the WPD-loop by abstracting one of its hydrogens to undergo 
hydrolysis, regenerating the active enzyme and releasing the inorganic phosphate 





Scheme 1. Mechanism of Protein Tyrosine Phosphatase catalyzed hydrolysis of substrates.[24, 29–31] 
 
Figure 1 shows the catalytic domain of the phosphatase (PTP1B).[32] In 
this figure the enzyme is highlighted in red, and the substrate (a second 








Figure 1. Description of catalytic domain of PTP1B protein  
tyrosine-phosphatases, after Jia and coworkers (1995).[32] 
 
Therefore, the study of the interaction of the catalytic site with several 
different ligands could help to define the minimal structural requirements essential for 
the best possible match among enzyme and ligand. A well designed ligand could, in 
principle, be selective for binding to a particular subtype of the enzyme to the 
detriment of all the other subtypes. Also considering the fact that these enzymes 
have a highly conserved catalytic domain, even in different subtypes, and that the 
phosphate cleavage is mediated by one (or more) nucleophilic sulfhydryl moieties 
(-C-S-H) at the active site (Scheme 1), a good starting guess for a new family of 
inhibitors could be the synthesis of compounds resembling the original substrates but 
being incapable of suffering the aforementioned transformation.[33] 
 
1.2.1. Protein tyrosine phosphatase 1B (PTP1B) 
 
The development of modulators to control the activity of proteins 





as a negative regulator in the process of insulin and leptin receptors, protein 
disorders that can lead to the development of type-2 diabetes, obesity, and 
osteoporosis.[34] Moreover, it is also related to some types of cancer such as breast 
and colorectal. In 2013, it was observed that overexpression of PTP1B is linked to 
the aggressiveness of the tumor and reduction of survival of the patient.[35] 
Therefore, it is an important target for the development of new drugs to inhibit its 
activity,[34–36] because their modulation may reduce tumor aggressiveness and 
extend the life of the patient. Due to the structural similarity in many families of PTPs, 
it is a challenging task to find specific inhibitors for each PTP. In this context, small 
molecular inhibitors of PTP1B will be promising drug candidates.[37] Recent studies 
also suggested that secondary binding pockets or peripheral binding sites nearby the 
active site should be used to design novel potent and selective PTP1B 
inhibitors.[37a] 
The PTP1B is a 37 kDa enzyme with 321 amino acids, 8 alpha helices, 
and 12 beta sheets. The first crystal structure of PTP1B was reported in 1994.[38] 
The motif CX5R containing the catalytic cysteine is the only significant area of 
structural similarity between PTP1B and other PTPs. This sequence forms a loop 
where the phosphate group of the substrate binds, and is known as P-loop or 
PTP-loop. Figure 2 shows the Apo structure with the catalytic cysteine residue of 
PTP1B active site (residues Cys215–Arg221, PDB ID: 2HNP), P-loop (in blue) and 
inhibitors with PTP1B complexes.[38, 39] Superposed onto the Apo structure, PTP1B 
complexes with compound 1 (PDB ID: 2QBP), 2 (PDB ID: 1T4J), and 3 (PDB ID: 
1T4J, 1PTV and 1G1H)[32, 40–42] are shown in Figure 2.1. This Figure also 
exemplify the structural and chemical diversity of different inhibitors able to bind to 
the active site (P-loop in blue, Cys215) and its surroundings, along with the 
conformation assumed by the WPD-loop (in its open and closed conformation) upon 
ligand binding (Trp179, brown), and secondary binding site (Tyr20, Arg24, His25, 
Ala27, Phe52, Arg254, Met258, Gly259). An allosteric site is also known (ligand on 






Figure 2. Cartoon drawings of representative PTP1B structures. (a) Apo structure (PDB ID: 2HNP) 
showing the catalytic cysteine, the P-loop (in blue) and the WPD-loop (in orange). (b) PTP1B complexes 
(PDB ID: 1PTV, 2QBP, 1T4J and 1G1H) showing the structural and chemical diversity of different 
ligands bound to the active site and its surroundings, along with the conformation assumed by the WPD-
loop upon ligand binding. An allosteric site is also known (ligand on the back side of the Figure 2b). 
 
 
Figure 2.1. Inhibitors for wild and mutant PTP1B enzymes.[32, 40–42] 
New inhibitors have been identified for PTP1B among them compound 4 
isolated from ethanolic extracts of Lamellodysidea herbaceous (an Indonesian 
marine sponge) with IC50 = 0.85 μM,[43] and some synthetic derivatives based on the 
structure of Ertiprotafib (compound 5) with IC50 of 1.3 μM,[44] and licorice flavonoids 









Figure 3. Examples of some PTP1B inhibitors recently described in the literature (2013). 
Compound 4 isolated from the ethanolic extract of Lamellodysidea herbaceous, synthetic 
derivatives based on the structures of Ertiprotafib (5) and Licorice flavonoid (6). 
 
In 2013, Rakse and co-workers designed and synthesized 3-acetamido-4-
methyl benzoic acid derivatives as novel inhibitors for PTP1B. Compounds 7 to 11 
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Figure 4. Novel inhibitors for PTP1B based on 3-acetamido-4-methyl benzoic acid derivatives. 
 
Also using structure-based optimization, new benzoic acid derivatives were 
identified as protein tyrosine phosphatase (PTP1B) inhibitors. Docking studies aided 
the rationalization of the observed PTP inhibitory profile and they already showed 
inhibitory activity toward human PTPs implicated in insulin resistance. Observed IC50 
values for these set of compounds were in micromolar range.[19, 47–48] 
Recently, new inhibitors have been identified for PTP1B among them 
some bis-aromatic amides (compound 12). These molecules showed inhibition 
against PTP1B with IC50 value = 19.27 ± 1.80 μM (Figure 5).[49] Further, 2-
substituted benzoxazoles (compound 13) are also good inhibitors for PTP1B and 
showed themselves as promising leading compounds. These compounds showed 
activity in mid-micromolar range.[50] In addition, crystal structure of PTP1B in 
complex with novel PTP1B inhibitor has been published recently (13, PDB ID: 4I8N, 
Figure 5).[50b]  
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Figure 5. Examples of new PTP1B inhibitors: substituted 
 bis-aromatic amide (12) and 2-substituted benzoxazoles (13). 
 
Further, benzotriazole derivatives and compounds containing a 
difluoromethylphoshonate moiety (compounds 14 to 17) also showed PTP1B 
inhibition with IC50 values of 5 nM range (Figure 6).[51] Benzotriazoles have been 
identified as good inhibitors for several biological targets. Benzotriazoles cover a 
wide range of research fields, such as antimycobacterial, antimycotic, antimicrobial, 




Figure 6. Structures of benzotriazole and difluoromethylphoshonate moiety. 
 
12 (IC50 = 19.27 ± 1.80 μM) 





1.2.2. Low-molecular-weight protein tyrosine phosphatase (LMW-PTP) 
 
The Low-Molecular-Weight protein tyrosine phosphatases (LMW-PTPs) 
belong to a unique class of tyrosine phosphatases and are widely distributed in 
prokaryotes and eukaryotes. It performs critical roles in many biological 
processes.[52, 53] This enzyme is overexpressed in many types of cancer cells, such 
as breast, colon, lung and a group of neuroblastoma samples.[54] Its study has 
become of particular interest for understanding cancer biology and the establishment 
of new strategies for disease therapies.[55]  
LMW-PTP is a cytoplasmic enzyme of 18.0 kDa, expressed in a wide 
variety of mammalian tissues. The active site also contains the motif CX5R, where X 
can be any amino acid residue. This sequence forms a loop, where the phosphate 
group binds to the substrate, and is known as P-loop (Figure 7).[56] A unique feature 
of LMW-PTP in all the protein tyrosine phosphatases is the presence of two cysteines 
(positions CYS 12 and 17) in the catalytic site, unlike other PTPs, which have only 
one cysteine. This additional cysteine gives the LMW-PTP the ability to quickly regain 
its activity after the oxidative processes in which it participates, acting as an 
intracellular sensor for the intensity of the redox state. In this context, it is known that 
the regulation of the LMW-PTP activity can occur by a refined redox system and both 
nitric oxide and H2O2 reversibly inactivate the LMW-PTP.[56, 57] 
 
 
Figure 7. Crystal structure of LMW-PTP showing the catalytic cysteine (CYS 12 and 17), a P-loop 






In the literature, Maccari and Ottanà described various classes of LMW-
PTP inhibitors such as phosphonic acids (a), IC50 in millimolar range, as well as 
sulfonic and benzoic acid derivatives (b) as shown in micromolar range (Figure 
8).[19, 47, 48, 58] 
 
 
Figure 8. Some reported inhibitors to LMW-PTP bearing phosphonic (a), 
and sulfonic or carboxylic acids (b) with IC50 values range in mM to μM. 
 
The literature reports a complex of LMW-PTP with 2-(N-morpholino) 
ethanesulfonic acid (PDB ID: 5PNT, Figure 7),[56] and also phenylmethanesulfonic 
acid (PMS, Figure 9a).[59] In these structures, the ligand phenylmethanesulfonic 
acid was a hydrolysis product of the protease inhibitor phenylmethylsulfonyl fluoride 
(PMSF) was identified by Prof. Ricardo and Miranda’s group. Figure 9b shows 2D 
schematic representation of ligand (PMS) with LMW-PTP Ligplot+ diagram. In Figure  





Gly14, Ile16, Cys17 and Arg18 (In green color dot lines); hydrophobic interactions 
with aminoacid residues Cys12, Asn15, Glu50, Asp129 and Tyr131 (In red color arc 
with spokes); and among other interactions also observed with amino acid residue 
Tyr131 (such as π-π stacking interactions).  
 
 
            
 
Figure 9. (a) Crystal complex of phenylmethanesulfonic acid (PMS) with LMW-PTP  
(PDB ID: 4Z9A); and (b) 2D representation of interaction mode of PMS at active site. 
 
Based on the crystal structure of LMW-PTP complex containing the 
phenylmethanesulfonic acid (Figure 9a),[59] a series of compounds (Figure 10) was 
designed and studied by molecular docking. This subset of structures have been 
prepared by our group (IQ-UNICAMP) and tested for enzyme inhibition assays and 
cocrystallization studies. They exhibited inhibition at millimolar range. Among these 
prototypes, even the simplest compound, benzylphosphonic acid (MK-0, Figure 10), 









Figure 10. Structures of the first PTP inhibitor series designed and synthesized based on 
the crystallographic structure containing the ligand PMS with LMW-PTP (PDB ID: 4Z9A). 
 
Therefore, we studied the action of benzylphosphonic and benzylsulfonic 
acids, as well as some other molecular series, as inhibitors of these enzymes. We 
also started a rational and systematic design of more selective inhibitors for this 
group of tyrosine-phosphatase enzymes. Despite its minor activity for LMW-PTP, 
benzylphosphonic acid (MK-0, PDB ID: 4Z9B), was able to bind efficiently to the 
enzyme active site when crystallized (Figure 11a). Monocrystal DRX results 
suggested some points in the molecule which could be functionalized to improve the 
efficiency and selectivity of the future ligand generations not only for LMW-PTP, but 
also for other PTPs. DRX results and enzymatic assays were also performed by Prof. 
Ricardo Aparício’s research group, and these results have been recently published in 
the literature.[59] We have also perfomed docking studies for MK-0 against LMW-
PTP and 2D representation of Ligplot+ diagram showed in Figure 11b. In these 
results, we identified hydrogen bond interactions with amino acid residues Cys12, 
Leu13, Gly14, Asn15, Ile16, Cys17, and Arg18 (In green dot lines); hydrophobic 
interactions with aminoacid residues Asp129 and Tyr131 (In red color arc with 
spokes). Morever, π-π stacking interactions also observed with amino acid residue 
Tyr131. 
In the aforementioned work, our research group has expressed, purified 
the tyrosine-phosphatases (PTP1B and LMW-PTP) and apo crystal structures were 
determined. Apo structures of LMW-PTP enzyme showed in Figure 12 [59], and 
PTP1B (is a 34.7 kDa enzyme which containd a conserved active site and 298 amino 







         
 
Figure 11. (a) Monocrystal DRX view of tyrosine-phosphatase enzyme LMW-PTP and 
benzylphosphonic acid (MK-0, PDB ID: 4Z9B) complex emphasizing the active site. 





Figure 12. Crystal structure of Apo LMW-PTP. Active 







Figure 13. Crystal structure of Apo PTP1B and important structural elements for catalysis and design 
of inhibitors. (a) Secondary structure elements of the PTP1B. The alpha carbon of catalytic cysteine is 
shown as stick in red and catalytic P-loop in blue, substrate recognition pY-loop in orange, and WPD-
loop (acts as a general acid/base during catalysis, purple) which close the site during catalysis. 
(b) Surface of PTP1B, Cys215 at the bottom of the catalytic site in depth the 9Å regulated by Tyr46 in 
orange. (c) It illustrates a more detailed view of the active site. Zoom of catalytic cysteine loop with 
Cysteine C215 in red and arginine R221 in green (PDB ID: 3A5J).[60] 
 
1.3 Docking studies 
 
Computational docking studies are good starting points for the design of 
inhibitors, especially when protein structure is available. Thousands of possible 
orientations among compounds and the protein are evaluated and, in general, the 
lowest energy arrangement is assumed to be the mode of interaction of that 
compound with the macromolecular target (Scheme 2).[61] 
Docking software consists of two components: a search algorithm to 
investigate a large number of possible solutions in order to find an optimal solution; 
and a score function capable of predicting the energy of interaction between the 





Molecular docking programs differ in the way they deal with the flexibility 
of the enzyme and the ligand, and also in its search algorithm scoring function. 
Docking protocols are usually described in terms of searching and scoring function or 
evaluation algorithm. Search algorithms, in turn, should suggest all possible binding 
modes between the ligand and the receptor. Connection modes are generated and 
classified, accurately and efficiently, with a template for scoring. The score function 
must be able to identify the correct experimental connection mode between all 
possibilities unveiled by the search algorithm. Usually, score functions indicate 
chemical complementarity between the ligand and the receptor and should be fast 
enough to handle a large number of potential solutions. 
 
Scheme 2. Schematic representation of docking a small molecule ligand to a protein              
producing a protein:ligand complex (Adapted from Chen and co-workers).[61] 
 
  
1.4 Fragment Based Drug Discovery (FBDD) 
 
Several chemical technologies have impacted drug discovery in previous 
decades: 
• 1960s: Natural-Product based leads 
• 1970s: Computational Methods such as Quantitative Structure-Activity 
Relationships (QSAR) 
• 1980s: Fragment-Based Drug Discovery (FBDD) 
• 1990s: Combinatorial Chemistry and High throughput screening (HTS) 
From 1950’s to 1980’s medicinal chemists had limited tools for drug 
discovery and spent much time for synthesizing compounds compared to current 





the "serendipity" when the discovery process occurs at random, had a big role. Since 
in vitro assays only became available after the years of 1980 and 1990, in vivo 
models were used as initial tests.[63] 
In these days, there is a wide range of advanced tools and technologies 
for synthesis, analyses and purification. Extensive libraries of compounds have 
become available to perform large-scale trials in high throughput screening (HTS). In 
addition, the genetic revolution made possible the use of defined molecular targets 
and drug-design based on the structure of the target.[63] The chemical space size is 
also one of the obstacles encountered in the development of bioactive molecules. 
The boundaries of this area may be defined by specific interactive connections 
between small molecules and macromolecular targets, as well as through the 
knowledge of some physicochemical properties of ligands or information on the target 
topology. To navigate the vast chemical-biological space, medicinal chemists use 
strategies such as drug design based on the structure of the receptor or ligand, 
including the use of methods in molecular docking, structure-activity relationship 
studies (SAR).[64] Abbott laboratory, one of the leading pharmaceutical company, 
conducted both fragment-based and HTS screens against forty-five protein targets 
over a 10-year period and they had found interesting chemically tractable hits for 
76% of these targets using FBDD, conversely they had found 53% positive results 
when HTS was used.[65] 
A recurrent approach in medicinal chemistry is the search for enzyme 
inhibitors by modifying substrates or cofactors. When this strategy is not successful, 
a new starting point needs to be identified. A possibility may be the use of large-scale 
inhibition assays, although it has the disadvantage of having a high cost. Another 
option is the virtual screening of compounds which have the possibility to interact 
accordingly with the macromolecular target. In this context, studies involving 
fragments have become attractive in the last decade, mainly in the early stages of 
drug design. It allows the identification of small molecules with low affinity and higher 
solubility which can be used as starting point for optimization and preparation of more 
potent inhibitors. Fragment-Based Drug Discovery (FBDD) has been used to identify 
fragments that bind cooperatively and could be linked chemically to form inherent 






The history of FBDD begins with William Jencks, of Brandeis University, 
by introducing the concept of a molecule that could be perceived as a combination of 
two or more fragments. Thirty-four years ago he proposed the theory behind FBDD, 
which describes the Gibbs Free Energy changes for the binding of a molecule to a 
protein.[67] Subsequently, Goodford developed a computer program called as GRID 
where small molecules and termed probes are used for mapping interaction sites in 
proteins.[68] In mid-1990s, several experimental techniques became sufficiently fast 
to be useful in large-scale studies. Since that time, it has explored and played a role 
in the discovery of, at least, twenty-six drugs that have entered in the clinical trials. 
These successes have, in turn, strongly stimulated the pharmaceutical community 
(both industrial and academic groups) to use a fragment-based approach in their lead 
discovery campaigns over the past ten years.[69]  
Fragment-based approach has been widely used throughout the world in 
both academic groups and industries such as Universities and non-profit research 
institutions (Uppsala University, University of Arizona, Leiden University, and 
Burnham Institute, etc.); pharmaceutical and biotechnology companies (Abbott, 
Vernalis, AstraZeneca, Ibis Therapeutics, Astex Therapeutics, SGX Pharmaceuticals, 
Plexxikon, Sunesis, Merck, Wyeth Pharmaceuticals, Pfizer, Novartis, Lilly, Hoffmann-
La Roche, Sareum, Schering-Plough, Evotec, Takeda, AbbVie and Genentech).[65, 
70] Since its proposal, dozens of reviews have been published on various aspects 
and several approaches techniques of FBDD[71] and there are also three books 
related to this topic.[72–74] 
FBDD adopts a collaborative strategy, what means that the addition of 
functional groups or summoned different fragments with small affinity enhances the 
affinity of the whole ligand. FBDD requires small molecular mass fragments with low-
affinity that bind at adjacent regions of the target active site and then grow this into 
larger molecules with higher affinity and specificity to lead drugs.[75, 76] These 
fragments can provide some spatial and structural information of the exact mode of 
binding to guide fragment optimization. Once a fragment attached at the active site of 
the target protein, a new ligand can be developed into potent drugs, particularly when 
their binding mode to target protein has been determined by three-dimensional 
structural elucidations through X-ray crystallography or nuclear magnetic resonance 





different suppliers, and approximately 400,000 of these passed in the commonly 
used fragment-like filter ‘the rule of three’ (RO3).[78, 79] In another approach, Chan 
and co-workers looked for chemical fragments that form hydrogen bonds to the most 
common residues (aspartic acid, glutamic acid, arginine, and histidine) found in 
binding sites to generate a fragment library.[80] 
Few years ago, it was estimated that the number of molecules in 
chemical-biological space are around 100 million.[81] As result of the two different 
conceptions, fragment library can capture more diverse chemical variability using a 
smaller number of compounds than HTS approaches can do. Normally, about half of 
all HTS trials fails because of the poor quality of the starting point molecule, not to 
mention that HTS is a very expensive technique and has a bad cost-benefit ratio.[82] 
In mounting fragment libraries some criteria must be used to improve efficiency and 
velocity, such as the “rule of three” (RO3), where all fragments should have 
molecular weight lower than 300 Da, adequate polarity (clogP ≤ 3) and a small 
number of hydrogen bond acceptors/donors ≤ 3.[65] Further, Veber and co-workers 
also indicated that the number of rotatable bonds and polar surface area must also 
be small (NROT ≤ 3 and PSA ≤ 60Å2) in fragment selection.[83, 84] 
FBDD was first proposed in 1996 using SAR / NMR method at Abbott 
Laboratories.[85] In 2002 the first compound, LY-517717 (Lilly/Protherics), an 
inhibitor of factor Xa currently in clinical phase II, was designed applying this strategy 
and using SPR (surface plasmon resonance) to monitor the activity.[70a, 71, 86] 
In 2003, the use of FBDD suffered a great increase with the publication of the so-
called 'rule of three' (RO3) by scientists from Astex Therapeutics.[79b, 87] 
In FBDD, fragments identified as inhibitors can be optimized by increasing 
its size using mainly four approaches for convert fragments into a drug-like leading 
compound: a) Fragment linking (Figure 14); b) Fragment evolution or growing (Figure 
15); c) In Situ fragment self-assembly (Figure 16), and d) Fragment optimization 
(Figure 17).[88] 
a) Fragment linking: In this approach is necessary to know how and where 
fragments interact in regions near the surface of the protein. A suitable linker that can 
maintain the binding interactions of the individual fragments is used to join them to 
form a lead structure. The linker must not affect the interaction mode of isolated 





examples of this approach.[85, 89–95] 
 
 
Figure 14. a) First fragment binds at the target in a specific position. b) Second fragment binds at an 
adjacent target site. c) The two fragments are joined together by a linking group to form lead molecule. 
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b) Fragment evolution or growing: In this case, the orientation of the 
fragment interaction site is used to decide how to grow the fragment to pick up 
additional interactions in adjacent to the interaction site, to increase the binding 







Figure 15. a) First fragment binds at the target in a specific position. 
b) Additional fragments were connected to the first to increase affinity. 
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c) In Situ fragment self-assembly: The lead compound is formed by self-
assembly and combination of two fragments groups have reacted one to each other 
trough a reactive point. Here, the protein catalyzes the synthesis of its inhibitor 
without any (covalent) attachment of the protein to the inhibitor. In Situ fragment 





Combinatorial Chemistry (DCC), (2) Tethering with Extenders, and (3) In Situ Click 
Chemistry.[100–102] Table 3 shows some examples of this approach.[103–107] 
 
 
Figure 16. a) Two different fragments bind at the target in two adjacent sites. 
b) The lead molecule is formed only if the adjacent sites are close enough. 
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d) Fragment optimization: Initially, the lead compound is optimized by 
Fragment-Based approach. After that, each fragment is replaced by another fragment 
to improve pharmacokinetic properties. Table 4 shows some examples of this 
approach.[86, 108–112]  
 
Figure 17. a) Lead molecule has been discovered by fragment-based approach. 
b) Lead molecule is re-engineered for optimization of a particular property. 
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The lack of complexity in fragments increases the chance to happen an 
interaction or molecular recognition, albeit weak ones at this time, due to a small 
complementarity. On the other hand, there is also a possibility of non-specific 
interaction. Furthermore, the small size of fragments decreases the chance of 
detection of this interaction. A valuable concept to avoid such drawbacks in FBDD is 
the ligand efficiency (LE). It was first applied by Pfizer's scientists to describe the 
average free energy of interaction for each fragment, and it is useful to compare 
different series of compounds and their effectiveness for binding. Figure 18 shows 
the increase of binding efficiency of a parent compound during its evolution using 
both HTS and FBDD approaches. When this study starts with a drug-like compound, 
which already has a molecular mass very close to the common drugs, the 
optimization process requires efficiency gain without increasing its size. If the 
molecular weight is too high, the prototype will lose performance. On the other hand, 
when working with small fragments, optimization can be done with molecular mass 
gain. Many published examples show that the use of LE for a fragment plays a key 
role during a fragment-to-lead drug study (IC50 improved from mM to nM).[113–117]  
 
 
Figure 18 - Increase of binding efficiency of a fragment hit during its molecular 
elaboration. HTS and FBDD were used together to guide structural evolution. 
The dotted lines show the limits of molecular weight for efficience using "Rule of 5" 





Ligand efficiency (LE) is described as the free energy of ligand binding 
(∆G) divided by the number of ‘heavy’ atoms (non-hydrogen atoms, N, at equations i 
and ii just below). LE values greater than 0.3 kcal mol-1 per heavy atom could be 




Where  (ii) 
 
The above equations imply that a library of compounds with good aqueous 
solubility and an assay system capable of quantifying weak interactions are critical 
prerequisites for an approach based on fragments. Good fragment hits make a small 
number of high-quality interactions with the target, have binding affinities in the range 
of 0.1−10 mM, and must be soluble at least 10-2 mol L-1 in buffers or 10-1 mol L-1 in 
dimethylsulfoxide (DMSO) for stock solutions. Those restraints imply in the “Rule of 
3” (RO3) - low molecular weight, adequate polarity, and a small number of hydrogen 
bond acceptors/donors – as described earlier. 
Over the past few years, due to increasing interest in the use of FBDD, 
several methodologies have been developed and applied in this area. Sensitive 
analytical techniques for detection/quantification, a crucial issue in these studies, 
were developed and applied including isothermal titration calorimetry (ITC), nuclear 
magnetic resonance (NMR), mass spectrometry (MS), surface plasmon resonance 
(SPR), and fluorescence-base thermal shift (TS). Each of these techniques has 
different observables, detection, and sensitivity capabilities.[117a, 119−121]  
As example, Table 5 shows the comparison of some physico-chemical 
properties of a set of 40 fragments identified by crystallographic screening against 
three different targets.[122] Results show that these structural hits have a molecular 
weight lower than 300 Da, with a number of hydrogen bond donors (HBD), hydrogen 
bond acceptors (HBA), ClogP, and number of rotatable bonds (NROT) all equal to, or 
smaller than three. In addition, the polar surface area (PSA) is lesser than 60 Å2. 
Based on these results, “Rule of 3” would be considered a guideline in the design of 










“Rule of Three” 
(RO3) 
Other properties 
MW HBA HBD ClogP NROT PSA 
Aspartic 
protease 
13 228 1.1 2.9 2.7 3.5 44 
Serine protease 13 202 1.7 3.1 1.8 2.9 56 
Kinase 14 204 2.5 2.0 1.6 1.7 61 
“RO3” 
guidelines 
- <300 ≤3.0 ≤3.0 ≤3.0 - - 
 
There are large numbers of FBDD based drugs against different targets in 
clinical trials drugs.[70, 71, 123, 124] The first fragment-derived drug (Vemurafenib 
(PLX4032), a B-Raf enzyme inhibitor) was discovered by Plexxikon and approved in 
clinical trials (INN, marketed as Zelboraf, 2011) for the treatment of late-stage 
melanoma.[125] Recently, AbbVie and Genentech discovered a second drug, 
Venetoclax (ABT-199) a selective Bcl-2 inhibitor, using a Fragment-Based approach. 
Venetoclax was approved in clinical trials and is being used for the treatment of 
chronic lymphocytic leukemia.[126] Table 6 shows, a recent list containing thirty-two 














Table 6: Some examples of drugs developed using FBDD and currently in the clinical trials. 
Drugs Originator Targets 
 
Approved 
Vemurafenib (PLX4032) Plexxikon B-Raf (V600E) inhibitor 




FMS, KIT, and FLT3-ITD 
inhibitor 
Verubecestat (MK-8931) Merck BACE1 inhibitor 
AZD3293 AstraZeneca/Astex/Lilly BACE1 inhibitor 
 
Phase 2 
AT7519 Astex CDK1, 2, 4, 5, 9 inhibitor 
AT9283 Astex Aurora, JAK2 inhibitor 
AZD5363 AstraZeneca/Astex/CR-UK AKT inhibitor 
Erdafitinib Johnson&Johnson/Astex FGFR1-FGFR4 inhibitor 
Indeglitazar Plexxikon pan-PPAR agonist inhibitor 
LY2886721 Lilly BACE1 inhibitor 
LY517717 Lilly/Protherics FXa inhibitor 
Navitoclax (ABT-263) Abbott Bcl-2/Bcl-xL inhibitor 
NVP- AUY922 Vernalis/Novartis HSP90 inhibitor 
Onalespib (AT13387) Astex HSP90 inhibitor 
 
Phase 1 
ABL001 Novartis BCR-ABL inhibitor 
ABT-518 Abbott MMP-2 & 9 inhibitor 
ABT-737 Abbott Bcl-2/Bcl-xL inhibitor 
ASTX660 Astex XIAP/cIAP1 inhibitor 
AT13148 Astex 
AKT, S6K1, ROCK 
inhibitor 
AZD3839 AstraZeneca BACE1 inhibitor 
AZD5099 AstraZeneca 
Bacterial topoisomerase II 
inhibitor 
BCL201 Vernalis/Servier/Roche BCL-2 inhibitor 
DG-051 deCODE LTA4H inhibitor 
IC-776 Lilly/ICOS LFA-1 inhibitor 
LP-261 Locus Tubulin binder inhibitor 
LY2811376 Lilly BACE1 inhibitor 
PF06650833 Pfizer IRAK4 inhibitor 
PLX5568 Plexxikon Kinase inhibitor 
SGX-393 SGX BCR-ABL inhibitor 
SGX-523 SGX Met inhibitor 





1.5 Biology-Oriented Synthesis (BIOS) 
 
Natural product frameworks emerge via biosynthesis by proteins and fulfill 
multiple functions via interaction with them. Such scaffolds were selected by 
evolution along huge periods of time and are endowed with relevance and offer 
outstanding starting points in chemical space for ligand design and development of 
new drugs. Although the chemical space is enormous, nature uses much fewer 
building blocks to develop its own chemical space, which is also a large one. 
Biology oriented synthesis (BIOS) shapes on these statements and 
employs core structures outlined from natural products as input for compound 
libraries. Usually, literature refers to such collections by means of “natural product 
derived”. The structures used as model are not necessarily identical, but closely 
related, to a natural product core structure. In this approach, compounds are built up 
by insertion of different functional groups and substituents, but not specifically at the 
same position found in the natural product model. Stereochemistry may also be 
altered. 
Structural Classification of Natural Products (SCONP) is a BIOS correlated 
concept and, as well as BIOS, is used to identify subspaces of vast chemical space 
and serve as hypothesis generating tools for synthesis efforts and discovery of new 
compounds. Both strategies emphasize diversity around a biologically pre-validated 
starting point in the vast chemical space to produce compound libraries.[127–131] 
Using BIOS and SCONP approaches, Nören-Müller discovered four inhibitor classes 
(Cytisine, Furanodictin A and indole derivatives) for seven different tyrosine 
phosphatases (PTP1B, SHP-2, VE-PTP, MptpA and MptpB) and dual-specificity 
phosphatases (CDC25A and VHR) in 2006.[128] For PTP1B, SHP-2, VE-PTP and 
MptpB, IC50 values were found in micromolar range (Figure 19). Remarkably, 
screening of Natural Product derived compounds did not furnish active compounds 
against MptpA, CDC25A and VHR at 100 μM. 
Furthermore, three yohimbine alkaloids were identified as CDC25A 









21 (IC50 = 2.08 ± 0.29 μM; VE-PTP) 22 (IC50 = 2.45 ± 0.28 μM; VE-PTP) 23 (IC50 = 2.47 ± 0.93 μM; SHP-2) 
 
24 (IC50=3.95±1.49 μM; SHP-2) 
(IC50=5.86 ± 1.35 μM; PTP-1B) 
25 (IC50 = 1.13 ± 0.63 μM; MptpB) 26 (IC50 = 2.38 ± 1.17 μM; MptpB) 
 
27 (IC50 = 0.36 ± 0.12 μM; MptpB) 28 (IC50 = 0.43 ± 0.17 μM; MptpB) 
 
Figure 19. Structures of cytisine, furanodictin A and indole  




29 (Yohimbine, IC50 = 22.3 μM) 30 (Ajmalicine, IC50 = 31.6 μM) 31 (Reserpine, IC50 = 63.7 μM) 
 






2. Objectives and working plan 
 
The aim of this research proposal is to investigate, design and synthesize 
inhibitors for different protein tyrosine-phosphatase enzymes: PTP1B, LMW-PTP and 
CDC25B. There are only few described ligands for these enzymes in the literature, 
and there is no three dimensional description of their active sites. PTPs are validated 
drug targets for various therapeutic indications. Thus, we have been involved in the 
optimization of chemical series, which are capable of inhibiting their activity against 
selected protein tyrosine phosphatases as biological targets. In this context, we 
proposed an approach to the study and development of PTP inhibitors with drug-like 
molecules. 
 
Based on this rationale, the specific aims of this work are: 
 
i. Design and screening by computational methods of potential inhibitors 
for PTP1B. 
ii. Structural modifications using Biology-Oriented Synthesis (BIOS) and 
Fragment-Based Drug Discovery (FBDD) approach. 
iii. Synthesize prominent putative inhibitors for PTP1B. 
iv. Build a collection of commercially available and synthetic molecular 
fragments. 
iv. Carry out in-vitro enzyme inhibition assays. 
v. Determine the crystal structure of the complex between target and 
phosphatase-active compounds. 
vi. Determine the Quantitative Structure–Activity Relationship (QSAR) and 
Structure–Activity Relationship (SAR) for PTP1B inhibition. 
vii. Identify important interacting chemical groups and propose 







3. Results and discussion 
 
Based on available information on PTPs, we proposed ten series of 
compounds to be studied in this work. The compounds planned for the PTP1B, were 
also assessed against LMW-PTP and CDC-25B. Therefore, we studied the action of 
oxamic, sulfamic, carboxylic, cinnamic, thioacetic, thioacetamide, phosphonic, 
sulfonic and boronic acids as inhibitors of these enzymes and begin a rational and 
systematic design of more selective inhibitors for this group of tyrosine-phosphatase 
enzymes. 
 
3.1. Docking studies 
 
3.1.1. Compounds selection for the study 
  
Experimental information from crystal structures of complexes between 
the target enzymes and ligands was not available. Therefore, an attempt to identify 
possible trends in the activity of the compounds against PTP1B was done with basis 
on computational docking studies. With the necessary caution one needs in 
analyzing theoretical predictions, an effort was made in order to propose preliminary 
hypothesis which might be helpful in distinguishing possible structural features 
related to the different inhibition scores observed. 
Docking studies has been carried out using virtual library of compounds. 
We have selected five compound series as shown in Figure 21: (N-phenylamino) 
oxoacetic acids (series 1); N-phenylsulfamic acids (series 2); phenylisooxazole 
carboxylic acids (series 3); thioacetic acids (series 4); and using FBDD strategies, 
N-(2-(1H-benzo[d]imidazol-2-ylthio) acetamido) benzoic acid (series 5) derivatives 






Figure 21. General structures of 1–5 series of compounds derived from docking and FBDD approach. 
 
These series of compounds are predicted to have interactions not only 
with the amino acid residues at active site (P-loop, Cys215–Arg221), but also with 
another binding site (known as secondary binding site) with amino acid residues 
(Tyr20, Arg24, His25, Ala27, Phe52, Arg254, Met258, Gly259), which may improve 
inhibition activity. In this context, we showed the interaction of representative 
compounds from each series. 2D representations of protein-ligand interactions 
showed in Figure 22–26 and Appendix I were generated using LIGPLOT+ program. 
During the process of designing the new compounds, we privileged close 
related scaffolds. Thus, we would not expect such compounds to present very 
different modes of binding within the active site by simply changing a single atom, as 
can be seen from the LigPlot analysis presented in Appendix I.  
 In the case of (N-phenylamino)oxoacetic acids (series 1), hydrogen 
bonds were observed with amino acid residues Ala217, Gly220, Arg221 and Asp181 
(showed in dashed lines in green colour between the atoms); as weel as hydrophobic 
interactions with amino acid residues Cys215, Ser216, Ala217, Ile219, Gly220, 
Gly262, Val49, Asp181, Phe182 and Tyr46 (represented by a large red arc with 
spokes radiating towards the ligand atoms, and radiating back to the ligand atoms as 
a small red arc with spokes). Due problems in tinting LIGPLOT+ representations the 
diagrams of MKR-26a and 40a compounds were omitted by not depict faithfully the 






    
 
 
        
Figure 22. Schematic 2D representation of (N-phenylamino)oxoacetic acids (series 1) with PTP1B. 
 
In the case of N-phenylsulfamic acids (series 2) primary interactions are 
hydrogen bonds with amino acid residues Ser216, Ala217, Gly220, Arg221 and 
Asp181 (showed in dashed lines in green colour between the atoms); and 
hydrophobic interactions with amino acid residues Cys215, Ala217, Ile219, Gly262, 
Phe182 and Tyr46 (represented by a large red arc with spokes radiating towards the 
ligand atoms, and radiating back to the ligand atoms as a small red arc with spokes), 







            
 
 
Figure 23. Schematic 2D representation & docking pose                                                                   
view of N-phenylsulfamic acids (series 2) with PTP1B. 
 
In the case of isoxazole carboxylic acids (series 3) main interactions are 
hydrogen bonds with amino acid residues Gly220 and Arg221 (in dashed lines in 
green colour between the atoms); and hydrophobic interactions with amino acid 
residues Cys215, Ala217, Ile219, Gly262, Asp181, Phe182 and Tyr46 (a large red 
arc with spokes radiating towards the ligand atoms, and radiating back to the ligand 









              
 
Figure 24. Schematic 2D representation & pymol view 
of isooxazole carboxylic acids (series 3) with PTP1B. 
 
In the case of thioacetic acids (series 4, Figure 25), hydrogen bonds were 
observed with amino acid residues Arg254 (dashed lines in green color between the 
atoms); hydrophobic interactions with amino acid residues Ile219, Met258, Gly259, 
Arg24, Ala27, Asp48 and Val49 (a large red arc with spokes radiating towards the 






       
Figure 25. Schematic 2D & 3D representation of thioacetic acids (series 4) with PTP1B. 
 
Using Fragment-Based approach (FBDD) [72–74, 79b] and docking tool, 
N-(2-(1H-benzo[d]imidazol-2-ylthio)acetamido)benzoic acid derivatives (series 5 in 
Figure 26 were designed through fragment growing method. This methodology 
involves the addition of fragments in the molecule to achieve interactions at the 
secondary binding site, which might improve the results. In this case, hydrogen 
bonds were observed with amino acid residues Gly220, Arg221, Gly262, Asp48 and 
Asp181 (showed in dashed lines in green colour between the atoms); and 
hydrophobic interactions with amino acid residues Cys215, Ala217, Ile219, Gly220, 
Gly259, Met258, Ala27, Ser28, Val49, Asp181, Tyr46 and Phe182 (represented by a 
large red arc with spokes radiating towards the ligand atoms, and radiating back to 
the ligand atoms as a small red arc with spokes). 
Moreover, in these series, electrostatic interactions were observed with the 
side chain of Asp181 and Arg221; Van der Waals and π-π stacking interactions also 
identified with amino acid residues Tyr46 and Phe182, but they were not showed by 
LIGPLOT+ software. 
Based on the LIGPLOT+ representations for PTP1B, results suggest that 
substitution at positions ortho and para a hydrophobic group (as in MKR-11a and 
MKR-19a) could decrease the inhibitory activity. The same result was also obtained 
when the benzyl group was replaced by a quinoline ring (MKR-33a compound). 






        
Figure 26. Schematic 2D representation of N-(2-(1H-benzo[d]- 
imidazol-2-ylthio)acetamido)benzoic acids (series 5) with PTP1B. 
 
3.2. Compounds selection using Biology–Oriented Synthesis (BIOS) 
 
We also used BIOS to investigate the behavior of phosphonic acids 
(series 6), sulfonic acids (series 7), boronic acids (series 8), carboxylic acids 
(series 9), and cinnamic acids (series 10) as enzymatic inhibitors of tyrosine-
phosphatases (Figure 27). These groups must be attached to a benzylic position, or 
an aromatic ring, in order to mimic the natural substrate: a phosphorylated tyrosine 
residue. Due to structural resemblance among the compounds of series 6–10 and 
the natural substrates, we anticipated a prompt recognition of them by the enzymes. 
However, in this case, the synthesised compounds are unable to achieve the 
heteroatom-oxygen bond cleavage by the proposed mechanism, which could 
produce interference in the biological process. 
The similarity among monophosphate, sulfamic, sulfonic and phosphonic 
groups is evident, which justifies the inhibiting expected for these compound 
class.[132] It is expected that the boron is quaternarized after a nucleophilic addition of 
one of the several sulfhydryls groups. Therefore, such tetrahedral intermediate also 
has some resemblance with monophosphate group furnishing the observed biological 







Figure 27. General structures of 6–10 series of compounds selected from BIOS. Upper left: Natural 
substrate for tyrosine-phosphatases enzymes. Upper right: Proposed structures unable to achieve the 





3.3.1. Compounds of series 1–10 
 
Synthesis has been carried out for (N-phenylamino)oxoacetic acids 
(series 1), N-phenylsulfamic acids (series 2), N-(2-(1H-benzo[d]imidazol-2-ylthio) 
acetamido) benzoic acids (series 5), phosphonic acids (series 6), sulfonic acids 
(series 7) and boronic acids (series 8). Some compounds in series 3, 4, 7, 8, 9 and 
10 are commercially available, and were purchased from commercial suppliers. The 
entire set of obtained compounds is shown in Figure 28 (a & b). In total, One 
hundred and sixty seven compounds (ninety-seven synthesized and seventy 
acquired compounds) were selected for biological assays. The NMR spectra of 








Figure 28 a. Commercially available compounds used in 







Figure 28 b. Commercially available compounds used in 





3.3.1.1. Synthesis of substituted (N-phenylamino)oxoacetic acids (series 1) 
 
Condensation of substituted anilines with ethyl oxalyl chloride furnished 
the o, m, p - substituted (N-phenylamino) oxoacetic acid ethyl esters (II), which 
underwent hydrolysis to obtain (N-phenylamino) oxoacetic acids (III) in 15–70% 
yields (Scheme 3 and Table 7).[94, 134] 
The products were characterized by ¹H–NMR spectroscopy, where it was 
possible to assign all the signals to the hydrogen atoms of the molecule. 1H–NMR 
ester signals indicated the success of the reaction, as well as the carbonyl signals in 
the 13C–NMR spectrum observed between 165.0 to 155.0 ppm. Infrared spectroscopy 
showed carboxylic acid O-H streching between 3000–2500 (br, v) cm–1, C=O stretch 
1780–1710 (s) cm–1; amide N-H stretching of carbonyl between 3550–3300 (m) cm–1 
and C=O stretching (amide I band) 1690–1630 (s) cm–1 respectively. All compounds 










Table 7. List of all synthesized (N-phenylamino)oxoacetic acid derivatives. The 
signal (*) is related to anilines (n=0), benzyl (n=1), or phenylethyl (n=2) amines. 
Compound R (ortho)* R (meta)* R (para)* n* 
MKR-24a F H H 0 
MKR-28a H F H 0 
MKR-25a H H F 0 
MKR-5a H Cl H 0 
MKR-10a H H Cl 0 
MKR-23a Br H H 0 
MKR-9a H Br H 0 
MKR-8a H H Br 0 
MKR-26a I H H 0 
MKR-7a H I H 0 
MKR-40a H H I 0 
MKR-12a H OH H 0 
MKR-13a H H OH 0 
MKR-11a OCH3 H H 0 
MKR-31a H OCH3 H 0 
MKR-51a H H OC2H5 0 
MKR-55a CH3 H H 0 
MKR-52a H CH3 H 0 
MKR-19a H H CH3 0 
MKR-42a H H Br 1 
MKR-38a H NO2 H 1 
MKR-50a H H COOH 1 
MKR-41a OCH3 H H 1 
MKR-44a CH3 H H 1 
MKR-37a H H Br 2 
MKR-36a H H NO2 2 
MKR-20a H CH3 H 2 
    
















3.3.1.2. Synthesis of N-phenylsulfamic acids (series 2) 
 
N-phenylsulfamic acids (V) were obtained by treatment of aniline with 
chlorosulfonic acid (Scheme 4).[135, 136] The compounds were obtained in 25-30% 
yield.  
The compounds KSR-1 & 3 were analysed by 1H–NMR spectroscopy 
which revealed the absence of –NH2 signals. IR spectroscopy showed bands for 
(S=O streching at 1296, 1171 and O-H stretching 2931 cm–1 for KSR-3, and S=O 
streching 1298, 1174 and O-H stretching 2832 cm–1 for KSR-1). The compounds 
were also analysed by mass spectroscopy using negative mode ESI-MS. 
 
 
       
Scheme 4. Synthesis of N-phenylsulfamic acids. 
 
3.3.1.3. Synthesis of substituted N-(2-(1H-benzo[d]imidazol-2-ylthio) 
acetamido)benzoic acid derivatives (series 5) 
 
Step 1: Condensation of an aminobenzoic acid with chloroacetyl chloride 
furnished a (2-chloroacetamido)benzoic acid (VII) in 25–80% yield (Scheme 5).[46, 
137]  
 
      






Carbonyl group signals in IR and NMR spectroscopy confirmed the 
structures of compounds KS-0, 0b & 0c. 13C–NMR signals were observed between 
169–165 ppm. On the other hand, infrared spectroscopy showed bands for carboxylic 
acid O-H stretching between 3300–2500 cm–1, C=O stretching 1780–1710 cm–1; 
amide N-H stretching of carbonyl between 3550–3300 cm–1 and C=O stretching 
1690–1630 cm–1. 
Step 2: Coupling of the intermediate KS-0 with N-mercaptobenzimidazoles 
in the presence of base formed the derivatives of N-(2-(1H-benzo[d]imidazol-2-
ylthio)acetamido)benzoic acid (VIII, Scheme 6 and Table 8).[46, 69] The compounds 
were obtained in 50– 85% yield. 
The products were characterized by 1H–NMR spectroscopy, where it was 
observed a singlet of the methylene group between 4.53–3.77 ppm. Furthermore, 
13C–NMR showed carbonyl carbons signals at 167.5–163.4 ppm. In infrared 
spectroscopy, the carboxylic acid O-H stretch was observed at 3000–2500 cm–1, as 
well as C=O stretching at 1780–1710 cm–1, C-O stretching at 1320–1210 cm–1; 




Scheme 6. Synthesis of 3-(2-(1H-benzo[d]imidazol-2-ylthio)acetamido)benzoic acids. 
 
Table 8. List of all synthesized 3-(2-(1H-benzo[d]imidazol-2-ylthio)acetamido)benzoic acid derivatives. 
Compound R R1 
KS-1 OCH3 H 
KS-2 OC2H5 H 
KS-3 NO2 H 
KS-4 CH3 H 
KS-5 Cl H 






3.3.1.4. Synthesis of substituted benzylphosphonic acids (series 6) 
 
The preparation of alkylphosphonates is a long-known reaction (Arbuzov 
reaction) in the organic chemistry, as well as the proposed changes in the synthetic 
route.[138] The reactions were performed in different conditions (method A and B), 
but intermediate X is common for both approaches. Only the last step, the hydrolysis 
conditions, was different.  
The products were characterized by 1H–NMR and 13C–NMR 
spectroscopies, where a doublet was observed due to the coupling between the 
methylene group and phosphorous atom. The coupling constant was found between 
2J = 20–23 ppm for proton and 1J = 130–137 ppm for carbon. A 31P–NMR spectrum 
was also obtained for each compound in this series. 
Method A: 
Benzylphosphonic acid derivatives (XI) were prepared by the nucleophilic 
substitution reaction between benzyl bromide or chloride (IX) and triethyl phosphite 
(Arbuzov reaction) to obtain intermediate (X), followed by hydrolysis to the products 
(Scheme 7).[139–141] Phosphonic acid derivatives were isolated in 15–70% yield 
and are shown in Table 9.  
 
 
Scheme 7. Synthesis of substituted benzylphosphonic acids. 
Method B: 
The synthesis of phosphonic acids (XI) was performed in different 
condition from diethyl phosphonates (X). These phosphonates have been subjected 
to silylation with trimethylsilyl chloride, with consequent formation of bis-trimethylsilyl 
phosphonate. The hydrolysis of these compounds in mild conditions resulted in the 
formation of phosphonic acids (Scheme 8) with 15–70% yield (in Table 9).[142]  
 
 





Table 9. List of all benzylphosphonic acids synthesised from method A & B. 
Compound R (ortho) R (meta) R (para) 
MK-0 H H H 
MK-0a H H NO2 
MK-9 H H CH2Cl 
MK-11a F H H 
MK-11b H F H 
MK-11 H H F 
MK-29 CF3 H H 
MK-30 H CF3 H 
MK-7a H H CF3 
MK-1 H H Cl 
MK-47 Br H H 
MK-2 H H Br 
MK-9a H H CH2Br 
MK-35 H H OCH3 
MK-13 H H COOH 
MK-15 H H NH2 
MK-27 CH3 H H 
MK-28 H CH3 H 
MK-12 H H CH3 
MK-41 H H CN 
    






















3.3.1.5. Synthesis of substituted sodium phenylmethanesulfonates (series 7) 
 
Sodium salts of benzenemethanesulfonic acids, (XII, Table 10) were 
prepared by the reaction of benzyl halide (IX) with sodium sulfite in water as solvent 
at reflux (Scheme 9).[143] Compounds were obtained in 25–85% yield. 
The products were characterized by 1H–NMR and 13C–NMR 
spectroscopies. NMR signals for benzylic proton and carbon atoms of sodium 
phenylmethanesulfonates have higher chemical shifts than benzylic halides. The 
main band observed in the infrared spectrum was the S=O stretching between 1195–
1168 cm–1. All compounds were analysed by mass spectroscopy using electrospray 
ionisation (ESI-MS) in negative mode. 
 
 






Table 10. List of all synthesised sodium phenylmethanesulfonates derivatives. 
Compound R (ortho) R (meta) R (para) 
MK-24a F H H 
MK-24b H F H 
MK-24 H H F 
MK-32 CF3 H H 
MK-33 H CF3 H 
MK-8 H H CF3 
MK-3 H H Cl 
MK-4 Br H H 
MK-10 H H Br 
MK-36 H H OCH3 
MK-5 H H NO2 
MK-42 H H CN 
MK-40 H H COOH 
MK-45 H H CH2OH 
MK-25 CH3 H H 
MK-26 H CH3 H 
MK-21 H H CH3 
    














3.3.1.6. Synthesis of substituted benzylboronic acids (series 8)  
 
The Grignard reaction with trimethyl borate was utilized to construct the 
carbon-boron bond. The Grignard reagent was prepared from a benzyl halide (IX) 
and magnesium turnings in anhydrous aprotic solvents (such as diethyl ether or 





dialkylboronate esters (XIII) followed by acidic hydrolysis to furnish benzylboronic 
acid derivatives (XIV) in 25–40% overall yield (Scheme 10 and Table 11).[144, 145] 
 
 
Scheme 10. Synthesis of benzylboronic acid derivatives. 
 
Table 11. List of benzylboronic acid derivatives prepared. 
Compound R (ortho) R (meta) R (para) 
KA-0 H H H 
KA-2 F H H 
KA-1 H H F 
KA-8 Br H H 
KA-12 H H OCH3 
KA-5 CH3 H H 




3.4. Inhibition assays  
 
The compounds described in Section 3.3 and Appendix III were 
successfully synthesised, purified and characterized by spectroscopic techniques 
such as 1H-NMR, 13C-NMR, 31P-NMR, 19F-NMR, IR and mass spectrometry. So, we 
moved towards the screening against phosphatases, not only PTP1B (the principal 
target of this work), but also using other two protein tyrosine phosphatases as 
biological targets, known as LMW-PTP and CDC25B. As described earlier, it was 
also considered an important target for the development of selective novel inhibitors. 
In this manner, it is possible to check the discrimination of the new inhibitors against 
PTP1B, LMW-PTP and CDC25B. 
 
3.4.1. PTP1B 
One hundred and fifty-four compounds (Figure 28, Section 3.3 or Appendix 
III) were assayed against PTP1B. The enzymatic activity was monitored via a single 
point quenched product reaction with the substrate analog p-nitrophenylphosphate 





For PTP1B, one hundred and thirteen compounds showed at least 50% 
inhibition. Compound KM-26 showed absorption at 405 nanometer (nm), and 
consequently it was discarded. Additionally, twenty-four compounds (MK-16; KM-6/, -
22/, -24/, -28/, -30/, -31/, -32/, -33; KA-0/, -1/, -2/, -5/, -7/, -8/, -12; KS-0b/, -0c; KS-
1/, -2/, -3, -4/, -5/, and -6) formed precipitate during the established conditions and 




Figure 29a. PTP1B enzyme activity (%) after single concentration assay 
test in the presence of designed compounds (First set of compounds). 
 
The best results were obtained for thirty-six compounds (MKR-17a/, -18a/, 
-9a/, -10a/, -23a/, -7a/, -26a/, -40a/, -37a, -36a/, -20a; MK-11/, -29/, -7a/, -1/, -35/, -6/, 
-27/; MK-10/, -37/, -5/, -45/, -38/, -25/, -26/, -21; KSR-6ab/, -6e/, -6d/, -6b/, -6g/, -6h/, 
-6i; and KAM-12/, -8/, -3) which showed at least 90% inhibition. A remarkable result 





PTP1B (Figure 29a). Therefore, MKR-25a could be an interesting compound for 
further comprehension of this enzyme and its inhibitors. Compounds MK-38 (IC50 = 
2.33 µM) and KSR-6ab (IC50 = 5.0 µM) showed the best IC50 values for PTP1B. 
These results suggest that these compounds may be interesting for further structural 




Figure 29b. PTP1B enzyme activity (%) after single concentration assay 
test in the presence of designed compounds (Second set of compounds). 
 
Ligplot+ calculations for PTP1B suggested that substitution at ortho and 
para positions by hydrophobic groups (compounds MKR-11a and MKR-19a) should 
decreased the inhibitory activity. Experimental results also pointed it out when the 
benzyl group was replaced by a quinoline ring (MKR-33a compound). Halogen 
substituents at any position appear to be advantageous for the inhibitory process. 
Appendix IV presents inhibition values in percentage (100% minus the 





structures of complexes between the enzymes and ligands were not achieved since 
all obtained monocrystals didn’t have the ligands in the active site. In spite of that, an 
attempt to identify possible trends in the activity of the compounds against PTP1B 




The same set of compounds (Figure 28, Section 3.3 and Appendix III) 
was assayed against LMW-PTP1B. The enzymatic activity was monitored via single 
point quenched product reaction with the substrate analog p-nitrophenylphosphate 









In the case of LMW-PTP, fourty-five compounds showed at least 50% of 
inhibition for LMW-PTP. Compounds MK-46a and KM-26 showed absorption at    
405 nM and were discarded. Additionally, twenty-six compounds (MKR-33a; MK-16; 
KSR-6; KM-6/, -22/, -24/, -28/, -30/, -31/, -32/, -33; KA-0/, -1/, -2/, -5/, -7/, -8/, -12; 
KS-0b/, -0c; KS-1/, -2/, -3/, -4/, -5/, -6)  formed precipitate using the established 




Figure 30b. LMW-PTP enzyme activity (%) for single concentration assay. 
 
The best results were obtained for twenty-two compounds (MKR-17a/,       
-40a/, -42a/, -37a, -36a; MK-48/, -49/, -35/, -6/, -15; MK-5/, -40/, -25/, -26; KSR-6h/,  
-6i/, 0f/, -3; and KAM-12/, -8/, -3, -4) which showed at least 85% inhibition. 
Remarkable results were obtained for twenty-one compounds (MK-47; MK-34, -4/; 
KSR-6a; KM-3/, -2/, -15/, -7/, -11/, -4/, -10/, -25/, -27; KSR-0d/, -0e; KM-29; KSR-1; 
KAM-1, -11/, -9/, -7), which increased the activity for LMW-PTP (Figure 30a & b). 





cell cycle in different types of tumors.[146–148] Therefore, these noteworthy results 
may be interesting for further development of inhibitors and additional studies in cell 
lines. 
Plots of inhibition in percentage (100% minus the value of the enzyme 




The same set of compounds (Figure 28, Section 3.3 or Appendix III) 
above mentioned was used for inhibition assays against CDC25B. The enzymatic 
activity was monitored via a single point quenched product reaction with the substrate 
analog p-nitrophenylphosphate (pNPP). Activity results for these assays shown that 
none of them (series 1–10) was a good inhibitor against CDC25B (Figure 31). Only, 
few compounds (MK-21, 36, 37; KM-19; KSR-0b, 0d, 0f; KS-4; KAM-6, 7; KA-12) 
shown at least 25% of inhibition for CDC25B. Appendix V shows inhibition in 




























The single dose inhibition results were used to choose which compounds 
would be tested further to determine the IC50 values. The IC50 values can quantify the 
potency of ligands on PTP1B and LMW-PTP inhibition. For IC50 determination the 
protocol conditions described at experimental section was adopted and the 
compounds were assayed in a concentration range varying from 5 mM to 5 µM.  
The IC50 was calculated using dose-response curve and plotted in a graph 
of inhibitor concentration versus residual enzyme activity. The plotted graphs were 




The selection criteria for compounds used in IC50 assay was 90% 
inhibition or greater at the single point test. Few other less active compounds have 
also been chosen just to perform statistical analysis with more confidence. Selected 
compounds are chosen from Figures 29a & b. 
At Table 12, IC50 values for the selected sixty-nine (69) compounds 
against PTP1B are shown in millimolar (mM) concentration. All values reside on the 
95% confidence interval (CI 95%), showed in the third column. Compound MKR-17a 
was precipitated at established conditions and, so, not included in these results. All 
IC50 values reside in the micromolar (µM) to millimolar (mM) range. The best IC50 
values for this set of compounds were MKR-18a (IC50 = 70.2 µM), MK-38 (IC50 = 2.33 
µM), KSR-6f (IC50 = 89.5 µM), and KSR-6ab (IC50 = 5.0 µM) and were highlighted 
with a star mark. The dose-response curves were attached in Appendix VI. 
Table 12 – IC50 and CI 95% values for selected compounds against PTP1B (values in mM). 
  PTP1B   
Compound IC50 (mM) CI 95% 
MKR-18a 0.07 0.06226 to 0.07911 
MKR-9a 0.85 0.6725 to 1.075 
MKR-23a 0.23 0.1010 to 0.5153 
MKR-7a 0.18 0.1501 to 0.2213 
MKR-8a 1.11 0.8811 to 1.398 
MKR-26a 0.53 0.4532 to 0.6293 
MKR-5a 0.32 0.2866 to 0.3540 





Table 12 (Continuation) – IC50 and CI 95% values for selected compounds against PTP1B (values in mM). 
  PTP1B   
Compound IC50 (mM) CI 95% 
MKR-31a 1.36 1.147 to 1.614 
MKR-42a 0.44 0.3789 to 0.5165 
MKR-50a 1.30 1.121 to 1.497 
MKR-41a 1.19 1.060 to 1.327 
MKR-44a 0.69 0.5584 to 0.8506 
MKR-37a 0.13 0.1109 to 0.1423 
MKR-36a 0.11 0.07957 to 0.1556 
MKR-20a 0.13 0.07529 to 0.2386 
MK-11 1.03 0.8557 to 1.249 
MK-29 2.22 0.5623 to 8.773 
MK-30 1.26 1.043 to 1.509 
MK-7a 0.47 0.3017 to 0.7427 
MK-1 2.11 1.730 to 2.568 
MK-47 1.54 1.285 to 1.850 
MK-2 0.91 0.5058 to 1.634 
MK-48 0.93 0.7730 to 1.130 
MK-35 0.18 0.1701 to 0.1989 
MK-6 0.53 0.4647 to 0.5984 
MK-13 1.36 1.002 to 1.839 
MK-27 1.03 0.8167 to 1.302 
MK-28 0.92 0.7945 to 1.062 
MK-12 1.19 0.9581 to 1.471 
MK-3 1.52 1.336 to 1.738 
MK-10 1.06 0.9223 to 1.222 
MK-37 0.22 0.1891 to 0.2508 
MK-5 0.31 0.2940 to 0.3319 
MK-40 0.86 0.7077 to 1.043 
MK-45 1.21 0.7557 to 1.940 
MK-38 0.002 0.001513 to 0.003600* 
MK-25 0.23 0.2026 to 0.2673 
MK-26 0.32 0.2776 to 0.3589 
MK-21 2.06 1.793 to 2.376 
KSR-6ab 0.005 0.004450 to 0.005718* 
KSR-6 0.42 0.2314 to 0.7787 
KM-1 0.72 0.6144 to 0.8339 
KSR-6e 0.49 0.3875 to 0.6284 
KSR-6f 0.0895 0.07910 to 0.1013 * 
KSR-6d 0.19 0.1243 to 0.2975 
KSR-6c 0.48 0.4110 to 0.5716 





Table 12 (Continuation) – IC50 and CI 95% values for selected compounds against PTP1B (values in mM). 
  PTP1B   
Compound IC50 (mM) CI 95% 
KSR-6g 0.33 0.2868 to 0.3751 
KSR-6h 1.18 0.9311 to 1.504 
KSR-6i 0.33 0.2745 to 0.3867 
KM-2  0.65 0.5210 to 0.8080 
KM-15  0.62 0.5362 to 0.7202 
KM-14 0.31 0.2188 to 0.4356 
KM-9  0.97 0.7873 to 1.193 
KM-21  0.68 0.5522 to 0.8420 
KM-27  0.80 0.6319 to 1.014 
KSR-0  0.11 0.09785 to 0.1170 
KSR-0a 0.68 0.5708 to 0.7984 
KSR-0b  2.17 1.850 to 2.552 
KSR-0d 0.81 0.6767 to 0.9676 
KSR-0f 0.15 0.1398 to 0.1716 
KSR-3 0.89 0.8100 to 0.9778 
KSR-1  1.52 1.266 to 1.819 
KAM-12 0.25 0.2230 to 0.2692 
KAM-8 0.40 0.3405 to 0.4786 
KAM-10 0.23 0.1967 to 0.2685 
KAM-2 1.00 0.8541 to 1.164 





The selection criteria for compounds used in LMW-PTP IC50 assay was 
90% inhibition or greater at the single point test. Once again, few other less active 
compounds have also been chosen just to perform statistical analysis with more 
confidence. 
Selected compounds are exhibited at Figures 30a & b. IC50 values for the 
selected thirty compounds against LMW-PTP are shown in millimolar (mM) 
concentration at Table 13. All values reside on the 95% confidence interval (CI 95%) 
showed in the third column. The best IC50 values for this set of compounds were 
MKR-42a (IC50 = 0.55 mM), MKR-36a (IC50 = 0.39 mM), MK-48 (IC50 = 0.44 mM), 
MK-49 (IC50 = 0.39 mM), KAM-12 (IC50 = 0.16 mM), and KAM-4 (IC50 = 0.18 mM) and 





attached in Appendix VII. 
 










































Crystallization of proteins complexes with ligands is the preferred method 
to suggest ligand modifications since it allows the visualization of hydrogen bonding 




Compound IC50 (mM) CI 95% 
MKR-17a 1.20 1.002 to 1.442 
MKR-40a 1.18 1.051 to 1.334 
MKR-13a 1.25 1.118 to 1.398 
MKR-42a 0.55 0.5042 to 0.5966* 
MKR-41a 1.25 1.078 to 1.449 
MKR-44a 1.16 1.021 to 1.307 
MKR-37a 1.59 1.400 to 1.802 
MKR-36a 0.39 0.3563 to 0.4202* 
MK-48 0.44 0.3644 to 0.5364* 
MK-49 0.39 0.3379 to 0.4607* 
MK-35 0.82 0.7392 to 0.9194 
MK-6 1.82 1.631 to 2.035 
MK-15 1.49 1.366 to 1.614 
MK-3 3.44 2.940 to 4.025 
MK-10 2.89 2.604 to 3.205 
MK-5 1.05 0.9143 to 1.197 
MK-40 2.25 1.340 to 3.765 
MK-25 1.67 1.502 to 1.849 
MK-26 2.81 2.479 to 3.188 
MK-21 1.75 1.539 to 1.980 
KSR-6e 3.76 3.238 to 4.375 
KSR-6h 1.40 1.258 to 1.567 
KSR-6i 2.85 2.116 to 3.825 
KM-19  1.95 1.693 to 2.235 
KSR-0f  1.30 1.102 to 1.540 
KSR-3  1.43 1.179 to 1.744 
KAM-12 0.16 0.1524 to 0.1763* 
KAM-8 1.40 1.215 to 1.606 
KAM-3 1.52 1.374 to 1.686 





This technique may help in developing more potent or selective drugs against the 
target. Cocrystals of drug molecules with the protein fragments (small peptide 
fragments of the protein’s active site) can also provide further insights into the drug-
receptor interactions. 
The most potent inhibitors were selected to perform crystallization studies, 
then they were put for crystallization with PTP1B and also LMW-PTP. The crystal 
data were collected in two separate experiments, for PTP1B and LMW-PTP, both 
described in Section 4.4. After the structure refinement, ligands were not found in the 
active site of PTP1B or LMW-PTP. Although several crystals were obtained from our 
attempts, we only found the apo protein in the crystals for PTP1B and LMW-PTP. 
Furthermore, the compounds MK-0, MK-0a and MK-9, synthesised in this 
study, were also submitted for crystallization using different conditions against LMW-
PTP. In that case, crystallization conditions, inhibition assays, as well as the solved 
structures (apo structure - PDB ID: 4Z99; crystal complexes of benzylphosphonic 
acid - PDB ID: 4Z9B and phenylmethanesulfonic acid - PDB ID: 4Z9A) were reported 
in the doctoral thesis of Dr. Emanuella and also published in an article.[59, 149] 
 
3.6. Structure activity relationships (SAR & QSAR) 
 
SAR is the qualitative rationalization of the relationship between molecular 
structure and property, in this case, the biological activity. This analysis can help to 
design the new scaffolds, functional groups, and stereochemistry for protein 
inhibitors. In QSAR method, the relationship between a chemical structure and its 
biological activity is quantitative. Using IC50 values against PTP1B, we performed a 
QSAR analysis using the ISIDA/QSPR software. [150–152] 
  
3.6.1. Structure activity relationship (SAR) 
 
Preliminary analysis of IC50 results (SAR study) for these series of 
compounds showed intriguing results, emphasized just below: 
(i) The compounds of series 1 (the oxamic acid derivatives) are among 
the best inhibitors for both enzymes (PTP1B and LMW-PTP), but the spacer between 
aromatic ring and the functional organic group is a critical issue. Compounds with two 





methylene as spacer are less powerful inhibitors for both enzymes. Compounds 
without any spacer are active only against PTP1B. 
(ii) A compound of series 2 (sulfamic acid derivatives, in this case, 
KSR-1 & 3) are among the best inhibitors for both enzymes: PTP1B and LMW-PTP. 
(iii) Some compounds of series 3 (isooxazolecarboxylic acids) are good 
inhibitors for PTP1B, but none of them are among the best inhibitors for LMW-PTP. 
(iv) Series 4 (thioacetic acids) presents good inhibitors for PTP1B, but 
they aren’t  good ones for LMW-PTP. 
(v) Compounds of series 5 (the N-(2-(1H-benzo[d]imidazol-2-
ylthio)acetamido)benzoic acid derivatives) were precipitated for both enzymes 
(PTP1B and LMW-PTP). 
(vi) Some compounds of series 6 (phosphonic acid derivatives) are 
among the best inhibitors for PTP1B, but few of them are among the best inhibitors 
for LMW-PTP. 
(vii) Some compounds of series 7 (sulfonic acids) are among the best 
inhibitors for PTP1B, but few of them are among the best inhibitors for LMW-PTP. 
(viii) Some compounds of series 8 (boronic acids) are among the best 
inhibitors for PTP1B as well as LMW-PTP, but if it bears a spacer of one methylene 
group precipitated both enzymes.  
(ix) Some compounds of series 9 (the carboxylic acids) that carry a 
spacer of one or two methylene group are among the good  inhibitors for PTP1B, but 
none of them are among the best inhibitors for LMW-PTP. 
(x) Some compounds of series 10 (mandelic acids) are better inhibitors 
for PTP1B than LMW-PTP. 
(xi) None of the studied compounds (series 1–10) was capable to inhibit 
CDC25B considerably. 
 
3.6.2. Quantitative Structure-Activity Relationship (QSAR) 
 
The IC50 values for the selected compounds were used to accomplish 
QSAR analysis against PTP1B. All studied compounds are showed in Table 14. We 
chose ISIDA/QSPR Software to perform this study because it uses a “Substructural 
Molecular Fragments” (SMF) approach during QSAR modeling.[150–152] The SMF 





contribution of each small substructure to a given property. 
ISIDA/QSPR requires a set of molecular structures and their respective 
properties (in our case the IC50 values) as a chemical database file (a “.sdf” or similar 
file created from any chemical database engine). Moreover, the program also 
requires some inputs to guide the calculation (training group molecules, validation 
group molecules, statistical parameters, fragment descriptors, correlation equation, 
etc.). After several attempts we chose using “atoms and bonds” as fragment 
descriptors,[153, 154] and linear fitting equation with a fragment independent term 





Where  is the contribution of fragment "i",  is the total amount of 
fragments "i" in each molecule, and, as said before,  is the linear coefficient term. 
The  term is the same for corresponding fragment for all compounds within the 







Figure 32. User defined options used as input on ISIDA/QSPR 
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Table 14 – Studied compounds in Quantitative Structure Activity 
Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






1 0.9971 KAM-2 
 
2 0.107 KSR-0 
 
3 0.6751 KSR-0a 
 
4 2.173 KSR-0b 
 
5 1.524 MK-3 
 
6 1.062 MK-10 
 
7 0.3123 MK-5 
 
8 1.518 KSR-1 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






10 0.3087 KM-14 
 
11 0.8593 MK-40 
 
12 0.002334 MK-38 
 
13 1.187 MK-12 
 
14 1.031 MK-27 
 
15 0.9185 MK-28 
 
16 0.1839 MK-35 
 
17 0.2298 KAM-10 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






19 0.5274 MK-6 
 
20 0.328 KSR-6g 
 
21 0.3258 KSR-6i 
 
22 1.36 MKR-31a 
 
23 0.9689 KM-9 
 
24 1.183 KSR-6h 
 
25 0.1549 KSR-0f 
 















Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






27 1.186 MKR-41a 
 
28 0.4245 KSR-6 
 
29 0.1340 MKR-20a 
 
30 0.1776 KAM-3 
 
31 0.2450 KAM-12 
 
32 0.4037 KAM-8 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






34 2.108 MK-1 
 
35 0.9090 MK-2 
 
36 1.542 MK-47 
 
37 1.034 MK-11 
 
38 0.4734 MK-7a 
 
39 2.221 MK-29 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






41 1.357 MK-13 
 
42 0.9346 MK-48 
 
43 0.7158 KM-1 
 
44 2.064 MK-21 
 
45 0.2328 MK-25 
 
46 0.3157 MK-26 
 
47 1.211 MK-45 
 
48 0.8504 MKR-9a 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






50 0.2281 MKR-23a 
 
51 0.1823 MKR-7a 
 
52 0.4472 MKR-40a 
 
53 0.5341 MKR-26a 
 
54 0.3185 MKR-5a 
 
55 0.6819 KM-21 
 
56 0.6489 KM-2 
 
57 0.2178 MK-37 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






59 0.4424 MKR-42a 
 
60 0.1113 MKR-36a 
 
61 0.4935 KSR-6e 
 
62 0.1794 KSR-6b 
 
63 0.08954 KSR-6f 
 
64 0.4847 KSR-6c 
 






Table 14 (continuation) – Studied compounds in Quantitative Structure 
Activity Relationship (QSAR) modelling using ISIDA-QSPR software. 
 
Compound 






66 1.295 MKR-50a 
 
67 0.1256 MKR-37a 
 
68 0.6214 KM-15 
 





Usually, ISIDA/QSPR builds up to 1276 structure-property models 
involving four linear and non-linear fitting equations and 315 molecular descriptors to 
perform the analysis. All these 315 descriptors along with their brief meaning, 
cumulative incidence, and average regression coefficients (which will serve as a 
measure of their estimate across these models) are considered during the calculus. 
These models have accounted for up to 81.26 (R2=0.8126) percent variance in the 
observed inhibition, root-mean-squared error (RMSE) of 0.4384, and mean absolute 
error (MAE) of 0.3668. The whole equation would have 316 terms and would be 
impracticable to deal. Nevertheless, linear regression for the total data set in the 
present study demonstrated that the fragment descriptors (CO-6-O, B-5*CB, CB*3-
CO, Cl-8-O, O-8=O, F-7-O, and CB*8-CO) appear to be the governing factors for the 
enzyme inhibition as shown in Table 15 and Figure 34. Used notation for fragment 
identification is based on Carhart’s description,[155] in which CO-6-O means a 





indicates an aromatic carbon, “=O” is a sp2 oxygen, and “*” is an aromatic double 
bond.[155] CO-6-O substructure has the highest influence on PTP-1B inhibition. On 
the other hand, B-5*CB substructure, which means a boron atom five bonds away 
from an aromatic carbon atom, has the second highest influence. 
Table 15 shows that B-5*CB, CB*3-CO, and CB*8-CO are the principal 
molecular descriptor reducing PTP1B IC50 values. On the other hand, CO-6-O, Cl-8-
O, O-8=O, and F-7-O are the chief molecular descriptor increasing PTP1B IC50 
values. 
 
Table 15. Leading fragments governing PTP1B inhibition 
Term Contribution Standard deviation 
 0.72479 0.08125 
CO-6-O 0.64575 0.28883 
B-5*CB -0.44245 0.16782 
CB*3-CO -0.34308 0.14585 
Cl-8-O 0.28868 0.09519 
O-8=O 0.16614 0.07280 
F-7-O 0.16346 0.06063 









As an example of substructure counting by ISIDA/QSPR, MKR-18 (Figure 
34, entry 58 in Table 14, as well as in compound chemical database and the 
equation outlined at Figure 33), has experimental IC50 0.07018 and predicted IC50 
0.06040 (difference of 0.00978). The primary substructure counting for MKR-18 
during its evaluation were O-8=O (once), F-7-O (four times) and CB*8-CO (twice), 
and CB*3-CO (three times), as depicted at Figure 34. Cumulative value considering 
only these four substructures and the independent term would give +0.22037 
(0.72479+10.16614+40.16346-2-0.14758-3-0.34308) as result. Of course, there 
are many other terms to be counted, and the predicted value obtained using this 
model was actually 0.06040. In Figure 34 substructures with red colour reduce IC50 








4. Experimental description 
 




Docking results were used to understand the binding mode of compounds 
into the enzyme active site and to select the priority compounds for synthesis step. 
More than one hundred structures of PTP1B with different ligands have been 
downloaded from the PDB and carefully analyzed by using Pymol software v1.5 
(http://pymol.org/).[156] According to the literature and crystallographic data of 
PTP1B, we proposed more than 2500 compounds to be evaluated. All programs 
were excuted under Linux Slackware, version 13:37, in the Structural Biology 
Laboratory of Crystallography - LaBEC, Institute of Chemistry / UNICAMP. 
The crystallographic data file PDB ID: 2F71, which contains the inhibitor 
1,2,3,4-tetrahydroisoquinolinyl sulfamic acid in the active site,[136a]  was selected for 
the simulation.  Using this results, we have designed five small molecule series as 
new chemotypes for synthesis such as (N-phenylamino)oxoacetic acids (series 1), 
N-phenylsulfamic acids (series 2), isoxazole carboxylic acids (series 3), and 
thioacetic acids (series 4). Based on the docking studies and inhibition assays of 
these four series results, we proposed and synthesised a new series of N-(2-(1H-
benzo[d]imidazol-2-ylthio)acetamido)benzoic acids (series 5) using the Fragment-
Based Drug Discovery (FBDD) approach.[72–74, 79b] The docking study of series 5 
compounds suggested to have suitable features to act as inhibitors against PTP1B. 
To highlight structural similarities and differences between the different 
ligands, their mode of binding in the PTP1B active site was also studied by docking. 
Schematic diagrams of protein-ligand interactions were calculated and visualized 
with the program LigPlot+.[157, 158] For better understanding, the plots generated 
were presented as showed in Figures 25–29 and Appendix I in this work. These five 
series of compounds have been chosen because they presented good shape and 
chemical complementary with the active site (P-loop) through hydrogen bonds with 
amino acid residues located at the bottom of the active site pocket. They also 
presented hydrophobic interactions established with amino acid residues. LigPlot+ 





used to make 2D representation of the protein-ligand interactions which show 
hydrogen bond, hydrophobic, van der Waals as well as π- stacking.  
FRED v2.2.5 [159] (Fast Rigid Exhaustive Docking - Academic License 
obtained from the OpenEye Scientific Software) was used to determine possible 
positions for a set of designed compounds, resulting in a final list with the score for 
each compound. FRED is a docking program for rigid structures. So, the evaluation 
of the flexibility of the compound required a multiconformational collection of each 
molecule as input file. For this reason, the set of compounds was subjected to a 
protocol for the generation of 3D conformations using the programs Makefraglib 
v.2.4.3 and OMEGA (OMEGA version 2.4.3. OpenEye Scientific Software, Santa Fe, 
NM, http://www.eyesopen.com).[160, 161] 
The simulation was performed in the FRED_RECEPTOR module that 
comes with the package FRED program. Here, water and ligand molecules were 
removed from protein structure, and the active site was defined. This area is 
surrounded and guided by catalytic triad the protein. FRED docks all conformers at a 
single receptor using an exhaustive search algorithm. After that, the top scoring 
poses are optimized and assigned with a final score. Chemgauss3 was used in both 




All solvents were treated according to procedures outlined by Armarego 
and Chai.[164] Organic layers were dried over anhydrous Na2SO4. Concentration 
under reduced pressure was performed by rotary evaporation (~30 torr) at 20–40 °C. 
Flash column chromatography was performed as described elsewhere,[165] 
employing Merck silica gel 60 (spherical, diameter range 40–100 µm). Analytical thin-
layer chromatography (TLC) was performed on Merck analytical plates pre-coated 
with silica gel 60 F254 (0.25 mm thick). TLC plates were visualized by exposure to 
ultraviolet light (UV) and/or exposure to phosphomolybdic acid solution followed by 
brief heating on a hot plate. Infrared (IR) spectra were recorded on a Therm Scientific 
Nicolet iS5 Fourier transform spectrophotometer and are reported in wavenumbers 
(cm–1). Proton nuclear magnetic resonance (1H–NMR) spectra and carbon nuclear 
magnetic resonance (13C–NMR) spectra were determined on Brüker (5.9 T, 9.4 T, 





downfield from tetramethylsilane as the internal standard and coupling constants 
were in hertz (Hz). The following abbreviations were used for spin multiplicity: s = 
singlet, d = doublet, t = triplet, m = multiplet, br = broad. High resolution mass 
spectrometry (HRMS) analyses were carried out in a Waters Micromass-Q-TOF 
(ESI/APCI, negative mode, unless stated otherwise), Ultra high-resolution Fourier 
transform ion cyclotron resonance mass spectrometer (FT–ICR Ultra, ESI/MS, 
negative mode, unless stated otherwise), or Fourier Transform Mass Spectrometry 
(FTMS–LTQ Orbitrap XL–ESI, negative mode, unless stated otherwise). 
 
4.2.1. General procedure for the synthesis of substituted (N-phenylamino) 
oxoacetic acids (series 1) 
 
Triethylamine (1.2 mmol) was added to a well stirred solution of the aniline 
(1.0 mmol) in dichloromethane (25 ml). The solution was cooled to 0 °C and 
ethyloxalyl chloride (1.0 mmol) was added dropwise. The reaction mixture was stirred 
at room temperature for 24 h until the starting materials disappeared. After that, the 
reaction mixture was diluted with 30 ml of dichloromethane and washed with 1M aq. 
HCl, followed by aqueous. NaHCO3 and brine solution. The organic layer was 
separated, dried over Na2SO4, and volatiles were removed under reduced pressure 
to furnish o, m, p - substituted (N-phenylamino)oxoacetic acid ethyl ester.[94, 134]   
The isolated ester prepared above was dissolved in 30 ml of THF and 1M 
NaOH solution (25 ml) was added to the medium. The reaction mixture was stirred 
for 72 h at room temperature.[94, 134]  After that, it was washed with diethyl ether 
and the aqueous layer had its pH adjusted to 1.0–2.0 with conc.HCl. The product 
was extracted with ethyl acetate and the extracts were dried over Na2SO4 prior to 
evaporation of the solvent in a rotary evaporator to obtain the substituted (N-
phenylamino)oxoacetic acid as a white solid. 
  
4.2.1.1. 2-[(2-Fluorophenyl)amino]-2-oxoacetic acid (MKR-24a) 
 
 
Yield 52%; Found m.p. 119–123 °C; 1H NMR (CD3OD, 400 MHz): δH 





162.6, 158.1, 155.7 [d, br, 1J(13C–19F) = 244.9 Hz], 128.1 [d, 3J(13C–19F) = 7.7 Hz], 
125.9 [d, 2J(13C–19F) = 11.3 Hz],125.7 [d, 4J(13C–19F) = 3.7 Hz], 125.0, 116.7 [d, 
2J(13C–19F) = 19.4 Hz]; 19F NMR (CD3OD, 470 MHz): δ (ppm) -128.1 (s); IR (ATR) 
max = 3378, 3228, 1760, 1695, 1620, 1595, 1542, 1487, 1459, 1346, 1252, 1178, 
1102, 1035, 944, 927, 850, 792, 748, 673 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: 
calcd. for C8H6FNO3 [M–H]– = 182.02535; observed [M–H]– = 182.02519. 
 
4.2.1.2. 2-[(3-Fluorophenyl)amino]-2-oxoacetic acid (MKR-28a) 
 
 
Yield 32%; Found: the m.p. was not observed up to 290 °C; 1H NMR 
(DMSO-d6, 500 MHz): δH (ppm) 7.73 (dt, J = 11.8 and 2.1 Hz, 1H), 7.57 (dd, J = 8.2  
and 0.8 Hz, 1H), 7.33 (q, J = 8.1 Hz, 1H), 6.88 (td, J = 8.5 and 2.1 Hz, 1H); 13C NMR 
(DMSO-d6, 125 MHz): δC (ppm) 162.7, 162.1, 162.1 [d, br, 1J(13C–19F) = 239.5 Hz], 
140.3 [d, 3J(13C–19F) = 11.0 Hz], 130.2 [d, 3J(13C–19F) = 9.5 Hz], 115.5 [d, 4J(13C–19F) 
= 2.4 Hz], 110.0 [d, 2J(13C–19F) = 20.9 Hz], 106.3 [d, 2J(13C–19F) = 26.1 Hz]; 19F NMR 
(DMSO-d6, 235 MHz): δ (ppm) -112.4 (s); IR (ATR) max = 3351, 3338, 3310, 1683, 
1617, 1600, 1541, 1494, 1451, 1397, 1259, 1208, 1136, 967, 864, 843, 767, 740, 
710 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H6FNO3 [M–H]– = 
182.02535; observed [M–H]– = 182.02533. 
 
4.2.1.3. 2-[(4-Fluorophenyl)amino]-2-oxoacetic acid (MKR-25a) 
 
 
Yield 39.5%; Found m.p. 155–159 °C, lit. 168–169 °C[166]; 1H NMR 
(CD3OD, 250 MHz): δH (ppm) 7.74–7.66 (m, 2H), 7.12–7.02 (m, 2H); 13C NMR 
(CD3OD, 62.5 MHz): δC (ppm) 163.0, 161.4 (d, br, 1J(13C–19F) = 241.8 Hz), 158.1, 
134.7 (d, 4J(13C–19F) = 2.6 Hz), 123.8 (d, 3J(13C–19F) = 8.0 Hz), 116.5 (d, 2J(13C–19F) 
= 22.6 Hz); 19F NMR (CD3OD, 235 MHz): δ (ppm) -119.0 (s); IR (ATR) max = 3332, 
1674, 1552, 1511, 1271, 1243, 1215, 1186, 1159, 1101, 1021,  837, 787, 728 cm-1; 







4.2.1.4. 2-[(Pentafluorophenyl)amino]-2-oxoacetic acid (MKR-17a) 
 
 
Yield 20%; Found m.p. 152–154 °C; 13C NMR (CD3OD, 100 MHz): δC 
(ppm) 161.6, 159.4, 144.9 (d, br, 1J(13C–19F) = 237.7 Hz, 1C), 142.0 (d, br, 1J(13C–
19F) = 246.2 Hz, 1C), 139.3 (d, br, 1J(13C–19F) = 250.2 Hz, 1C), 113.1 (t, 2J(13C–19F) = 
13.3 Hz, 1C); 19F NMR (CD3OD, 235 MHz): δ -148.2 (d, 3J(19F–19F) = -15.8 Hz), -
160.8 (t, 3J(19F–19F) = -20.5 Hz), -167.3 (t, 3J(19F–19F) = -18.1 Hz); IR (ATR) max = 
3312, 3248, 1762, 1713, 1652,  1546, 1528, 1503, 1455, 1355, 1260, 1234, 1188, 
1153, 1012, 994, 937, 729, 681 cm-1; HRMS (ESI–TOF) m/z: calcd. for C8H2F5NO3 
[M–H]– = 253.9877; observed [M–H]– = 253.9917. 
 
4.2.1.5. 4-(Carboxyformamido)- 2, 3, 5, 6-tetrafluorobenzoic acid (MKR-18a) 
 
 
Yield 15%; Found m.p. 178–180.2 °C; 13C NMR (CD3OD, 100 MHz): δC 
(ppm) 164.0, 149.0, 146.5, 137.3 [d, br, 1J(13C–19F) = 236.1 Hz], 137.1 [d, br, 1J(13C–
19F) = 229.5 Hz], 133.5, 98.4 [m, 2J(13C–19F) = 13.9 Hz]; 19F NMR (CD3OD, 470 
MHz): δ (ppm) -144.1 [d, 3J(19F–19F) = -12.4 Hz], -165.5 [d, 3J(19F–19F) = -12.3 Hz]; IR 
(ATR) max = 3525, 3417, 2972, 2898, 2640, 2557, 1686, 1643, 1606, 1537, 1496, 
1415, 1342, 1308, 1257, 1162, 1107, 941, 925, 784, 728 cm-1; FT–ICR Ultra 







4.2.1.6. 2-[(3-Chlorophenyl)amino]-2-oxoacetic acid (MKR-9a) 
 
 
Yield 35%; Found m.p. 137–140.1 °C, lit. 145 °C[167]; 1H NMR (CD3OD, 
250 MHz): δH (ppm) 7.86 (t, J = 1.9 Hz, 1H), 7.59 (dd, J = 8.2 and 0.8 Hz, 1H), 7.32 
(t, J = 8.1 Hz, 1H), 7.16 (dd, J = 8.0 and 0.9 Hz, 1H); 13C NMR (CD3OD, 62.5 MHz): 
δC (ppm) 162.8, 158.3, 140.0, 135.6, 131.3, 126.2, 121.6, 120.0; IR (ATR) max = 
3316, 3235, 1751, 1673, 1596, 1537, 1477, 1425, 1357, 1307, 1206, 1177, 873, 779 
cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H6ClNO3 [M–H]– = 197.99580, 
[(M+2)–H]– = 199.99285; observed [M–H]– = 197.99554, [M+2]––H = 199.99181. 
 
4.2.1.7. 2-[(4-Chlorophenyl)amino]-2-oxoacetic acid (MKR-10a) 
 
 
Yield 28%; Found m.p. 183–185 °C, lit. 190–191 °C[168]; 1H NMR 
(CD3OD, 500 MHz): δH (ppm) 7.72 (d, J = 8.9 Hz, 2H), 7.35 (d, J = 8.9 Hz, 2H); 13C 
NMR (CD3OD, 125 MHz): δC (ppm) 163.2, 158.7, 137.6, 131.3, 130.0, 123.2; IR 
(ATR) max = 3318, 3236, 1754, 1681, 1601, 1550, 1494, 1411, 1362, 1310, 1235, 
1210, 1180, 1089, 1013, 925, 823, 776, 741 cm-1; HRMS (ESI–TOF) m/z: calcd. for 
C8H6ClNO3 [M–H]– = 197.9958, [(M+2)–H] – = 199.9931; observed [M–H]– = 
197.9997, [(M+2)–H]– = 199.9984. 
 
4.2.1.8. 2-[(2-Bromophenyl)amino]-2-oxoacetic acid (MKR-23a) 
 
Yield 29%; Found m.p. 126–130 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 8.14 (dd, J = 8.2 and 1.4 Hz, 1H), 7.63 (dd, J = 8.0 and 1.2 Hz, 1H), 7.37 (td, J 
= 8.2 and 1.3 Hz, 1H), 7.11 (td, J = 7.7 and 1.5 Hz, 1H); 13C NMR (CD3OD, 62.5 
MHz): δC (ppm) 162.7, 157.5, 136.0, 134.0, 129.6, 128.2, 124.1, 116.4; IR (ATR) max 





949, 867, 845, 758,  688 cm-1; HRMS (ESI–TOF) m/z: calcd. for C8H6BrNO3 [M–H]– = 
241.9453, [(M+2)–H]– = 243.9433; observed [M–H]– = 241.9450, [(M+2)–H]– = 
243.9435. 
 
4.2.1.9. 2-[(3-Bromophenyl)amino]-2-oxoacetic acid (MKR-7a) 
 
 
Yield 68%; Found m.p. 136–139 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 8.02 (t, J = 1.9 Hz, 1H), 7.65 (ddd, J = 8.0, 1.9 and 1.2 Hz, 1H), 7.32 (dt, J = 
8.0 and 1.5 Hz, 1H), 7.26 (t, J = 8.0 Hz, 1H); 13C NMR (CD3OD, 100 MHz): δC (ppm) 
162.8, 158.4, 140.2, 131.6, 129.2, 124.6, 123.4, 120.4; IR (ATR) max = 3333, 3314, 
3230, 1765, 1755, 1673, 1590, 1545, 1477, 1354, 1276, 1200, 1177, 998, 918, 883, 
869, 844, 778, 674 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H6BrNO3 
[M–H]– = 241.94528, [(M+2)–H]– = 243.94323; observed [M–H]– = 241.94623, 
[(M+2)–H]– = 243.94304. 
 
4.2.1.10. 2-[(4-Bromophenyl)amino]-2-oxoacetic acid (MKR-8a) 
 
 
Yield 68%; Found m.p. 194–196 °C, lit. 194–195 °C[166]; 1H NMR 
(CD3OD, 500 MHz): δH (ppm) 7.66 (dd, J = 6.9 and 1.9 Hz, 2H), 7.49 (dd, J = 7.0 and 
1.9 Hz, 2H); 13C NMR (CD3OD, 125 MHz): δC (ppm) 162.9, 158.2, 138.0, 133.1, 
123.6, 119.0; IR (ATR) max = 3321, 3236, 1766, 1752, 1682, 1595, 1547, 1491, 
1406, 1358, 1305, 1235, 1208, 1179, 1074, 1010, 925, 815, 769, 736 cm-1; HRMS 
(ESI–TOF) m/z: calcd. for C8H6BrNO3 [M–H]– = 241.9453, [(M+2)–H]– = 243.9433; 






4.2.1.11. 2-[(2-Iodophenyl)amino]-2-oxoacetic acid (MKR-26a) 
 
 
Yield 28.5%; Found m.p. 159–160.9 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 8.0 (dd, J = 8.1 and 1.5 Hz, 1H), 7.90 (dd, J = 7.9 and 1.3 Hz, 1H), 7.42 (td, J 
= 7.8 and 1.4 Hz, 1H), 6.99 (td, J = 7.8 and 1.5 Hz, 1H); 13C NMR (CD3OD, 100 
MHz): δC (ppm) 162.8, 157.9, 140.7, 139.2, 130.4, 128.8, 124.4, 92.7; IR (ATR) max = 
3265, 1770, 1689, 1585, 1540, 1484, 1457, 1437, 1342, 1293, 1202, 1176, 1084, 
1015, 942, 915, 866, 760, 745, 685 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. 
for C8H6INO3 [M–H]– = 289.93141; observed [M–H]– = 289.93097. 
 
4.2.1.12. 2-[(3-Iodophenyl)amino]-2-oxoacetic acid (MKR-5a) 
 
 
Yield 23.3%; Found m.p. 168.8–170 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 8.18 (t, J = 1.8 Hz, 1H), 7.68 (ddd, J = 8.2, 2.0 and 0.8 Hz, 1H),  7.51 (ddd, J = 
7.9, 1.4 and 0.9 Hz, 1H), 7.11 (t, J = 8.1 Hz, 1H); 13C NMR (CD3OD, 125 MHz): δC 
(ppm) 162.8, 158.3, 139.9, 131.6, 130.5, 121.0, 94.6; IR (ATR) max = 3309, 3213, 
1753, 1682, 1588, 1548, 1476, 1369, 1207, 1181, 998, 929, 771, 752, 672 cm-1; 
FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H6INO3 [M–H]– = 289.93141; 
observed [M–H]– = 289.93155. 
 
4.2.1.13. 2-[(4-Iodophenyl)amino]-2-oxoacetic acid (MKR-40a) 
 
 
Yield 43%; Found m.p. 198.8–200 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.70–7.67 (m, 2H), 7.55–7.51 (m, 2H); 13C NMR (CD3OD, 100 MHz): δC (ppm) 
162.9, 158.2, 139.2, 138.6, 123.7, 89.5; IR (ATR) max = 3324, 3245, 1750, 1682, 
1589, 1538, 1485, 1352, 1305, 1205, 1173, 1062, 1006, 925, 814 cm-1; FTMS (LTQ 







4.2.1.14. 2-[(3-Hydroxyphenyl)amino]-2-oxoacetic acid (MKR-12a) 
 
 
Yield 32%; Found m.p. 192–195 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.31–7.29 (m, 1H), 7.15 (t, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.63–6.60 
(m, 1H); 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 163.1, 159.1, 157.9, 139.5, 130.8, 
113.5, 113.0, 108.9; IR (ATR) max = 2493, 2461, 1732, 1676, 1598, 1551, 1469, 
1283, 1261, 1209, 1150, 1080, 1004, 955, 866, 779, 716, 677 cm-1; HRMS (ESI–
TOF) m/z: calcd. for C8H7NO4 [M–H]– = 180.0297; observed [M–H]– = 180.0353. 
 
4.2.1.15. 2-[(4-Hydroxyphenyl)amino]-2-oxoacetic acid (MKR-13a) 
 
 
Yield 26%; Found m.p. 193.2–194.5 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.49 (d, J = 8.9 Hz, 2H), 6.77 (d, J = 8.9 Hz, 2H); 13C NMR (CD3OD, 62.5 
MHz): δC (ppm) 163.2, 157.7, 156.3, 130.4, 123.6, 116.4; IR (ATR) max = 3308, 
1760, 1675, 1556, 1516, 1452, 1338, 1311, 1243, 1175, 1109, 927, 836, 790, 748, 
686 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H7NO4 [M–H]– = 
180.02968; observed [M–H]– = 180.03036. 
 
4.2.1.16. 2-[(2-Methoxyphenyl)amino]-2-oxoacetic acid (MKR-11a) 
 
 
Yield 43%; Found m.p. 148.8–149.4 °C, lit. 148–149.5 °C[168]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 8.23 (dd, J = 8.1 and 1.3 Hz, 1H), 7.16 (td, J = 8.4 and 
1.3 Hz, 1H),  7.06 (d, J = 7.6, 1H), 7.0 (td, J = 8.0 and 0.8 Hz, 1H), 3.93 (s, 3H); 13C 
NMR (CD3OD, 62.5 MHz): δC (ppm) 162.9, 156.8, 150.5, 127.2, 126.9, 121.8, 121.1, 





1292, 1250, 1197, 1024, 937, 755, 737 cm-1; HRMS (ESI–TOF) m/z: calcd. for 
C9H9NO4 [M–H]– = 194.0453; observed [M–H]– = 194.0507. 
 
4.2.1.17. 2-[(3-Methoxyphenyl)amino]-2-oxoacetic acid (MKR-31a) 
 
 
Yield 35%; Found m.p. 165–168 °C, lit. 173–174 °C[168]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.40–7.39 (m, 1H), 7.25–7.23 (m, 2H), 6.75–6.72 (m, 
1H); 13C NMR (CD3OD, 100 MHz): δC (ppm) 163.0, 161.7, 158.1, 139.7, 130.8, 
114.0, 112.1, 107.6, 55.9; IR (ATR) max = 3335, 3171, 1751, 1689, 1612, 1559, 
1499, 1374, 1344, 1260, 1220, 1194, 1160, 1084, 1034, 903, 848, 841, 774, 736, 
710, 682 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C9H9NO4 [M–H]– = 
194.04533; observed [M–H]– = 194.04472. 
 
4.2.1.18. 2-[(4-Ethoxyphenyl)amino]-2-oxoacetic acid (MKR-51a) 
 
 
Yield 23%; Found m.p. 176–178.9 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.60–7.56 (m, 2H), 6.90–6.86 (m, 2H), 4.01 (q, J = 7.0 Hz, 2H), 1.36 (t, J = 7.0 
Hz, 3H); 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 163.2, 158.0, 157.8, 131.5, 123.4, 
115.7, 64.8, 15.3; IR (ATR) max = 3349, 3324, 3256, 3077, 2986, 2876, 1756, 1675, 
1548, 1514, 1479, 1359, 1310, 1253, 1213, 1178, 1117, 1081, 1054, 919, 842, 824, 
797, 769 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C10H11NO4 [M–H]– = 
208.06098; observed [M–H]– = 208.06221. 
 
4.2.1.19. 2-[(2-Methylphenyl)amino]-2-oxoacetic acid (MKR-55a) 
 
 
Yield 54%; Found m.p. 103–106 °C; 1H NMR (CD3OD, 250 MHz): δH 





MHz): δC (ppm) 163.1, 158.5, 135.9, 133.6, 131.8, 128.0, 127.6, 125.8, 17.9; IR 
(ATR) max = 3264, 1758, 1684, 1590, 1537, 1492, 1459, 1361, 1298, 1257, 1219, 
1195, 1178, 1114, 1051, 1032, 954, 933, 782, 748, 719 cm-1; FTMS (LTQ Orbitrap 
XL–ESI) m/z: calcd. for C9H9NO3 [M–H]– = 178.05042; observed [M–H]– = 
178.05052. 
 
4.2.1.20. 2-[(3-Methylphenyl)lamino]-2-oxoacetic acid (MKR-52a) 
 
 
Yield 29%; Found m.p. 116–121 °C, lit. 123 °C[167]; 1H NMR (CD3OD, 
500 MHz): δH (ppm) 7.52 (s, 1H), 7.50 (d, J = 8.1 Hz, 1H), 7.22 (t, J = 7.8 Hz, 1H), 
6.98 (d, J = 7.5 Hz, 1H), 2.33 (s, 3H); 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 163.3, 
158.3, 140.1, 138.5, 129.9, 127.1, 122.0, 118.9, 21.6; IR (ATR) max = 3340, 3307, 
3228, 1755, 1673, 1595, 1553, 1492, 1455, 1359, 1314, 1293, 1254, 1210, 1184, 
1035, 938, 919, 900, 791, 779, 735, 683 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: 
calcd. for C9H9NO3 [M–H]– = 178.05042; observed [M–H]– = 178.05072. 
 
4.2.1.21. 2-[(p-Toluidino)amino]-2-oxoacetic acid (MKR-19a)  
 
 
Yield 58%; Found m.p. 165.9–168.9 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.57 (d, J = 6.8 Hz, 2H), 7.16 (d, J = 6.8 Hz, 2H), 2.32 (s, 3H); 13C NMR 
(CD3OD, 125 MHz): δC (ppm) 163.2, 158.0, 136.4, 136.0, 130.5, 121.9, 21.1; IR 
(ATR) max = 3325, 3235, 1759, 1681, 1599, 1549, 1513, 1355, 1318, 1240, 1202, 
1172, 922, 818, 777, 732 cm-1; HRMS (ESI–TOF) m/z: calcd. for C9H9NO3 [M–H]– = 






4.2.1.22. 2-[(Quinolin-3-yl)amino]-2-oxoacetic acid (MKR-33a)  
 
 
Yield 63.5%; Found m.p. 227–229 °C; 1H NMR (DMSO-d6, 500 MHz): δH 
(ppm) 11.28 (s, -NH), 9.20 (d, J = 2.4 Hz, 1H), 8.88 (d, J = 2.0 Hz, 1H), 8.02 (dd, J = 
3.3 Hz , 2H), 7.74 (td, J = 7.7 and 1.1 Hz, 1H), 7.64 (t, J = 7.5 Hz, 1H); 13C NMR 
(DMSO-d6, 125 MHz): δC (ppm) 161.6, 157.5, 144.4, 143.3, 131.7, 129.2, 128.1, 
127.6, 127.4, 125.3; IR (ATR) max = 3271, 1716, 1673, 1609, 1570, 1491, 1392, 
1357, 1279, 1240, 1197, 1175, 1153, 963, 907, 767, 752, 713 cm-1; HRMS (ESI–
TOF) m/z: calcd. for C11H8N2O3 [M–H]– = 215.0457; observed [M–H]– = 215.0509. 
 
4.2.1.23. 2-(Thiazol-2-ylamino)-2-oxoacetic acid (MKR-54a)  
 
 
Yield 15%; Found m.p. 219–224 °C; 1H NMR (DMSO-d6, 500 MHz): δH 
(ppm) 7.55 (d, J = 3.5 Hz, 1H), 7.33 (s, J = 3.5 Hz, 1H); 13C NMR (DMSO-d6, 125 
MHz): δC (ppm) 161.2, 158.2, 157.5, 138.1, 115.1; IR (ATR) max = 3123, 3098, 1693, 
1553, 1428, 1328, 1285, 1251, 1180, 949, 831, 778 cm-1; FTMS (LTQ Orbitrap XL–
ESI) m/z: calcd. for C5H4N2O3S [M–H]– = 170.98644; observed [M–H]– = 170.98634. 
 
4.2.1.24. 2-[(4-Bromobenzyl)amino]-2-oxoacetic acid (MKR-42a) 
 
 
Yield 18%; Found m.p. 167–169 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.46 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.3 Hz, 2H), 4.40 (s, 2H); 13C NMR 





(ATR) max = 3277, 2450, 2411, 1757, 1733, 1684, 1540, 1488, 1454, 1407, 1370, 
1301, 1248, 1203, 1178, 1071, 1011, 999, 942, 825, 797, 734 cm-1; FTMS (LTQ 
Orbitrap XL–ESI) m/z: calcd. for C9H8BrNO3 [M–H]– = 255.96093, [(M+2)–H]– = 
257.95888; observed [M–H]– = 255.96246, [(M+2)–H]– = 257.95905. 
 
4.2.1.25. 2-[(3-nitrobenzyl)amino]-2-oxoacetic acid (MKR-38a) 
 
 
Yield 17%; Found m.p. 154.8–158.5 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 8.19 (s, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 7.5 Hz, 1H), 7.57 (t, J = 7.8 
Hz, 1H), 4.55 (s, 2H); 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 162.7, 160.7, 149.9, 
141.8, 135.1, 131.0, 123.6, 123.4, 43.7; IR (ATR) max = 3370, 2920, 2848, 1683, 
1527, 1478, 1433, 1350, 1312, 1290, 1247, 1097, 1017, 806, 742, 696, 672 cm-1; 
FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C9H8N2O5 [M–H]– = 223.03550; 
observed [M–H]– = 223.03638. 
 
4.2.1.26. 4-[(Carboxyformamido)methyl]benzoic acid (MKR-50a) 
 
 
Yield 18.5%; Found m.p. 213.5–215 °C; 1H NMR (DMSO-d6, 500 MHz): δH 
(ppm) 9.43 (t, J = 6.3 Hz, -NH), 7.90 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.2 Hz, 2H); 13C 
NMR (DMSO-d6, 125 MHz): δC (ppm) 167.2, 162.1, 158.6, 143.7, 129.5, 127.4, 42.3; 
IR (ATR) max = 3269, 1765, 1679, 1613, 1553, 1427,  1364, 1341, 1319, 1294, 1256, 
1182, 1118, 1062, 1018, 995, 942, 852, 828, 803, 779, 757 cm-1; FTMS (LTQ 






4.2.1.27. 2-[(2-Methoxybenzyl)amino]-2-oxoacetic acid (MKR-41a) 
 
 
Yield 16%; Found m.p. 95.7–98.9 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.24 (td, J = 7.5 and 1.5 Hz, 1H), 7.20 (d, J = 7.4 Hz, 1H), 6.94 (d, J = 8.2 Hz, 
1H), 6.90 (t, J = 7.5 Hz, 1H), 4.44 (s, 2H), 3.83 (s, 3H); 13C NMR (CD3OD, 100 MHz): 
δC (ppm) 162.9, 160.0, 158.8, 130.1, 129.7, 126.5, 121.6, 111.6, 56.0, 40.1; IR (ATR) 
max = 3282, 2945, 2837, 2444, 1766, 1675, 1604, 1543, 1495, 1462, 1437, 1371, 
1346, 1290, 1247, 1182, 1049, 1031, 991, 795, 754 cm-1; FTMS (LTQ Orbitrap XL–
ESI) m/z: calcd. for C10H11NO4 [M–H]– = 208.06098; observed [M–H]– = 208.06065. 
 
4.2.1.28. 2-[(2-Methylbenzyl)amino]-2-oxoacetic acid (MKR-44a) 
 
 
Yield 25%; Found m.p. 156–159.7 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.23–7.21 (m, 1H), 7.16–7.12 (m, 3H), 4.45 (s, 2H), 2.32 (s, 3H); 13C NMR 
(CD3OD, 100 MHz): δC (ppm) 162.9, 160.2, 137.3, 136.6, 131.4, 129.0, 128.7, 127.2, 
42.5, 19.2; IR (ATR) max = 3351, 3171, 2480, 1759, 1675, 1553, 1496, 1463, 1430, 
1353, 1301, 1262, 1189, 1114, 1081, 1051, 996, 927, 845, 741, 727 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C10H11NO3 [M–H]– = 192.06607; observed [M–






4.2.1.29. 2-[(1-Phenylethyl)amino]-2-oxoacetic acid (MKR-27a) 
 
 
Yield 37.6%; Found m.p. 131–134.4 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.38–7.21 (m, 5H), 5.05 (q, J = 7.0 Hz, 1H), 1.52 (d, J = 7.0 Hz, 3H); 13CNMR 
(CD3OD, 62.5 MHz): δC (ppm) 162.9, 159.4, 144.2, 129.6, 128.3, 127.2, 50.8, 21.8; 
IR (ATR) max = 3300, 2980, 2942, 1760, 1678, 1546, 1491, 1447, 1357, 1339, 1308, 
1242, 1177, 1128, 1095, 1070, 1015, 902, 850, 826, 783, 770, 757, 708, 696 cm-1; 
HRMS (ESI–TOF) m/z: calcd. for C10H11NO3 [M–H]– = 192.0661; observed [M–H]– = 
192.0682. 
 
4.2.1.30. 2-[(4-Bromophenylethyl)amino]-2-oxoacetic acid (MKR-37a) 
 
 
Yield 15%; Found m.p. 158.7–160 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.41 (d, J =8.4 Hz, 2H), 7.14 (d, J = 8.4, 2H), 3.47 (t, J = 7.4 Hz, 2H), 2.81 (t, J 
= 7.4 Hz, 2H); 13C NMR (CD3OD, 100 MHz): δC (ppm) 162.8, 160.2, 139.5, 132.7, 
131.9, 121.3, 42.1, 35.6; IR (ATR) max = 3289, 1763, 1678, 1551, 1488,  1348, 1077, 
1010, 779 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C10H10BrNO3 [M–H]– = 
269.97658, [(M+2)–H]– = 271.97453; observed [M–H]– = 269.97693, [(M+2)–H]– = 
271.97342. 
 
4.2.1.31. 2-[(4-Nitrophenylethyl)amino]-2-oxoacetic acid (MKR-36a) 
 
 
Yield 16%; Found m.p. 158–160 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 8.16 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 3.55 (t, J = 7.2 Hz , 2H), 3.35 
(s, br, –NH), 2.99 (t, J = 7.2 Hz, 2H); 13C NMR (CD3OD, 100 MHz): δC (ppm) 162.8, 





1606,1598, 1515, 1452, 1362, 1342, 1244, 1177, 1110, 1050, 891, 854, 769, 751, 
700 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C10H10N2O5 [M–H]– = 
237.05115; observed [M–H]– = 237.05147. 
 
4.2.1.32. 2-[(3-Methylphenylethyl)amino]-2-oxoacetic acid (MKR-20a) 
 
 
Yield 38%; Found m.p. 92–94.9 °C; 1H NMR (CD3OD, 250 MHz): δH (ppm) 
7.18–7.12 (m, 1H), 7.03–6.98 (m, 3H), 3.46 (t, J = 7.5 Hz, 2H), 2.79 (t, J = 7.5 Hz, 
2H), 2.29 (s, 3H); 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 162.8, 160.1, 140.0, 139.3, 
130.6, 129.5, 128.3, 126.9, 42.5, 36.2, 21.5; IR (ATR) max = 3723, 3699, 3619, 3592, 
3289, 3269, 1769, 1667, 1609, 1551, 1485, 1466, 1381, 1348, 1296, 1254, 1241, 
1178, 1048, 905, 794, 720, 697, 668 cm-1; HRMS (ESI–TOF) m/z: calcd. for 
C11H13NO3 [M–H]– = 206.0817; observed [M–H]– = 206.0846. 
 
4.2.2. General procedure for the synthesis of N-phenylsulfamic acids (series 2) 
 
To a solution of aniline (0.004 mmol) in chloroform (8 ml), triethylamine 
(0.004 mmol) was added dropwise. The reaction mixture was cooled to 0 °C, and 
chlorosulfonic acid (0.004 mmol) was added dropwise to reaction mixture while 
maintaining the temperature.[135, 136] The resulting mixture was allowed to warm to 
room temperature and stirred for 3 h. A 6 M HCl solution was added to reaction 
mixture, filtered and washed with cold water). The compounds were recrystallized 
from ethanol. The solid compounds were dried in oven at 60 °C under vacuum.  
       
4.2.2.1. (4-Chlorophenyl)sulfamic acid (KSR-3) 
 
 
Yield 28%; Found m.p. 232–235 °C; 1H NMR (DMSO-d6, 400 MHz): δH 





δC (ppm) 138.2, 129.2, 126.6, 120.8; IR (ATR) max = 2931, 1617, 1565, 1518, 1492, 
1296, 1199, 1171, 1117, 1064, 1023, 868, 815, 828 cm-1; FTMS (LTQ Orbitrap XL–
ESI) m/z: calcd. for C6H6ClNO3S [M–H]– = 205.96787, [(M+2)–H]– = 207.96492; 
observed [M–H]– = 205.96811, [(M+2)–H]– = 207.96449. 
 
4.2.2.2. (4-Methoxyphenyl)sulfamic acid (KSR-1) 
 
 
Yield 25%; Found m.p. 245–247 °C; 1H NMR (D2O, 400 MHz): δH (ppm) 
7.57 (d, J = 8.8 Hz, 2H), 7.27 (d, J = 8.9 Hz, 2H), 3.95 (s, 3H); 13C NMR (D2O, 100 
MHz): δC (ppm) 156.5, 131.0, 127.9, 123.0, 121.7, 113.9, 56.1; IR (ATR) max = 2832, 
2601, 1614, 1511, 1455, 1441, 1298, 1251, 1174, 1134, 1086, 1031, 825, 815, 727, 
708, 699 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C7H9NO4S [M–H]– = 
202.01740; observed [M–H]– = 202.01749. 
  
4.2.3. General procedure for the synthesis of substituted N-(2-(1H 
benzo[d]imidazol-2-ylthio)acetamido)benzoic acid derivatives (series 5) 
 
Step 1: Preparation of α-chloroacetamido intermediate: - Condensation of 
aminobenzoic acids (1.0 mmol) with chloroacetyl chloride (1.0 mmol) in the presence 
of N, N-dimethylformamide (20 ml) to form the N-(2-chloroacetamido)benzoic acids. 
[46, 137] The solid compounds were recrystallized from ethanol and dried in oven at 
60 °C under vacuum. 
 
4.2.3.1. 3-(2-Chloroacetamido)benzoic acid (KS-0) 
 
 
Yield 75%; Found m.p. 227–230 °C, lit. 230–232 °C[169]; 1H NMR 
(DMSO-d6, 250 MHz): δH (ppm) 10.5 (s, 1H), 8.22 (s, 1H), 7.81 (d, J = 8.5 Hz, 1H), 





62.5 MHz): δC (ppm) 167.0, 165.0, 138.7, 131.4, 129.2, 124.6, 123.5, 120.1, 43.5; IR 
(ATR) max = 3277, 3088, 1674, 1595, 1553, 1456, 1412, 1309, 1273, 1256, 1208, 
1174, 1085, 1000, 973, 945, 899, 822, 806, 757, 718, 699, 680 cm-1; FTMS (LTQ 
Orbitrap XL–ESI) m/z: calcd. for C9H8ClNO3 [M–H]– = 212.01145, [(M+2)–H]– = 
214.00850; observed [M–H]– = 212.01198, [(M+2)–H]– = 214.00838. 
 
4.2.3.2. 4-(2-Chloroacetamido)benzoic acid (KS-0b) 
 
 
Yield 78%; Found m.p. 260–262 °C, lit. 263–265 °C[170]; 1H NMR 
(DMSO-d6, 250 MHz): δH (ppm) 10.6 (s, 1H), 7.92 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.7 
Hz, 2H), 4.29 (s, 2H); 13C NMR (DMSO-d6, 62.5 MHz): δC (ppm) 166.9, 165.2, 142.5, 
130.5, 125.8, 118.7, 43.6; IR (ATR) max = 3337, 3011, 1673, 1607, 1592, 1521, 
1423, 1406, 1320, 1294, 1271, 1246, 1184, 1118, 1017, 944, 857, 798, 772, 694, 
682 cm-1. FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C9H8ClNO3 [M–H]– = 
212.01145, [(M+2)–H]– = 214.00850; observed [M–H]– = 212.01247, [(M+2)–H]– = 
214.00906. 
 
4.2.3.3. 4-(2-Chloroacetamido)isophthalic acid (KS-0c) 
 
 
Yield 25%; Found m.p. 236–238 °C; 1H NMR (DMSO-d6, 500 MHz): δH 
(ppm) 12.0 (s, 1H), 8.64 (d, J = 8.7 Hz, 1H), 8.56 (d, J = 2.0 Hz, 1H), 8.14 (dd, J = 8.7 
and 2.0 Hz, 1H), 4.48 (s, 2H); 13C NMR (DMSO-d6, 125 MHz): δC (ppm) 168.8, 166.2, 
165.8, 143.5, 135.0, 132.5, 125.3, 119.5, 116.5, 43.6; IR (ATR) max = 3124, 1707, 
1689, 1662, 1593, 1531, 1479, 1424, 1404, 1389, 1320, 1266, 1201, 1167, 1141, 
1083, 970, 935, 910, 860, 804, 761 cm-1. FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. 
for C10H8ClNO5 [M–H]– = 256.00128, [(M+2)–H]– = 257.99832; observed [M–H]– = 





Step 2: Coupling of the precursor 3-(2-chloroacetamido)benzoic acid (1.0 
mmol) with N-mercaptobenzimidazoles (1.0 mmol) in the presence of acetone (20 ml) 
and K2CO3 (1.0 mmol) at reflux for 12–20 h to yielded 3-(2-(1H-benzo[d]imidazol-2-
ylthio)acetamido)benzoic acid derivatives.[46, 137]  
 




Yield 58%; Found m.p. 227–230 °C; 1H NMR (DMSO-d6, 400 MHz): δH 
(ppm) 10.7 (s, 1H), 7.79 (d, J = 8.5 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.44 (t, J = 7.9 
Hz, 1H), 7.38 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 6.80 (dd, J = 8.8 and 2.3 
Hz, 1H), 4.28 (s, 2H), 3.77 (s, 3H); 13C NMR (DMSO-d6, 100 MHz): δC (ppm) 164.1, 
163.4, 152.8, 145.6, 136.1, 135.6, 130.3, 128.4, 126.2, 121.4, 120.2, 116.8, 111.6, 
108.2, 93.8, 52.5, 33.4; IR (ATR) max = 3313, 3261, 2925, 2826, 1669, 1614, 1561, 
1487, 1370, 1335, 1273, 1225, 1204, 1173, 1155, 1112, 1032, 991, 897, 820, 755 
cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C17H15N3O4S [M–H]– = 356.07050; 
observed [M–H]– = 356.07169. 
 




Yield 66%; Found m.p. 210–212 °C; 1H NMR (DMSO-d6, 500 MHz): δH 
(ppm) 10.9 (s, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 8.9 
Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 7.10 (d, J = 2.1 Hz, 1H), 7.02 (dd, J = 8.9 and 2.2 
Hz, 1H), 4.53 (s, 2H), 4.08 (q, J = 6.9 Hz, 2H), 1.35 (t, J = 6.9 Hz, 3H); 13C NMR 





129.1, 127.7, 124.5, 123.3, 119.9, 114.6, 114.1, 96.6, 63.9, 36.8, 14.5; IR (ATR) max 
= 2978, 2888, 1693, 1621, 1594, 1563, 1488, 1444, 1394, 1337, 1305, 1270, 1170, 
1112, 1039, 957, 896, 816, 756 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 
C18H17N3O4S [M–H]– = 370.08615; observed [M–H]– = 370.08768. 
 




Yield 81%; Found m.p. 250–253 °C; 1H NMR (DMSO-d6, 600 MHz): δH 
(ppm) 10.6 (s, 1H), 8.30 (d, J = 1.1 Hz, 1H), 8.25 (s, 1H), 8.05 (dd, J = 8.8 and 2.1 
Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.7 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 
7.44 (t, J = 7.9 Hz, 1H), 4.39 (s, 2H); 13C NMR (DMSO-d6, 150 MHz): δC (ppm) 167.1, 
166.0, 142.2, 139.0, 131.4, 129.1, 124.4, 123.2, 119.9, 117.6, 36.2; IR (ATR) max = 
3265, 1683, 1620, 1595, 1558, 1520, 1475, 1427, 1334, 1227, 1170, 1066, 954, 894, 
842, 817, 737 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C16H12N4O5S [M–
H]– = 371.04502; observed [M–H]– = 371.04520. 
 




Yield 62%; Found m.p. 175–178 °C (decomposed); 1H NMR (DMSO-d6, 
600 MHz): δH (ppm) 10.8 (s, 1H), 8.24 (t, J = 1.7 Hz, 1H), 7.79 (ddd, J = 8.0 and 0.9 
Hz, 1H), 7.64 (dt, J = 7.7 and 1.2 Hz, 1H), 7.45–7.42 (m, 2H), 7.34 (s, 1H),  7.09 (d, J 
= 7.6 Hz, 1H), 4.39 (s, 2H), 2.41 (s, 3H); 13C NMR (DMSO-d6, 150 MHz): δC (ppm) 
167.5, 166.4, 149.7, 139.4, 133.1, 131.9, 129.6, 124.9, 123.7, 120.3, 113.8, 113.5, 





1454, 1422, 1403, 1342, 1301, 1272, 1246, 1181, 957, 899, 806, 754 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C17H15N3O3S [M–H]– = 340.07559; observed 
[M–H]– = 340.07736. 
 




Yield 65%; Found m.p. 230–234 °C; 1H NMR (DMSO-d6, 600 MHz): δH 
(ppm) 10.6 (s, 1H), 8.24 (t, J = 1.7 Hz, 1H), 7.80 (ddd, J = 8.1 and 1.0 Hz, 1H), 7.64 
(dt, J = 7.7 and 1.2 Hz, 1H), 7.51 (d, J = 1.9 Hz, 1H), 7.46–7.43 (m, 2H), 7.15 (dd, J = 
8.5 and 2.0 Hz, 1H), 4.32 (s, 2H); 13C NMR (DMSO-d6, 150 MHz): δC (ppm) 167.0, 
166.2, 151.6, 139.0, 131.4, 129.1, 126.0, 124.3, 123.2, 121.7, 119.8, 36.2; IR (ATR) 
max = 3305, 1694, 1617, 1595, 1576, 1452, 1418, 1395, 1339, 1312, 1272, 1245, 
1181, 1059, 955, 916, 894, 861, 804, 756, 702 cm-1; FTMS (LTQ Orbitrap XL–ESI) 
m/z: calcd. for C16H12ClN3O3S [M–H]– = 360.02096, [(M+2)–H]– = 362.01801; 
observed [M–H]– = 360.02255, [(M+2)–H]– = 362.01935. 
 
4.2.3.9. 3-(2-((5,6-dichloro-1H-benzo[d]imidazol-2-yl)thio)acetamido) 
benzoic acid (KS-6) 
 
 
Yield 53%; Found m.p. 261–263 °C; 1H NMR (DMSO-d6, 600 MHz): δH 
(ppm) 10.6 (s, 1H), 8.24 (s, 1H), 7.78 (dd, J = 8.1 and 1.0 Hz, 1H), 7.70 (s, 2H), 7.64 
(d, J = 7.7 Hz, 1H), 7.44 (t, J = 7.9 Hz, 1H), 4.32 (s, 2H); 13C NMR (DMSO-d6, 150 
MHz): δC (ppm) 167.1, 166.0, 153.4, 139.0, 132.2, 131.4, 129.1, 124.7, 124.3, 123.9, 





1563, 1485, 1450, 1415, 1377, 1288, 1213, 1184, 1095, 982, 861, 754 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C16H11Cl2N3O3S [M–H]– = 393.98199, [(M+2)–
H]– = 395.97904; observed [M–H]– = 393.98248, [(M+2)–H]– = 395.97906. 
 
4.2.4. General procedure for the synthesis of substituted benzylphosphonic 




Triethylphosphite (0.5 mL, 0.0029 mmol) was added to the substituted 
benzyl bromide or chloride (500 mg, 0.0029 mmol) in a round bottom flask under 
inert atmosphere and stirred at 135 °C for 12 h.[139] The crude reaction mixture was 
purified by column chromatography silica gel with AcOEt/hexane (50:50, rf = 0.44) as 
eluent to yield as a colorless oil (72–90%). The dialkyl benzylphosphonates were 
treated with concentrated HCl (8 ml) and stirred under reflux for 24 h in a round 
bottom flask.[139–141] The reaction mixture was cooled to room temperature and the 
resulting precipitate was filtered, washed with cold water. The products were 




Dialkyl benzylphosphonates were prepared as described in method A, but 
hydrolysis conditions were modified as result of compounds instability. Dialkyl 
benzylphosphonates (1.0 mmol), dry acetonitrile (15 ml) and sodium iodide (3.0 
mmol) were mixed together, and then trimethylsilyl chloride (TMSCl) (3.0 mmol) was 
combined dropwise at 0 °C under N2 atmosphere.[142] The reaction mixture was 
stirred for 2–3 h at room temperature and reaction was monitored by TLC. After 
completion of the reaction, the sodium salt was filtered off the solution and washed 
with acetonitrile. The acetonitrile was distilled off the solution and the crude reaction 
mixture was treated with methanol (15 ml) and stirred for 30 minutes at room 
temperature to quench the excess of TMSCl. The solvent was removed under 
reduced pressure to result in silyl esters. The crude silyl ester was treated with water 
(10 ml) and stirred for 20 minutes at room temperature and cooled to 10 °C. The solid 
was filtered, wash with cold water and recrystallized from ethyl acetate and diethyl 





4.2.4.1. Synthesis of benzylphosphonic acid (MK-0) 
 
Synthesis was followed through method A.  
 
 
Yield 70%; Found m.p. 160–163 °C, lit. 166 °C [139, 142a]; 1H NMR 
(DMSO-d6, 250 MHz): δH (ppm) 7.30–7.17 (m, 5H), 2.94 [d, br, 2J(1H–31P) = 21.4 Hz, 
2H]; 13C NMR (DMSO-d6, 62.5 MHz): δC (ppm) 134.2 [d, 2J(13C–31P) = 8.6 Hz], 129.8 
[d, 3J(13C–31P) = 6.5 Hz], 128.0 [d, 4J(13C–31P) = 2.5 Hz], 126.0 [d, 5J(13C–31P) = 3.0 
Hz], 35.4 [d, br, 1J(13C–31P) = 131.4 Hz]; 31P NMR (DMSO-d6, 101 MHz): δ 20.9 (s); 
IR (ATR) max =  1491, 1458, 1260, 1074, 989, 942, 782, 701, 693 cm-1; HRMS (ESI–
TOF) m/z: calcd. for C7H9O3P [M–H]– = 171.0211; observed [M–H]– = 171.0201. 
 
4.2.4.2. Synthesis of (4-Nitrobenzyl)phosphonic acid (MK-0a)  
 
Synthesis was followed through method A. 
 
 
Yield 60%; Found m.p. 224–227 °C, lit. 226 °C[171]; 1H NMR (CD3OD, 
250 MHz): δH (ppm) 8.04 (d, J = 8.3 Hz, 2H), 7.41 (d, J = 8.3 Hz, 2H), 3.14 [d, br, 
2J(1H–31P) 22.0 Hz, 2H]; 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 148.3 [d, 5J(13C–
31P) = 3.6 Hz], 143.0 [d, 2J(13C–31P) = 9.2 Hz], 132.1 [d, 3J(13C–31P) = 6.1 Hz], 124.5 
[d, 4J(13C–31P) = 2.9 Hz], 36.1 [d, br, 1J(13C–31P) = 132.5 Hz]; 31P NMR (CD3OD, 101 
MHz): δ 21.9 (s); IR (ATR) max = 1609, 1599, 1519, 1491, 1419, 1403, 1344, 1267, 
1180, 1153, 1107, 1073, 984, 969, 949, 860, 823, 771, 697 cm-1; HRMS (ESI–TOF) 











4.2.4.3. Synthesis of [4-(Chloromethyl)benzyl]phosphonic acid (MK-9) 
 
Synthesis was followed through method B. 
 
 
Yield 30%; Found m.p. 151–153 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.14 (s, 4H), 4.41 (s, 2H, -CH2Cl), 2.93 [d, 2J(1H–31P) = 22.1 Hz, 2H]; 13C NMR 
(CD3OD, 100 MHz): δC (ppm) 137.8, 135.0 [d, 2J(13C-31P) = 7.5 Hz], 131.4 [d, 
3J(13C-31P) = 5.7 Hz], 129.9, 46.8 (-CH2Cl), 35.8 [d, br, 1J(13C–31P) = 136.0 Hz]; 31P 
NMR (CD3OD, 202 MHz): δ 23.9 (s); IR (ATR) max = 1515, 1420, 1409, 1261, 1227, 
1109, 1092, 992, 970, 954, 941, 844, 800, 757, 713, 671 cm-1; HRMS (ESI–TOF) 
m/z: calcd. for C8H10ClO3P [M–H]– = 218.9978, [(M+2)–H]– = 220.9951; observed [M–
H]– = 218.9985, [(M+2)–H]– =  220.9961. 
 
4.2.4.4. (2-Fluorobenzyl)phosphonic acid (MK-11a) 
 
Synthesis was followed through method A. 
 
 
Yield 32.5%; Found m.p. 172.8–174 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.42–7.36 (m, 1H), 7.30–7.20 (m, 1H), 7.14–7.02 (m, 2H), 3.15 [d, br, 2J(1H–
31P) = 21.6 Hz, 2H]; 13C NMR (CD3OD, 62.5 MHz): δC (ppm) 162.5 [dd, br, 1J(13C–
19F) = 243.8 Hz, 3J(13C–31P) = 7.0 Hz], 133.2 (t, J = 4.5 Hz], 129.7 [dd, 3J(13C–19F) = 
8.0 Hz, 3J(13C–31P) = 3.6 Hz], 125.3 (t, J = 3.4 Hz), 121.8 (q, 2J(13C–19F) = 15.6 Hz, 
2J(13C–31P) = 9.3 Hz), 116.3 (dd, 2J(13C–19F) = 22.2 Hz, 4J(13C–31P) = 3.0 Hz), 28.6 
[dd, br, 1J(13C–31P) = 136.3 Hz, 3J(13C–19F) = 2.7 Hz]; 31P NMR (CD3OD, 101 MHz): δ 
23.0 (s); 19F NMR (CD3OD, 235 MHz): δ -119.0 (d); IR (ATR) max = 1587, 1497, 
1458, 1400, 1268, 1235, 1180, 1085, 1062, 998, 949, 861, 770, 705 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C7H8FO3P [M–H]– = 189.01168; observed [M–






4.2.4.5. (3-Fluorobenzyl)phosphonic acid (MK-11b) 
 
Synthesis was followed through method A.  
 
 
Yield 29%; Found m.p. 126–128 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.29 [q, 3J(1H–19F) = 7.7 Hz], 1H), 7.12 (d, J = 7.5 Hz, 1H), 7.07 (d, J = 10.0 
Hz, 1H), 6.95 (t, J = 8.5 Hz, 1H), 3.13 [d, br, 2J(1H–31P) = 21.8 Hz, 2H]; 13C NMR 
(CD3OD, 62.5 MHz): δC (ppm) 164.3 [dd, br, 1J(13C–19F) = 242.2 Hz, 4J(13C–31P) = 
3.2 Hz], 137.4 (t, J = 8.5 Hz), 131.1 (dd, J = 8.3 and 2.7 Hz), 127.0 (dd, J = 6.4 and 
2.6 Hz), 117.7 [dd, 2J(13C–19F) = 21.9 Hz, 3J(13C–31P) = 6.0 Hz], 114.4 [dd, 2J(13C–
19F) =  21.1 Hz, 5J(13C–31P) = 3.3 Hz], 35.7 [d, br, 1J(13C–31P) = 133.8 Hz]; 31P NMR 
(CD3OD, 101 MHz): δ 23.3 (s), 19F NMR (CD3OD, 235 MHz): δ -116.0 (d); IR (ATR) 
max = 1613, 1590, 1491, 1482, 1445, 1411, 1272, 1241, 1179, 1132, 1066, 994, 952, 
941, 930, 870, 788, 767, 736, 688 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 
C7H8FO3P [M–H]– = 189.01168; observed [M–H]– = 189.01169. 
 
4.2.4.6. (4-Fluorobenzyl)phosphonic acid (MK-11)  
 
Synthesis was followed through method A.  
 
 
Yield 38%; Found m.p. 170.8–173.5 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.31 [t, 4J(1H–19F) = 5.6 Hz, 2H], 7.05 [t, 2J(1H–19F) = 8.6 Hz, 2H], 3.09 [d, br, 
2J(1H–31P) = 21.4 Hz, 2H]; 13C NMR (CD3OD, 100 MHz): δC (ppm) 163.4 [d, br, 
1J(13C–19F) = 241.7 Hz], 132.6 [dd, 3J(13C–19F) = 7.1 Hz and 3J(13C–31P) = 6.7 Hz], 
130.6 [d, 2J(13C–31P) = 8.8 Hz], 116.1 [d, 2J(13C–19F) = 21.4 Hz], 35.1 [d, br, 1J(13C–
31P) = 134.8 Hz]; 31P NMR (CD3OD, 101 MHz): δ 22.3 (s); 19F NMR (CD3OD, 235 
MHz): δ -119.0 (d); IR (ATR) max = 1737, 1609, 1509, 1277, 1208, 1177, 1158, 1089, 
1065, 997, 954, 928, 839, 777 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 





4.2.4.7. [2-(Trifluoromethyl)benzyl]phosphonic acid (MK-29)  
 
Synthesis was followed through method A. 
 
 
Yield 32%; Found m.p. 186–188 °C, lit. 190–192 °C[172]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.72 (d, J = 6.0 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.58 
(t, J = 7.7 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 3.37 [d, br, 2J(1H–31P) = 22.4 Hz, 2H]; 13C 
NMR (CD3OD, 100 MHz): δC (ppm) 133.9 [d, 3J(13C–31P) = 5.0 Hz], 133.4 [d, 2J(13C–
31P) = 8.5 Hz], 133.0, 130.2 [qd, 2J(13C–19F) = 29.3 Hz and 3J(13C–31P) = 7.6 Hz], 
128.1 [d, 4J(13C–31P) = 3.1 Hz], 127.2 [dd, 3J(13C–19F) = 5.6 Hz and 4J(13C–31P) = 2.2 
Hz], 126.0 [q, br, 1J(13C–19F = 271.4 Hz], 32.3 [d, br, 1J(13C–31P) = 135.3 Hz]; 31P 
NMR (CD3OD, 101 MHz): δ 20.4 (s); 19F NMR (CD3OD, 470 MHz): δ -60.2 (s); IR 
(ATR) max = 1732, 1302, 1182, 1103, 1061, 1033, 987, 962, 962, 777, 717 cm-1; FT–
ICR Ultra (ESI/MS) m/z: calcd. for C8H8F3O3P [M–H]– = 239.00849; observed [M–H]– 
= 239.00900. 
 
4.2.4.8. [3-(Trifluoromethyl)benzyl]phosphonic acid (MK-30)  
 
Synthesis was followed through method A. 
 
 
Yield 38%; Found m.p. 161–163 °C, lit. 163–165 °C[172]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.63 (s, 1H), 7.58–7.46 (m, 3H), 3.21 [d, br, 2J(1H–31P) 
= 21.8 Hz, 2H]; 13C NMR (CD3OD, 100 MHz): δC (ppm) 136.2 [d, J(13C–31P) = 9.0 
Hz], 134.8 [d, J(13C–31P) = 6.0 Hz], 131.8 [qd, 2J(13C–19F) = 31.7 Hz and 4J(13C–31P) 
= 3.0 Hz], 130.2 [d, J(13C–31P) = 2.8 Hz], 127.6 [dd, 3J(13C–31P) = 6.2 Hz and 3J(13C–
19F) = 3.8 Hz], 125.8 [q, br, 1J(13C–19F) = 269.8 Hz], 124.5 [d, J(13C–31P) = 7.2 Hz], 
35.8 [d, br, 1J(13C–31P) = 134.0 Hz]; 31P NMR (CD3OD, 101 MHz): δ 21.2 (s); 19F 
NMR (CD3OD, 470 MHz): δ -64.0 (s); IR (ATR) max = 1444, 1403, 1328, 1269, 1184, 





m/z: calcd. for C8H8F3O3P [M–H]– = 239.00849; observed [M–H]– = 239.00919. 
 
4.2.4.9. Synthesis of 4-(Trifluoromethyl)benzylphosphonic acid (MK-7a) 
 
Synthesis was followed through method A.  
 
 
Yield 42%; Found m.p. 170.8–172 °C, lit. 163–174 °C[172]; 1H NMR 
(CD3OD, 250 MHz): δH (ppm) 7.59 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 7.7 Hz, 2H), 3.20 
[d, 2J(1H–31P) = 22.0 Hz, 2H]; 13C NMR (CD3OD, 125 MHz): δC (ppm) 139.6 [d, 
2J(13C–31P) = 8.7 Hz], 131.7 [d, 3J(13C–31P) = 6.2 Hz], 129.9 [qd, 2J(13C–19F) = 31.9 
Hz and 5J(13C–31P) = 3.1 Hz], 126.3 [t, 4J(13C–31P) = 3.7 Hz], 126.0 [q, br, 1J(13C–19F) 
= 269.4 Hz], 36.0 [d, br, 1J(13C–31P) = 133.7 Hz]; 31P NMR (CD3OD, 202 MHz): δ 
22.8 (s); 19F NMR (CD3OD, 235 MHz): δ -64.0 (d); IR (ATR) max = 1614, 1420, 1315, 
1266, 1148, 1110, 1103, 1066, 992, 946, 848, 834, 768, 707 cm-1; HRMS (ESI–TOF) 
m/z: calcd. for C8H8F3O3P [M–H]– = 239.0027; observed [M–H]– = 239.0085. 
 
4.2.4.10. (2, 3, 4, 5, 6-Pentafluorobenzyl)phosphonic acid (MK-31) 
 
Synthesis was followed through method A. 
 
 
Yield 25%; Found m.p. 218–220 °C (decomposed); 1H NMR (CD3OD, 400 
MHz): δH (ppm) 3.22 [d, br, 2J(1H–31P) = 21.0 Hz, 2H]; 13C NMR (CD3OD, 100 MHz): 
δC (ppm) 146.8 [d, br, 1J(13C–19F) = 248.6 Hz, 1C], 141.5 [d, br, 1J(13C–19F) = 248.6 
Hz], 139.0 [d, br, 1J(13C–19F) = 243.1 Hz], 109.9 [d, 2J(13C–19F) = 13.8 Hz], 23.3 [d, 
br, 1J(13C–31P) = 137.4 Hz]; 31P NMR (CD3OD, 101 MHz): δ 17.7 (s); 19F NMR 
(CD3OD, 470 MHz): δ -143.5 (dt, J(19F–19F) = -20.1 and -5.0 Hz), -160.3 (td, J(19F–
19F) = -20.0 and -6.6 Hz), -166.1 (td, J(19F–19F) = -19.7 and -7.7 Hz); IR (ATR) max = 
1655, 1525, 1503, 1259, 1187, 1124, 1073, 1027, 1014, 970, 936, 770, 727 cm-1; 





observed [M–H]– = 260.97351. 
 
4.2.4.11. 4-Chlorobenzylphosphonic acid (MK-1) 
 
Synthesis was followed through method A.  
 
 
Yield 52%; Found m.p. 174–176 °C, lit. 165–166 °C[142a]; 1H NMR 
(CD3OD, 250 MHz): δH (ppm) 7.29 (s, 4H), 3.09 [d, br, 2J(1H–31P) = 21.6 Hz, 2H]; 13C 
NMR (CD3OD, 125 MHz): δC (ppm) 133.6 (d, 5J = 4.2 Hz), 133.5 (d, 2J = 9.2 Hz), 
132.6 (d, 3J = 6.3 Hz), 129.5 (d, 4J = 3.1 Hz), 35.3 [d, br, 1J(13C–31P) = 134.4 Hz]; 31P 
NMR (CD3OD, 101 MHz): δ 21.9 (s); IR (ATR) max = 1488, 1414, 1255, 1208, 1175, 
1142, 1110, 1099, 1011, 943, 924, 833, 815, 768, 680 cm-1; FTMS (LTQ Orbitrap 
XL–ESI) m/z: calcd. for C7H8ClO3P  [M–H]– = 204.98213, [(M+2)–H]– = 206.97918; 
observed [M–H]– = 204.98280, [(M+2)–H]– = 206.97910. 
 
4.2.4.12. (2-Bromobenzyl)phosphonic acid (MK-47) 
 
Synthesis was followed through method A.  
 
 
Yield 59%; Found m.p. 182–184 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.57 (d, J = 8.0 Hz, 1H), 7.48 (dt, J = 7.6 and 1.9 Hz, 1H), 7.30 (t, J = 7.5 Hz, 
1H), 7.13 (td, J = 7.7 and 1.8 Hz, 1H), 3.40 [d, br, 2J(1H–31P) = 22.0 Hz, 2H]; 13C 
NMR (CD3OD, 62.5 MHz): δC (ppm) 134.6 [d, J(13C–31P) = 8.9 Hz], 134.1 [d, J(13C–
31P) = 2.8 Hz], 133.0 [d, J(13C–31P) = 5.1 Hz], 129.5 [d, J(13C–31P) = 3.6 Hz], 128.6 [d, 
J(13C–31P) = 3.3 Hz], 126.1 [d, J(13C–31P) = 8.4 Hz], 35.7 [d, br, 1J(13C–31P)] = 135.0 
Hz]; 31P NMR (CD3OD, 101 MHz): δ 22.8 (s); IR (ATR) max = 2969, 2906, 1568, 
1474, 1438, 1407, 1285, 1265, 1202, 1176, 1047, 1028, 965, 939, 833, 773, 740, 
707 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C7H8BrO3P [M–H]– = 






4.2.4.13. (4-Bromobenzyl)phosphonic acid (MK-2) 
 
Synthesis was followed through method A. 
 
 
Yield 57%; Found m.p. 175–179 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.44 (d, J = 8.1 Hz, 2H), 7.23 (dd, J = 8.3 Hz and 4J(1H–31P) = 2.0 Hz, 2H), 
3.08 [d, br, 2J(1H–31P) = 21.6 Hz, 2H]; 13C NMR (CD3OD, 125 MHz): δC (ppm) 134.1 
[d, 2J(13C–31P) = 8.7 Hz], 132.9 [d, 3J(13C–31P) = 5.0 Hz], 132.5, 121.5, 35.5 [d, br, 
1J(13C–31P) = 133.7 Hz]; 31P NMR (CD3OD, 202 MHz): δ 23.3 (s); IR (ATR) max = 
1741, 1491, 1406, 1232, 1102, 1073, 995, 951, 823, 746, 705 cm-1; HRMS (ESI–
TOF) m/z: calcd. for C7H8BrO3P [M–H]– = 248.9316, [(M+2)–H]– = 250.9296; 
observed [M–H]– = 248.9323, [(M+2)–H]– = 250.9297. 
 
4.2.4.14. [4-(Bromomethyl)benzyl]phosphonic acid (MK-9a) 
 
Synthesis was followed through method B. 
 
 
Yield 15%; Found m.p. 185–189 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.37–7.27 (m, 4H), 4.54 (s, 2H, -CH2Br), 3.11 [d, br, 2J(1H–31P) = 21.8 Hz, 2H]; 
13C NMR (CD3OD, 62.5 MHz): δC (ppm) 138.1 [d, 5J(13C–31P) = 3.9 Hz], 134.9 [d, 
2J(13C–31P) = 8.9 Hz], 131.4 [d, 3J(13C–31P) = 6.3 Hz], 130.3 [d, 4J(13C–31P) = 3.2 Hz], 
35.7 [d, br, 1J(13C–31P) = 133.9 Hz], 34.0 (-CH2Br); 31P NMR (CD3OD, 101 MHz): δ 
23.8 (s); IR (ATR) max = 1628, 1510, 1420, 1403, 1381, 1263, 1225, 1194, 1144, 
1113, 1035, 987, 937, 842, 812, 740, 719, 705 cm-1; HRMS (ESI–TOF) m/z: calcd. 
for C8H10BrO3P [M–H]– = 262.9473, [(M+2)–H]– = 264.9453; observed [M–H]– = 









4.2.4.15. [(6-Bromobenzo[d][1,3]dioxol-5-yl)methyl]phosphonic acid (MK-48) 
 
Synthesis was followed through method B.  
 
 
Yield 65%; Found m.p. 220–223 °C; 1H NMR (CD3OD, 500 MHz): δH 
(ppm) 7.03 (s, 1H), 6.95 (d, J = 2.2 Hz, 1H), 5.96 (s, 2H), 3.26 [d, br, 2J(1H–31P) = 
21.6 Hz, 2H]; 13C NMR (CD3OD, 125 MHz): δC (ppm) 149.0 (t, J(13C–31P) = 3.5 Hz, 
2C), 127.3 [d, J(13C–31P) = 9.3 Hz], 116.2 [d, J(13C–31P) = 9.7 Hz], 113.6 [d, J(13C–
31P) = 2.9 Hz], 112.0 [d, J(13C–31P) = 4.5 Hz], 103.4, 35.5 [d, br, 1J(13C–31P) = 135.9 
Hz]; 31P NMR (CD3OD, 101 MHz): δ 23.0 (s); IR (ATR) max = 2907, 1507, 1483, 
1406, 1392, 1251, 1235, 1211, 1093, 1038, 1008, 971, 943, 930, 872, 792 cm-1; 
FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H8BrO5P [M–H]– = 292.92145, 
[(M+2)–H]– = 294.91940; observed [M–H]– = 292.92203, [(M+2)–H]– = 294.91901. 
 
4.2.4.16. (2-Bromo-5-methoxybenzyl)phosphonic acid (MK-49) 
 
Synthesis was followed through method B. 
  
 
Yield 42%; Found m.p. 190–194 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.43 (d, J = 8.8 Hz, 1H), 7.06 (t, J = 2.9 Hz, 1H), 6.73 (dt, J = 8.8 and 2.6 Hz, 
1H), 3.77 (s, 3H), 3.32 [d, br, 2J(1H–31P) = 22.0 Hz, 2H]; 13C NMR (CD3OD, 62.5 
MHz): δC (ppm) 160.5 [d, J(13C–31P) = 3.3 Hz], 135.4 [d, J(13C–31P) = 8.8 Hz], 134.5 
[d, J(13C–31P) = 2.8 Hz], 118.2 [d, J(13C–31P) = 5.1 Hz], 116.4 [d, J(13C–31P) = 8.5 
Hz], 115.6 [d, J(13C–31P) = 3.4 Hz], 56.0, 35.9 [d, br, 1J(13C–31P) = 134.9 Hz]; 31P 
NMR (CD3OD, 101 MHz): δ 22.8 (s); IR (ATR) max = 2969, 2942, 2912, 2840, 1735, 
1592, 1573, 1479, 1419, 1397, 1287, 1241, 1155, 1101, 1049, 1000, 947, 939, 870, 
817, 773, 697  cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H10BrO4P [M–H]– 







4.2.4.17. (4-Methoxylbenzyl)phosphonic acid (MK-35) 
 
Synthesis was followed through method B. 
  
 
Yield 52%; Found m.p. 200–203 °C, lit. 204–205 °C[142a]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.21 (dd, J = 8.8 and 2.6 Hz, 2H), 6.85 (d, J = 8.2 Hz, 
2H), 3.76 (s, 3H), 3.04 [d, br, 2J(1H–31P) = 21.2 Hz, 2H]; 13C NMR (CD3OD, 100 
MHz): δC (ppm) 160.1 [d, J(13C–31P) = 3.3 Hz], 132.0 [d, J(13C–31P) = 6.4 Hz], 126.3 
[d, J(13C–31P) = 9.2 Hz], 115.0 [d, J(13C–31P) = 2.8 Hz], 55.8, 35.0 [d, br, 1J(13C–31P) 
= 135.1 Hz]; 31P NMR (CD3OD, 101 MHz): δ 23.2 (s); IR (ATR) max = 1609, 1581, 
1515, 1439, 1302, 1254, 1102, 1080, 1025, 992, 954, 946, 831, 770  cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C8H11O4P [M–H]– = 201.03167; observed [M–
H]– = 201.03134. 
 
4.2.4.18. (3, 5-Dimethoxybenzyl)phosphonic acid (MK-6) 
 
Synthesis was followed through method B.  
 
 
Yield 35%; Found m.p. 221–223 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 6.49 (t, J = 2.4 Hz, 2H), 6.35 (q, J = 2.2 Hz, 1H), 3.76 (s, 6H), 3.05 [d, br, 
2J(1H–31P) = 21.6 Hz, 2H]; 13C NMR (CD3OD, 100 MHz): δC (ppm) 162.3 [d, J(13C–
31P) = 2.9 Hz], 136.5 [d, J(13C–31P) = 8.7 Hz], 109.1 [d, J(13C–31P) = 6.4 Hz], 99.8 [d, 
J(13C–31P) = 3.3 Hz], 55.8, 36.2 [d, br, 1J(13C–31P) = 133.9 Hz]; 31P NMR (CD3OD, 
101 MHz): δ 22.6 (s); IR (ATR) max = 1609, 1596, 1480, 1425, 1343, 1210, 1163, 
1140, 1096, 1066, 1053, 994, 957, 833, 688 cm-1; FT–ICR Ultra (ESI/MS) m/z: calcd. 






4.2.4.19. 4-(Phosphonomethyl)benzoic acid (MK-13) 
 
Synthesis was followed through method A.  
 
 
Yield 50%; Found m.p. 276–278 °C, lit. 282–285 °C[173]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.96 (d, J = 7.8 Hz, 2H), 7.42 (dd, J = 8.4 and 2.4 Hz, 
2H), 3.20 [d, br, 2J(1H–31P) = 22.1 Hz, 2H]; 13C NMR (CD3OD, 100 MHz): δC (ppm) 
169.9, 140.4 [d, J(13C–31P) = 9.1 Hz], 131.2 [d, J(13C–31P) = 6.2 Hz], 131.0 [d, J(13C–
31P) = 3.0 Hz], 130.3 [d, J(13C–31P) = 3.3 Hz], 36.2 [d, br, 1J(13C–31P) = 133.1 Hz]; 31P 
NMR (CD3OD, 202 MHz): δ 23.0 (s); IR (ATR) max = 2825, 2674, 2559, 1697, 1611, 
1578, 1426, 1318, 1293, 1269, 1210, 1193, 1130, 1109, 1095, 1058, 983, 975, 940, 
865, 845, 786, 735, 695  cm-1. FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H9O5P 
[M–H]– = 215.01093; observed [M–H]– = 215.01180. 
 
4.2.4.20. Sodium (4-aminobenzyl)phosphonate (MK-15) 
 
Synthesis was followed through method A.  
 
 
Yield 28%; Found: the m.p. was not observed up to 280 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.14 (d, J = 6.6 Hz, 2H), 6.80 (d, J = 8.0 Hz, 2H), 2.83 [d, br, 
2J(1H–31P) = 19.7 Hz, 2H]; 13C NMR (D2O, 62.5 MHz): δC (ppm) 143.4 [d, J(13C–31P) 
= 3.0 Hz], 130.3 [d, J(13C–31P) = 5.7 Hz], 127.7 [d, J(13C–31P) = 8.6 Hz], 116.4 [d, 
J(13C–31P) = 2.6 Hz], 35.4 [d, br, 1J(13C–31P) = 126.6 Hz]; 31P NMR (D2O, 101 MHz): 
δ 20.0 (s); IR (ATR) max = 2603, 1628, 1576, 1566, 1515, 1438, 1337, 1228, 1155, 
1088, 1060, 929, 850, 829, 768, 748, 699 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: 









4.2.4.21. (2-Methylbenzyl)phosphonic acid (MK-27) 
 
Synthesis was followed through method A.  
 
 
Yield 59%; Found m.p. 194–197 °C, lit. 153–153.5 °C [174]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.27–7.24 (m, 1H), 7.16–7.10 (m, 3H), 3.14 [d, br, 
2J(1H–31P) = 21.9 Hz, 2H], 2.38 (d, J = 1.5 Hz, 3H); 13C NMR (CD3OD, 100 MHz): δC 
(ppm) 138.2 [d, J(13C–31P) = 6.4 Hz], 132.9 [d, J(13C–31P) = 9.4 Hz], 131.9 [d, J(13C–
31P) = 5.3 Hz], 131.4 [d, J(13C–31P) = 3.2 Hz], 127.9 [d, J(13C–31P) = 3.7 Hz], 127.0 [d, 
J(13C–31P) = 3.4 Hz], 33.1 [d, br, 1J(13C–31P) = 134.5 Hz], 20.2; 31P NMR (CD3OD, 
101 MHz): δ 23.2 (s); IR (ATR) max = 1491, 1463, 1411, 1266, 1187, 1168, 1091, 
1048, 1013, 965, 947, 937, 847, 779, 736, 705 cm-1; FTMS (LTQ Orbitrap XL–ESI) 
m/z: calcd. for C8H11O3P [M–H]– = 185.03676; observed [M–H]– = 185.03616. 
 
4.2.4.22. (3-Methylbenzyl)phosphonic acid (MK-28) 
 
Synthesis was followed through method A.  
 
 
Yield 61%; Found m.p. 186–188 °C; 1H NMR (CD3OD, 400 MHz): δH 
(ppm) 7.18–7.02 (m, 4H), 3.06 [d, br, 2J(1H–31P) = 21.6 Hz, 2H], 2.31 (s, 3H); 13C 
NMR (CD3OD, 100 MHz): δC (ppm) 139.1 [d, J(13C–31P) = 2.9 Hz], 134.3 [d, J(13C–
31P) = 9.1 Hz], 131.7 [d, J(13C–31P) = 6.3 Hz], 129.4 [d, J(13C–31P) = 2.9 Hz], 128.3 [d, 
J(13C–31P) = 3.4 Hz], 128.1 [d, J(13C–31P) = 6.3 Hz], 35.9 [d, br, 1J(13C–31P)] = 134.0 
Hz], 21.5; 31P NMR (CD3OD, 101 MHz): δ 22.9 (s); IR (ATR) max = 1606, 1483, 1403, 
1277, 1239, 1049, 983, 949, 794, 692 cm-1; FTMS (LTQ Orbitrap–ESI) m/z: calcd. for 








4.2.4.23. (4-Methylbenzyl)phosphonic acid (MK-12) 
 
Synthesis was followed through method A.  
 
 
Yield 49%; Found m.p. 184.3–185.1 °C, lit. 185–187 °C [175]; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.18 (dd, J = 8.1 and 2.3 Hz, 2H), 7.10 (d, J = 7.9 Hz, 
2H), 3.07 [d, br, 2J(1H–31P) = 21.5 Hz, 2H], 2.29 (d, J = 2.1 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz): δC (ppm) 137.3 [d, J(13C–31P) = 3.6 Hz], 131.3 [d, J(13C–31P) = 
9.3 Hz], 130.9 [d, J(13C–31P) = 6.3 Hz], 130.1 [d, J(13C–31P) = 2.9 Hz], 35.5 [d, br, 
1J(13C–31P) = 134.4 Hz], 21.2; 31P NMR (CD3OD, 101 MHz): δ 24.6 (s); IR (ATR) max 
= 1514, 1268, 1096, 995, 968, 948, 938, 820, 696  cm-1; FTMS (LTQ Orbitrap XL–
ESI) m/z: calcd. for C8H11O3P [M–H]– = 185.03676; observed [M–H]– = 185.03668. 
 
4.2.4.24. (4-Cyanobenzyl)phosphonic acid (MK-41) 
 
Synthesis was followed through method B. 
  
 
Yield 56%; Found m.p. 171–173 °C; 1H NMR (CD3OD, 250 MHz): δH 
(ppm) 7.66 (d, J = 8.3 Hz, 2H), 7.49 (dd, J = 8.3 and 2.3 Hz, 2H), 3.21 [d, br, 2J(1H–
31P) = 22.2 Hz, 2H]; 13C NMR (CD3OD, 150 MHz): δC (ppm) 141.0 [d, J(13C–31P) = 
9.1 Hz], 133.3 [d, J(13C–31P) = 2.9 Hz], 132.1 [d, J(13C–31P) = 6.2 Hz], 119.9, 111.5 
[d, J(13C–31P) = 3.6 Hz], 36.3 [d, br, 1J(13C–31P) = 132.9 Hz]; 31P NMR (CD3OD, 101 
MHz): δ 22.2 (s); IR (ATR) max = 2237, 1608, 1507, 1417, 1408, 1254, 1174, 1130. 
1104, 1029, 939, 849, 830, 765, 740, 668  cm-1. FTMS (LTQ Orbitrap XL–ESI) m/z: 










4.2.4.25. (1,4-phenylenebis(methylene))diphosphonic acid (MK-16) 
 
Synthesis was followed through method A.  
 
 
Yield 32%; Found: the m.p. was not observed up to 280 °C, lit. 190 °C 
[176]; 1H NMR (DMSO-d6, 400 MHz): δH (ppm) 7.15 (s, 4H),  2.91 [d, br, 2J(1H–31P) = 
20.0 Hz, 2H]; 13C NMR (DMSO-d6, 100 MHz): δC (ppm) 131.7, 129.3, 35.0 [d, br, 
1J(13C–31P) = 131.7 Hz]; 31P NMR (DMSO-d6, 101 MHz): δ 21.1 (s); IR (ATR) max = 
1510, 1422, 1397, 1264, 1231, 1113, 1088, 993, 970, 942, 803, 749  cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C8H12O6P2 [M–H]– = 265.00309; observed [M–
H]– = 265.00385. 
 
4.2.5. General procedure for the synthesis of substituted sodium 
phenylmethanesulfonates (series 7) 
 
The mixture of substituted benzyl bromide or chloride (1.0 mmol) and 
sodium sulfite (Na2SO3) (1.0 mmol) were suspended in water (10 ml) in a round 
bottom flask.[143] The reaction mixture was refluxed at 95–100 °C for 24 h. After 
completion of the TLC, the solvent was evaporated and salts were recrystallized from 
ethyl acetate and ethanol to obtain the products as colorless solids. The solid 
compounds were dried in oven at 60 °C under vacuum.  
 
4.2.5.1. Sodium (2-fluorophenyl)methanesulfonate (MK-24a)  
 
 
Yield 58%; Found: the m.p. was not observed up to 250 °C; 1H NMR 
(CD3OD, 400 MHz): δH (ppm) 7.53 (td, J = 7.6 and 1.6 Hz, 1H), 7.32–7.26 (m, 1H), 
7.13 (td, J = 7.6 and 1.0 Hz, 1H), 7.07 (t, br, J = 9.0 and 0.8 Hz, 1H), 4.13 (s, 2H); 13C 
NMR (CD3OD, 125 MHz): δC (ppm) 162.8 [d, br, 1J(13C–19F) = 245.2 Hz], 133.9 [d, 





121.9 [d, 2J(13C–19F) = 15.0 Hz], 116.2 [d, 2J(13C–19F) = 22.3 Hz], 51.1; 19F NMR 
(CD3OD, 235 MHz): δ -119.7 (s); IR (ATR) max = 3000, 2956, 1587, 1496, 1456, 
1260, 1236, 1219, 1204, 1183, 1146, 1055, 785, 750, 713 cm-1; FTMS (LTQ Orbitrap 
XL–ESI) m/z: calcd. for C7H6FNaO3S [M–Na]– = 189.00217; observed [M–Na]– = 
189.00153. 
 
4.2.5.2. Sodium (3-fluorophenyl)methanesulfonate (MK-24b) 
 
 
Yield 50%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
500 MHz): δH (ppm) 7.48–7.43 (m, 1H), 7.28–7.16 (m, 3H), 4.22 (s, 2H); 13C NMR 
(D2O, 125 MHz): δC (ppm) 162.4 [d, br, 1J(13C–19F) = 241.7 Hz], 134.0 [d, 3J(13C–19F) 
= 8.1 Hz], 130.3 [d, 3J(13C–19F) = 8.6 Hz], 126.3 [d, 4J(13C–19F) = 2.7 Hz], 117.0 [d, 
2J(13C–19F) = 21.9 Hz], 114.8 [d, 2J(13C–19F) = 20.9 Hz], 56.4; 19F NMR (D2O,  235 
MHz): δ -114.1 (s); IR (ATR) max = 1660, 1618, 1592, 1489, 1450, 1237, 1214, 1174, 
1144, 1050, 1042, 950, 885, 792, 776, 746, 688 cm-1; FTMS (LTQ Orbitrap XL–ESI) 
m/z: calcd. for C7H6FNaO3S [M–Na]– = 189.00217; observed [M–Na]– = 189.00212. 
 
4.2.5.3. Sodium (4-fluorophenyl)methanesulfonate (MK-24) 
 
 
Yield 48%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.51–7.45 (m, 2H), 7.26–7.16 (m, 2H), 4.22 (s, 2H); 13C NMR 
(D2O, 100 MHz): δC (ppm) 162.4 [d, br, 1J(13C–19F) = 242.2 Hz], 132.1 [d, 3J(13C–19F) 
= 8.4 Hz], 127.7 [d, 4J(13C–19F) = 3.0 Hz], 115.3 [d, 2J(13C–19F) = 21.6 Hz], 56.0; 19F 
NMR (D2O, 235 MHz): δ -115.2 (s); IR (ATR) max = 2948, 1603, 1506, 1422, 1403, 
1215, 1193, 1144, 1094, 1049, 1011, 888, 833, 787, 757, 702 cm-1; FTMS (LTQ 
Orbitrap XL–ESI) m/z: calcd. for C7H6FNaO3S [M–Na]– = 189.00217; observed [M–








4.2.5.4. Sodium [(2-trifluoromethyl)phenyl]methanesulfonate (MK-32) 
 
 
Yield 38%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
600 MHz): δH (ppm) 7.82 (d, J = 7.9 Hz, 1H), 7.74 (d, J = 7.7 Hz, 1H), 7.70 (t, J = 7.6, 
1H), 7.60 (t, J = 7.7 Hz, 1H), 4.45 (s, 2H); 13C NMR (D2O, 150 MHz): δC (ppm) 132.7, 
132.1, 129.7, 128.7 [q, 2J(13C–19F) = 29.7 Hz], 128.4, 126.5 [q, 3J(13C–19F) = 5.4 Hz], 
124.3 [q, br, 1J(13C–19F) = 271.8 Hz], 53.4; 19F NMR (CD3OD, 235 MHz): δ -58.0 (d); 
IR (ATR) max = 3544, 3467, 3413, 1615, 1502, 1455, 1315, 1274, 1218, 1188, 1175, 
1139, 1103, 1065, 1029, 971, 883, 839, 793, 782, 772, 760, 724,  1236, 1219, 1204, 
1183, 1146, 1055, 785, 750, 732, 713 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. 
for C8H6F3NaO3S [M–Na]– = 238.99897; observed [M–Na]– = 238.99977. 
 
4.2.5.5. Sodium [(3-trifluoromethyl)phenyl]methanesulfonate (MK-33) 
 
 
Yield 35%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
400 MHz): δH (ppm) 7.80 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.71 (d, J = 7.8, 1H), 7.63 
(t, J = 7.7 Hz, 1H), 4.30 (s, 2H); 13C NMR (D2O, 100 MHz): δC (ppm) 134.0, 132.8, 
130.1 [q, 2J(13C–19F) = 31.8 Hz], 129.2,  127.0 [d, 3J(13C–19F) = 3.8 Hz], 124.8 [d, 
3J(13C–19F) = 3.8 Hz], 124.1 [q, br, 1J(13C–19F) = 269.9 Hz], 56.4; 19F NMR (D2O, 470 
MHz): δ -62.4 (s); IR (ATR) max = 2958, 2925, 1452, 1332, 1225, 1189, 1176, 1153, 
1118, 1075, 1053, 997, 916, 894, 810, 778, 704 cm-1; FT–ICR Ultra (ESI/MS) m/z: 
calcd. for C8H6F3NaO3S [M–Na]– = 238.99897; observed [M–Na]– = 238.99946. 
 
4.2.5.6. Sodium [(4-trifluoromethyl)phenyl]methanesulfonate (MK-8) 
 
 
Yield 38%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
600 MHz): δH (ppm) 7.75 (d, J = 7.7 Hz, 2H), 7.60 (d, J = 7.7, 2H), 4.28 (s, 2H); 13C 





[d, 3J(13C–19F) = 3.6 Hz], 124.3 [q, br, 1J(13C–19F) = 269.9 Hz], 56.5; 19F NMR (D2O, 
235 MHz): δ -62.3 (s); IR (ATR) max = 1655, 1620, 1417, 1326, 1162, 1118, 1047, 
1020, 853 cm-1; FT–ICR Ultra (ESI/MS) m/z: calcd. for C8H6F3NaO3S [M–Na]– = 
238.99897; observed [M–Na]– = 238.99932. 
 




Yield 32%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
400 MHz): δH (ppm) 4.36 (s, 2H); 13C NMR (D2O, 125 MHz): δC (ppm) 145.5 [d, br, 
1J(13C–19F) = 247.0 Hz], 141.0 [d, br, 1J(13C–19F) = 260.0 Hz], 137.4 [d, br, 1J(13C–
19F) = 248.3 Hz], 106.4 [t, 2J(13C–19F) = 13.9 Hz], 44.3; 19F NMR (D2O, 470 MHz): δ -
142.5 [dd, 3J(19F–19F) = -7.1 Hz], δ -154.8 [t, 3J(19F–19F) = -21.0 Hz], δ -162.9 [td, 
3J(19F–19F) = -6.3 Hz]; IR (ATR) max = 3011, 2958, 1660, 1531, 1509, 1276, 1203, 
1192, 1182, 1131, 1049, 992, 976, 887, 790, 732, 680 cm-1; FT–ICR Ultra (ESI/MS) 
m/z: calcd. for C7H2F5NaO3S [M–Na]– = 260.96448; observed [M–Na]– = 260.96466. 
 
4.2.5.8. Sodium (4-chlorophenyl)methanesulfonate (MK-3) 
 
 
Yield 45%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.45 (s, 4H), 4.20 (s, 2H); 13C NMR (D2O, 100 MHz): δC (ppm) 
133.4, 131.8, 130.5, 128.6, 56.2; IR (ATR) max = 2954, 1488, 1414, 1217, 1192, 
1173, 1145, 1103, 1049, 1013, 891, 825, 770, 714 cm-1; FTMS (LTQ Orbitrap XL–
ESI) m/z: calcd. for C7H6ClNaO3S [M–Na]– = 204.97262, [(M+2)–Na]– = 206.96967; 









4.2.5.9. Sodium (2-bromophenyl)methanesulfonate (MK-4) 
 
 
Yield 74%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.74 (d, J = 7.9 Hz, 1H), 7.58 (d, J = 7.4 Hz, 1H), 7.46 (t, J = 7.4 
Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 4.47 (s, 2H); 13C NMR (D2O, 100 MHz): δC (ppm) 
133.1, 132.4, 131.4, 129.9, 127.8, 124.9, 56.3; IR (ATR) max = 1616, 1477, 1433, 
1273, 1229, 1206, 1192, 1154, 1052, 1045, 1021, 948, 785, 749, 707 cm-1; FT–ICR 
Ultra (ESI/MS) m/z: calcd. for C7H6BrNaO3S [M–Na]– = 248.92210, [(M+2)–Na]– = 
250.92006; observed [M–Na]– = 248.92244, [(M+2)–Na]– = 250.92041. 
 
4.2.5.10. Sodium (4-bromophenyl)methanesulfonate (MK-10) 
 
 
Yield 47%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.62 (d, J = 7.1 Hz, 2H), 7.37 (d, J = 7.3 Hz, 2H), 4.19 (s, 2H); 
13C NMR (D2O, 100 MHz): δC (ppm) 132.1, 131.6, 131.0, 121.5, 56.3; IR (ATR) max = 
2940, 1483, 1411, 1398, 1239, 1218, 1191, 1174, 1145, 1053, 1009, 891, 823, 762, 
702 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C7H6BrNaO3S [M–Na]– = 
248.92210, [(M+2)–Na]– = 250.92006; observed [M–Na]– = 248.92264, [(M+2)–Na]– = 
250.91930. 
 




Yield 28%; Found: m.p. 242–245 °C (decomposed); 1H NMR (D2O, 250 
MHz): δH (ppm) 7.23 (s, 1H), 7.08 (s, 1H), 6.10 (s, 2H), 4.36 (s, 2H); 13C NMR (D2O, 
62.5 MHz): δC (ppm) 147.9, 147.1, 124.3, 115.7, 112.7, 111.4, 102.1, 56.1; IR (ATR) 
max = 3425, 1633, 1501, 1483, 1403, 1386, 1359, 1241, 1192, 1126, 1050, 1032, 
966, 928, 886, 831, 786, 772, 681 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 





292.91260, [(M+2)–Na]– = 294.90918. 
  
4.2.5.12. Sodium (2-bromo-5-methoxyphenyl)methanesulfonate (MK-46) 
 
 
Yield 62%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.58 (d, J = 8.9 Hz, 1H), 7.13 (d, J = 3.0 Hz, 1H), 6.91 (dd, J = 
8.9 and 3.0 Hz, 1H), 4.37 (s, 3H), 3.87 (s, 2H); 13C NMR (D2O, 62.5 MHz): δC (ppm) 
158.1, 133.6, 132.3, 117.4, 115.8, 115.7, 56.3, 55.6; IR (ATR) max = 3456, 2969, 
2931, 1640, 1593, 1479, 1463, 1400, 1315, 1273, 1242, 1198, 1172, 1146, 1115, 
1053, 1041, 1016, 947, 866, 820, 777, 701 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: 
calcd. for C8H8BrNaO4S [M–Na]– = 278.93267, [(M+2)–Na]– = 280.93062; observed 
[M–Na]– = 278.93240, [(M+2)–Na]– = 280.92886. 
 
4.2.5.13. Sodium (4-methoxylphenyl)methanesulfonate (MK-36) 
 
 
Yield 34%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
400 MHz): δH (ppm) 7.39 (d, J = 8.8 Hz, 2H), 7.04 (d, J = 8.8 Hz, 2H), 4.15 (s, 2H), 
3.87 (s, 3H); 13C NMR (D2O, 125 MHz): δC (ppm) 158.6, 131.7, 124.3, 114.1, 56.1, 
55.4; IR (ATR) max = 1510, 1119, 1055, 995, 957, 828, 776 cm-1; FTMS (LTQ 
Oribitrap XL–ESI) m/z: calcd. for C8H9NaO4S [M–Na]– = 201.02215; observed [M–
Na]– = 201.02185. 
 
4.2.5.14. Sodium (3, 5-dimethoxylphenyl)methanesulfonate (MK-37) 
 
 
Yield 70%; Found: m.p. 243.5–247.5 °C (decomposed); 1H NMR (D2O, 
400 MHz): δH (ppm) 6.69 (d, J = 2.2 Hz, 2H), 6.57 (t, J = 2.2 Hz, 1H), 4.15 (s, 2H), 
3.87 (s, 6H); 13C NMR (D2O, 100 MHz): δC (ppm) 160.0, 134.2, 108.9, 100.0, 56.9, 





1271, 1250, 1214, 1200, 1187, 1161, 1146, 1074, 1044, 940, 850, 811, 770, 696 cm-
1; FT–ICR Ultra (ESI/MS) m/z: calcd. for C9H11NaO5S [M–Na]– = 231.03272; 
observed [M–Na]– = 231.03308. 
 
4.2.5.15. Sodium (4-nitrophenyl)methanesulfonate (MK-5) 
 
 
Yield 85%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 8.31 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 4.38 (s, 2H); 
13C NMR (D2O, 100 MHz): δC (ppm) 147.3, 139.6, 131.4, 123.7, 56.5; IR (ATR) max = 
1634, 1613, 1538, 1494, 1351, 1272, 1213, 1189, 1134, 1055, 1015, 869, 860, 778, 
738, 702 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C7H6NNaO5S [M–Na]– = 
215.99667; observed [M–Na]– = 215.99663. 
 
4.2.5.16. Sodium (4-cyanophenyl)methanesulfonate (MK-42) 
 
 
Yield 52%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
400 MHz): δH (ppm) 7.83 (d, J = 8.1 Hz, 2H), 7.63 (d, J = 8.3 Hz, 2H), 4.32 (s, 2H); 
13C NMR (D2O, 100 MHz): δC (ppm) 137.6, 132.6, 131.1, 119.7, 110.5, 56.8; IR 
(ATR) max = 2948, 2233, 1603, 1499, 1416, 1240, 1217, 1193, 1174, 1143, 1053, 
1019, 896, 833, 776, 746, 696 cm-1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 
C8H6NNaO3S [M–Na]– = 196.00684; observed [M–Na]– = 196.00630. 
 
4.2.5.17. Sodium (4-carboxyphenyl)methanesulfonate (MK-40) 
 
 
Yield 35%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
500 MHz): δH (ppm) 8.02 (d, J = 7.9 Hz, 2H), 7.56 (d, J = 7.9 Hz, 2H), 4.28 (s, 2H); 
13C NMR (D2O, 125 MHz): δC (ppm) 170.6, 137.3, 130.6, 129.8, 129.5, 56.7; IR 
(ATR) max = 1681, 1613, 1428, 1292, 1217, 1190, 1135, 1058, 1021, 996, 943, 866, 





Na]– = 215.00142; observed [M–Na]– = 215.00140. 
 
4.2.5.18. Sodium [4-(hydroxymethyl)phenyl]methanesulfonate (MK-45) 
 
 
Yield 70%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.46 (s, 4H), 4.69 (s, 2H), 4.23 (s, 2H); 13C NMR (D2O, 100 
MHz): δC (ppm) 139.9, 131.1, 130.6, 127.6, 63.6, 56.6; IR (ATR) max = 2945, 1510, 
1414, 1222, 1193, 1147, 1128, 1059, 1046, 1018, 1005, 888, 839, 825, 757, 696 cm-
1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H9NaO4S [M–Na]– = 201.02215; 
observed [M–Na]– = 201.02150. 
 
4.2.5.19. Sodium (1,4-phenylene)dimethanesulfonate (MK-38) 
 
 
Yield 83%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.49 (s, 4H), 4.26 (s, 4H); 13C NMR (D2O, 100 MHz): δC (ppm) 
131.5, 130.5, 56.6; IR (ATR) max = 2945, 1510, 1420, 1400, 1221, 1192, 1143, 1046, 
1017, 968, 891, 833, 817, 743 cm-1. FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for 
C8H8Na2O6S2 [M–Na]– = 286.96600; observed [M–Na]– = 286.96579. 
 
4.2.5.20. Sodium (2-methylphenyl)methanesulfonate (MK-25) 
 
 
Yield 35%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.44–7.34 (m, 4H), 4.30 (s, 2H), 2.46 (s, 3H); 13C NMR (D2O, 
100 MHz): δC (ppm) 138.2, 131.4, 130.6, 130.2, 128.3, 126.1, 54.1, 18.8; IR (ATR) 
max = 1658, 1494, 1414, 1209, 1170, 1134, 1046, 996, 790, 737, 707 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C8H9NaO3S [M–Na]– = 185.02724; observed 







4.2.5.21. Sodium (3-methylphenyl)methanesulfonate (MK-26) 
 
 
Yield 38%; Found: the m.p. was not observed up to 250 °C; 1H NMR (D2O, 
250 MHz): δH (ppm) 7.40–7.31 (m, 4H), 4.19 (s, 2H), 2.40 (s, 3H); 13C NMR (D2O, 
100 MHz): δC (ppm) 138.8, 131.7, 131.0, 128.6, 127.3, 56.8, 20.4; IR (ATR) max = 
2958, 1609, 1491, 1222, 1188, 1174, 1150, 1056, 793, 772, 744, 696 cm-1; FTMS 
(LTQ Orbitrap XL–ESI) m/z: calcd. for C8H9NaO3S [M–Na]– = 185.02724; observed 
[M–Na]– = 185.02721. 
 
4.2.5.22. Sodium (4-methylphenyl)methanesulfonate (MK-21) 
 
 
Yield 35.5%; Found: the m.p. was not observed up to 250 °C; 1H NMR 
(D2O, 250 MHz): δH (ppm) 7.38–7.29 (m, 4H), 4.18 (s, 2H), 2.40 (s, 3H); 13C NMR 
(D2O, 100 MHz): δC (ppm) 138.3, 130.3, 129.2, 128.6, 56.5, 20.2; IR (ATR) max = 
2943, 1513, 1417, 1221, 1210, 1193, 1145, 1053, 1022, 888, 820, 781, 748, 702 cm-
1; FTMS (LTQ Orbitrap XL–ESI) m/z: calcd. for C8H9NaO3S [M–Na]– = 185.02724; 
observed [M–Na]– = 185.02667. 
 
4.2.6. General procedure for the synthesis of substituted benzylboronic acids 
(series 8)  
 
Benzyl bromide or chloride (1.0 mmol) dissolved in anhydrous diethyl 
ether, and then added dropwise to magnesium turnings (2.0 mmol) in a round bottom 
flask with stirring under N2 in an ice bath. After that, the reaction mixture was stirred 
further 20 minutes at room temperature. The Grignard solution was added dropwise 
to a solution of trimethyborate (1.0 mmol) in anhydrous diethyl ether at -78 °C. The 
reaction mixture was stirred at -78 °C for 15 minutes, and then warmed to room 
temperature.[144, 145] The resulting mixture was stirred for additional 1 h to obtain 
borane esters, and then the solution pH was adjusted to 1.0–2.0 with 6 M HCl. 





obtain the desired products as colorless solids.  
 
4.2.6.1. Benzylboronic acid (KA-0) 
 
 
Yield 37%; Found m.p. 48–50 °C; 1H NMR (CDCl3, 250 MHz): δH (ppm) 
7.38–7.24 (m, 5H), 3.00 (s, 2H); 13C NMR (CDCl3, 62.5 MHz): δC (ppm) 142.0, 128.6, 
128.5, 126.1, 38.1; IR (ATR) max = 3057, 3027, 2918, 2851, 1600, 1491, 1451, 1260, 
1177, 1142, 1064, 1028, 750, 697 cm-1. 
 
4.2.6.2. (2-Fluorobenzyl)boronic acid (KA-2) 
 
 
Yield 28%; Found m.p. 40–42 °C; 1H NMR (CDCl3, 250 MHz): δH (ppm) 
7.26–7.00 (m, 4H), 3.00 (s, 2H); 13C NMR (CDCl3, 62.5 MHz): δC (ppm) 161.4 [d, br, 
1J(13C–19F) = 243.4 Hz], 130.9 [d, 3J(13C–19F) = 5.1 Hz], 128.4 [d, 2J(13C–19F) = 15.8 
Hz], 128.0 [d, 3J(13C–19F) = 8.0 Hz], 124.1 [d, 4J(13C–19F) = 3.6 Hz], 115.4 [d, 2J(13C–
19F) = 22.0 Hz], 29.9; 19F NMR (CDCl3, 235 MHz): δ -119.0 (s); IR (ATR) max = 2936, 
2868, 1617, 1585, 1489, 1458, 1229, 1183, 1160, 1086, 1031, 945, 843, 758 cm-1. 
 
4.2.6.3. (4-Fluorobenzyl)boronic acid (KA-1) 
 
 
Yield 27%; Found m.p. 88–93 °C; 1H NMR (CDCl3, 250 MHz): δH (ppm) 
7.11–7.05 (m, 2H), 7.00–6.92 (m, 2H), 2.87 (s, 2H); 13C NMR (CDCl3, 100 MHz): δC 
(ppm) 161.6 [d, br, 1J(13C–19F) = 242.1 Hz], 137.2 [d, 4J(13C–19F) = 3.0 Hz], 130.0 [d, 
3J(13C–19F) = 7.7 Hz], 115.3 [d, 2J(13C–19F) = 21.0 Hz], 37.3; 19F NMR (CDCl3, 235 
MHz): δ -117.5 (s); IR (ATR) max = 2948, 2923, 2860, 1893, 1600, 1507, 1458, 1414, 








4.2.6.4. (2-Bromobenzyl)boronic acid (KA-8) 
 
 
Yield 32%; Found m.p. 81–83.5 °C; 1H NMR (CDCl3, 250 MHz): δH (ppm) 
7.54 (d, J = 7.7 Hz, 1H), 7.24–7.16 (m, 2H), 7.10–7.02 (m, 1H), 3.03 (s, 2H); 13C 
NMR (CDCl3, 125 MHz): δC (ppm) 140.8, 133.0, 130.8, 128.0, 127.6, 124.7, 36.6; IR 
(ATR) max = 3071, 3055, 2951, 2932, 2860, 1566, 1470, 1453, 1438, 1291, 1277, 
1154, 1095, 1039, 1018, 806, 751, 721 cm-1. 
 
4.2.6.5. (4-Methoxybenzyl)boronic acid (KA-12) 
 
 
Yield 31%; Found m.p. 127–130 °C, lit. 86–88 °C[144]; 1H NMR (CDCl3, 
250 MHz): δH (ppm) 7.07 (d, J = 7.4 Hz, 2H), 6.81 (d, J = 7.7 Hz, 2H), 3.78 (s, 3H), 
2.82 (s, 2H); 13C NMR (CDCl3, 62.5 MHz): δC (ppm) 158.0, 134.2, 129.6, 114.0, 55.4, 
37.5; IR (ATR) max = 3027, 3008, 2967, 2932, 2914, 2851, 2840, 1898, 1735, 1610, 
1581, 1505, 1463, 1441, 1367, 1301, 1242, 1176, 1143, 1095, 1030, 832, 724 cm-1. 
 
4.2.6.6. (2-Methylbenzyl)boronic acid (KA-5) 
 
 
Yield 26%; Found m.p. 66–68.5 °C; 1H NMR (CDCl3, 500 MHz): δH (ppm) 
7.20–7.13 (m, 4H), 2.88 (s, 2H), 2.34 (s, 3H); 13C NMR (CDCl3, 125 MHz): δC (ppm) 
140.4, 136.1, 130.4, 129.1, 126.3, 126.2, 34.3, 19.5; IR (ATR) max = 3058, 3019, 
2950, 2868, 1491, 1456, 1378, 1156, 1088, 1036, 866, 756, 725 cm-1. 
 
4.2.6.7. (4-Methylbenzyl)boronic acid (KA-7) 
 
 





(s, 4H), 2.87 (s, 2H), 2.33 (s, 3H); 13C NMR (CDCl3, 62.5 MHz): δC (ppm) 139.1, 
135.5, 129.2, 128.5, 37.8, 21.2; IR (ATR) max = 3046, 3019, 2945, 2917, 2854, 1895, 
1514, 1453, 1375, 1208, 1139, 1098, 1043, 811 cm-1. 
 
 
4.3. Enzyme inhibition assays 
 
The selected compounds were submitted to triage according to the 
protocols presented in below. Both tyrosine phosphatases (PTP1B & LMW-PTP) 
were available in institute of chemistry (IQ/UNICAMP). Additionally, CDC25B was 
available in the LNBIo-CNPEM group. The data was recorded for PTP1B and LMW-
PTP in Spectramax®M2e spectrometer. The protein CDC25B assays were carried 
out at LNBIo-CNPEM in HTS assay. The inhibition assays and IC50 were conducted 
with the help of Dr. Emanuella M. B. Fonseca, Dr. Maruska do Rocio Neufert 
Fernandes (IB / Unicamp), Dr. Daniela B. B. Trivella (LNBIo-CNPEM), Arthur Zanetti 
Nunes Fernandes (LNBIo-CNPEM) and Prof. Dr. Carmen Veríssima Ferreira (IB / 
Unicamp). The in-vitro PTP1B, LMW-PTP, and CDC25B inhibition screening studies 
for compounds were done using the following procedure: 
Brief procedure- Incubate the enzyme with the substrate para-nitrophenol 
(pNPP) and inhibitor. After a period of time, the reaction is stopped using NaOH. 
Then, the absorbance of the product para-nitrophenol (pNP), is recorded and the 
activity is obtained as the ratio of this value (obtained in the presence of inhibitor) to 
the absorbance seen without the inhibitor.  
Molecular device plate reader (96 well)- The micro plate reader can detect 
many common biological, biochemical microplate-based assays including enzyme-
linked immunosorbent assays (ELISAs), nucleic acid quantitation, protein 
quantitation, enzymatic activity, and cell signaling.[177] It offers a range of single-
mode readers and all standard detection modes such as absorbance, fluorescence 
and luminescence. Enzymatic activity was monitored via a single point quenched 








Figure 35 – Substrate reaction scheme for biological activity detection - The phosphatases 
remove the phosphate group to generate p-nitrophenol, which is deprotonated under alkaline 
conditions to produce p-nitrophenolate that has strong absorption at 405 nm. 
 
 
4.3.1. PTP1B and LMW-PTP 
 
Due to solubility restrictions, the final inhibitor concentrations were 1 mM for 
only three compounds (KSR-6aa, KAM-4 & 5). The remaining one-hundred and fifty-
one compounds were assayed in 5 mM solutions. The reaction mixture (80 μL) was 
composed of 100 mM sodium acetate as buffer (pH 5 for both PTP1B and LMW-PTP). 
The inhibitor was incubated with the protein in a solution buffer for 10 minutes at 37 °C. 
After incubation, the reaction was started by adding the 10 μL of probe (pNPP, p-
nitrophenyl phosphate, 1 mM). The enzymatic reaction occurred for 10 minutes at 37 
°C and then it was stopped by adding 100 μL of 1M NaOH. Product formation was 
measured by absorbance at 405 nm. The data were normalized to a DMSO and H2O 
control (100%) and expressed as percent of the residual activity. All the assays were 
conducted in triplicates. In either case, enzyme concentration did not exceed 0.1% of 
substrate.[178] Final phosphatases concentrations were 20 nM for PTP1B and 38 nM 
for LMW-PTP. In order to saturate the enzyme with a substrate concentration of at 




An HTS assay was used to evaluate CDC25B inhibition by the compounds 
following a previously established method.[179] This procedure was carried out using 
a Versette liquid handler (Thermo Scientific). Inhibitor solutions were prepared in 
96-wells polypropylene plates, in DMSO, at a concentration of 2 mM, and the final 





100 μM. The activity of phosphatases in the presence of DMSO/H2O solution 
(control) was considered as 100%. 
Each well was prepared by adding 45 μL of a solution containing purified 
CDC25B at 200 nM in 100 mM bis-tris propane (pH 8.2) and 0.005% (v/v) Triton X-
100 buffer. The inhibitor (2.5 μL at 2 mM) was added to the wells containing the 
enzyme/buffer solution and this mixture was incubated for ten minutes at room 
temperature. After the incubation period, the reaction was started by adding the 
2.5 μL of pNPP substrate. At 100 mM (final pNPP concentration was 5 mM), which 
was in the range of the enzyme KM value. The enzymatic reaction occurred for 
50 minutes at 37oC and stopped by adding 50 μL of 1M NaOH. Product formation 
(p-nitrophenol) was quantified by absorbance at 405 nm. The data was read out in a 
Claro Star plate reader (BMG Labtech). 
Data were normalized to the reaction conducted in the absence of inhibitor 
(DMSO and H2O only, at the same reaction conditions) and expressed as percent of 
residual enzyme activity. Positive and negative controls were carried out in each 
plate (n = 8/each/plate). The Z’ parameter was used to access assay quality and 
showed the results 0.79, 0.81 and 0.85. 
 
4.3.3. IC50 measurements 
 
4.3.3.1. PTP1B and LMW-PTP 
 
For IC50 values, same protocol was used for both enzymes. The IC50 
values of the enzyme were determined by dose-response curve.  We selected the 
compounds which showed at least 50% inhibition of enzyme activity. The 
concentrations of the compounds used in the assays were ranging from 5.0 mmol L-1 
to 5 μmol L-1. These concentrations were obtained according to a serial dilution 
method and followed to carry out the assay.  Enzymes and inhibitors were incubated 
in the same buffer solution (sodium acetate buffer pH 5) for 10 minutes before adding 
the substrate. After that, the substrate para-nitrophenyl phosphate (pNPP) was 
added. The relative absorbance was measured at 405 nm after 10 minutes of 
reaction. The final reaction was stopped by adding 1 mmol L-1 NaOH. All experiments 








We also tried to obtain protein-ligand complexes either by cocrystallization of 
protein and ligand, or by soaking apo protein crystals into a solution containing the ligands 




Based on IC50 values, most activity inhibitors were selected for 
crystallization in different conditions of solubility and buffer concentration. Two 
different concentrations of PTP1B enzyme (7 and 10 mg/ml)  as well as 10 mM Tris 
pH 7.5, 25 mM NaCl, and 3 mM DTT were utilized for crystallization at 4 ºC.[38] 
Crystals were grown by the sitting method using a 1:15 (1PTP1B: 15 inhibitor) molar 
ratio. Additionally, 4 μl of PTP1B-inhibitor solution was mixed with 4 μl of precipitating 
solution containing 0.1 M HEPES pH 7.5, 0.2 M magnesium acetate, and 10-20 % 
PEG 8000 at 4 ºC.[56, 180–183]  
Furthermore, apo crystal (without inhibitor) was soaked with a solution 
enriched with 50% (v/v) of ligands. The crystals started from 1-2 weeks of the initial 
step. The crystallization conditions are varied in each case. The data sets were 
collected, but after solving the structure the inhibitor did not appear in any of the 
electron density maps (Figure 36).  
 
 
Figure 36. Electron density map of Apo structure PTP1B showing the catalytic 










The  X-ray diffraction data was collected at 100 K on beamline I04 in the 
Diamond Light Source (Didcot-UK), using Pilatus a 6M detector ( = 0.9794 Å). The 
diffraction data was indexed, integrated and scaled using xia2 package. 
 
Structure solution and refinement 
 
The structure was solved by molecular replacement calculations with 
Phaser program[184] using the structure of apo PTP1B (PDB ID: 3A5J) as the 
search model. The structure was refined using Phenix[185] and COOT[186] for 
model building into σa-weighted 2Fo-Fc  and Fo-Fc electron density 
maps. Both R and Rfree were monitored in order evaluate the validity of the 





The most active compounds were selected and kept for crystallization in 
two ways as described below. The concentration of LMW-PTP used range from 9 to 
12 mg mL-1 and the concentration of inhibitor used was 10 times the concentration of 
LMW-PTP. The crystallization of LMW-PTP sets was performed using the hanging 
drop method. For this, LMW-PTP solution was mixed with reservoir solution 
containing buffer showed below (i & ii) in a proportion of 1:1. The crystals grow in two 
conditions: 
i) At 18 ° C, in a precipitating solution containing 0.1 mol L-1 MES pH 6.5, 
as a buffer, 15% PEG5000, and 20 mmol L-1 ammonium sulfate. The crystal data 
were collected, and after the strucre refinement, MES (2-(N-
morpholino)ethanesulfonic acid) was observed in the activity site of protein. 
ii) At 18 ° C, in a precipitating solution containing 0.1 mol L-1 malic acid: 
Tris pH 7.0 to 8.5 as a buffer, and 25-37% PEG5000 or 30-37% PEG2000. Crystals 
start up to grow from 1-2 weeks. The crystal data were collected and after the strucre 







Data collection and structure refinement 
 
The diffraction experiments were performed at cryogenic temperatures (~ 
100 K) using 30% (v/v) glycerol as cryoprotectant. The data was collected in the 
diffractometer Bruker Kappa Apex II Duo, with complete data obtain in couple of 
hours. The data reduction (integration and scaling) was performed with the APEX II 
software (Bruker).[188] The structure was solved by molecular replacement with the 
program Phaser[184] at the CCP4 package.[189] The construction and refinement of 
model are done with the program Coot[186] and Refmac5[190] implemented at 
CCP4 package.[189] 
 
4.5. Quantitative Structure–Activity Relationship (QSAR) 
  
In this work we have used the Software ISIDA-QSPR (Version 5.88.012, 
Build 15.08.2015) downloaded directly from the Prof. Solov’ev and Prof. Varnek 
research group site (Laboratoire de Chémoinformatique – Université Louis Pasteur, 
Strasbourg, France).[191–194] ISIDA-QSPR means “In Silico Design and Data 
Analysis - Quantitative Structure-Property Relationship” and it is a program that 
realizes “ensemble Multiple Linear Regression” (eMLR) analysis on the base of 
Substructure Molecular Fragment (SMF) descriptors. The ISIDA-QSPR is capable to 
combine forward and backward stepwise variable selection techniques. It generates 
a great number of models and employing training set, various types of SMF 
descriptors and different variable selection techniques. After that, it selects of the 
most relevant models using statistical tools and applies them to a test set. The 
program applies a “Consensus Model” to every test compound, i.e., estimates the 
target property as an average of all obtained values with a collection of individual 
models selected at the training stage. The program has a limited graphical 
presentation of results including the 2D molecular structures concatenated with data 
points of the linear regression of modelled and predicted data. The ISIDA-QSPR 








5. Conclusion and perspectives 
 
In this work, one hundred and sixty-seven compounds were designed and 
assayed against three different phosphatases: PTP-1B, LMW-PTP, and CDC25B. 
Among all compounds, ninety-seven was synthesised and seventy acquired from 
commercial suppliers. Compounds were arranged into ten different groups according 
to their developing strategy, and functional group. Series 1 to 5 arose from docking 
studies, and series 6 to 10 emerged from BIOS and/or FBDD. Table 16 shows 
details about the implemented classification. 
Table 16. List of all studied compounds ordered according to their 
chemical functionality, employed strategy for choice, and source. 
Series Chemical class Strategy Origin 
1 Oxamic acids Docking Synthesised 
2 Sulfamic acids Docking Synthesised 
3 Phenylisooxazole carboxylic acids Docking Purchased 
4 Thioacetic acids Docking Purchased 
5 Benzimidazole thioacetamides FBDD Synthesised 
6 Phosphonic acids BIOS Synthesised 
7 Sulfonic acids BIOS Synthesised & Purchased 
8 Boronic acids BIOS Synthesised & Purchased 
9 Carboxylic acids FBDD Purchased 
10 Cinnamic acids FBDD Purchased 
All compounds were screened against PTP-1B, LMW-PTP, and CDC25B 
using a single point inhibition assay and the most active molecules were selected to 
perform a dose-response inhibition evaluation. Table 17 presents details about the 
biological test for the five more active substances for each enzyme. 
 
Table 17. List of most active compounds against PTP1B and LMW-PTP ordered by series 
number. Some compounds were selected to perform dose-response inhibition assay against 
one enzyme only, since they didn’t present sufficient activity in the screening test. 
Compound code Compound series PTP1B IC50 LMW-PTP IC50 
MKR-18a 1 0.07mM - 
MKR-20a 1 0.13mM - 
MKR-36a 1 0.11mM 0.39mM 
MKR-42ª 1 0.44mM 0.55mM 
KSR-6ab 4 0.005mM - 
KSR-6f 4 0.0895 mM  
MK-48 6 0.93mM 0.44mM 
MK-49 6 - 0.39mM 
MK-38 7 0.002mM - 
KAM-4 8 - 0.18mM 
KAM-12 8 0.25 mM 0.16mM 






None of the studied compounds presented satisfactory activity against 
CDC25B. Compounds of series 4 (thioacetic acids) and 7 (sulfonic acids) showed 
some selectivity towards PTP1B phosphatase. Although some boronic acids (series 8) 
are the best inhibitors for LMW-PTP, they also exhibited activity against PTP1B, even 
they aren’t among its best five inhibitors. Despite the active site similarity for all 
phosphatases, a remarkable result was obtained for twenty-one compounds, which 
already increased the activity of LMW-PTP instead of reducing it. 
QSAR studies for PTP1B inhibition using Substructural Molecular 
Fragments (SMF) gave a consensus model accounting for up to 81.26 (R2=0.8126) 
percent variance in the observed activity with a root-mean-squared error (RMSE) of 
0.4384, and a mean absolute error (MAE) of 0.3668. The most significant SMF 
contributions for activity increasing found in the set of compounds were B-5*CB, 
CB*3-CO, and CB*8-CO. Conversely, substructures CO-6-O, Cl-8-O, O-8=O, and F-
7-O were the most relevant SMF to the decrease of the phosphatase activity. The 
results suggested that the simultaneous presence of two electronegative atoms at 6 
to 8 bonds away from each other is deleterious to inhibition activity. On the other 
hand, the presence of an electronegative atom 3 to 8 bonds away from a carbon 
atom in an aromatic ring, or a boron atom 5 bonds away from a carbon atom also in 
an aromatic ring, increase the biological activity. 
None of the studied compounds was capable of giving monocrystalline 
complexes with the phosphatases despite the different conditions used to accomplish 
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Appendix I – 2D representation Ligplot+ of protein-ligand plots of series 1, 2, 3, 4 & 








































Appendix II – Spectras of 1H-NMR, 13C-NMR, 31P-NMR & 19F-NMR. 
 
















































































































































































NAME        jul03kmrH11
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.21
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                   64
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800127 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 1: 1H-NMR (CD3OD, 400 MHz) of compound MKR-24a. 
 



















































































































NAME        jul03kmrH11
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               5.58
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.5 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251924 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




















8 Current Data Parameters
NAME         jul07krmF1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140707
Time              16.28
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT            MeOD
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  101
DW                4.400 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 3: 19F-NMR (CD3OD, 470 MHz) of compound MKR-24a. 
















































































































































NAME         jan07krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150107
Time              21.53
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  128
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700094 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






































































































































NAME         jan07krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               0.08
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 3072
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924689 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 5: 13C-NMR (DMSO-d6, 125 MHz) of compound MKR-28a. 









NAME     dez13MKR-28a(1)F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20141213
Time              17.06
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            DMSO
NS                   32
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2298.8
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0












































































































































NAME        jun08MKR-H4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              18.00
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                287.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299998 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 7: 1H-NMR (CD3OD, 250 MHz) of compound MKR-25a. 

































































































NAME        jun08MKR-C4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              18.08
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                812.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951434 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


















4 Current Data Parameters
NAME     jan31_MKR-25aF19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150131
Time              16.47
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   12
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                 3251
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 9: 19F-NMR (CD3OD, 235 MHz) of compound MKR-25a. 











































































































5 Current Data Parameters
NAME         jul22krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140722
Time              18.10
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.1 K
D1           5.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0















































































NAME         jul23mkrF3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140723
Time              10.35
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   16
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                  512
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0









Spectra 11: 19F-NMR (CD3OD, 235 MHz) of compound MKR-17a. 
































































































































4 Current Data Parameters
NAME         jun12krmH8
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              15.10
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251863 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0









































8 Current Data Parameters
NAME         jun17krmF5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              10.50
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT            MeOD
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  114
DW                4.400 usec
DE                 6.50 usec
TE                293.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 13: 19F-NMR (CD3OD, 470 MHz) of compound MKR-18a. 
























































































































































NAME     mai29MKR-9a(1)-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              11.04
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1296066 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

































































































NAME     mai29MKR-9a(1)-C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              11.35
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  703
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                  512
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8950420 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 15: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-9a. 




































































NAME         out21krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131021
Time              15.15
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  161
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700147 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




















































































NAME         out21krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20131021
Time              15.39
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1024
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922173 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






Spectra 17: 13C-NMR (CD3OD, 125 MHz) of compound MKR-10a. 










































































































































































NAME        jun08MKR-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              16.30
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                456.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299993 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

































































































NAME        jun08MKR-C1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              16.35
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  204
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                 1024
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951440 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 19: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-23a. 










































































































































































NAME        jul03kmrH13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.27
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0































































































9 Current Data Parameters
NAME        jul03kmrH13
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               8.28
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1925
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.6 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251874 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0







Spectra 21: 13C-NMR (CD3OD, 100 MHz) of compound MKR-7a. 




























































































NAME         out21krmH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131021
Time              17.21
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH           10302.198 Hz
FIDRES         0.314398 Hz
AQ            1.5903403 sec
RG                  128
DW               48.533 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700147 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




















































































NAME         out21krmH3
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20131021
Time              17.31
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922179 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






Spectra 23: 13C-NMR (CD3OD, 125 MHz) of compound MKR-8a. 
















































































































































































NAME        jul03kmrH10
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.18
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
































































































NAME        jul03kmrH10
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               4.26
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.5 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251881 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0







Spectra 25: 13C-NMR (CD3OD, 100 MHz) of compound MKR-26a. 






















































































































































































NAME         fev25krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150225
Time               8.02
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                303.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800076 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
































































































NAME         mai15krmC7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140515
Time              20.26
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1024
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922215 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 27: 13C-NMR (CD3OD, 125 MHz) of compound MKR-5a. 


























































































































NAME         jul03kmrH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.45
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



















































































NAME         jul03kmrH5
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              20.46
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                298.0 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251874 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0






Spectra 29: 13C-NMR (CD3OD, 100 MHz) of compound MKR-40a. 
























































































































































NAME         fev11mrkH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.45
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                298.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800076 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

































































































NAME        jun08MKR-C9
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              20.01
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951427 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 31: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-12a. 






























































NAME         jan20krmH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150120
Time              17.57
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 71.8
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




















































































NAME     jan14_MKR-13a(1)C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time               9.37
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                 1024
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951430 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






Spectra 33: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-13a. 





















































































































































NAME         fev11mrkH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.42
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  114
DW               62.400 usec
DE                 7.00 usec
TE                298.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800076 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






































































































NAME        jun08MKR-C8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130608
Time              19.44
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                406.4
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951438 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 35: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-11a. 


















































































































































NAME         jul03kmrH7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.52
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 90.5
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






































































































NAME         jul03kmrH7
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              23.50
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                297.7 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251885 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0







Spectra 37: 13C-NMR (CD3OD, 100 MHz) of compound MKR-31a. 
























































































































































NAME         fev11mrkH6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.57
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 71.8
DW               62.400 usec
DE                 7.00 usec
TE                298.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800077 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




























































































5 Current Data Parameters
NAME     jan31_MKR-51aC13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150131
Time              14.53
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                287.4
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951412 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






Spectra 39: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-51a. 





















































































































































NAME      mar12mkr55aH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150312
Time              12.10
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                    1
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                724.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                14.20 usec
PL1               -6.00 dB
SFO1        250.1315447 MHz
F2 - Processing parameters
SI                32768
SF          250.1299994 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







































































































NAME          mar12mkrC
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150312
Time              11.41
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.459602 Hz
AQ            1.0878977 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                11.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951411 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 41: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-55a. 



















































































NAME         jan20krmH4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150120
Time              17.52
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 80.6
DW               50.000 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






































































































NAME     jan17_MKR-52aC13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150117
Time              19.12
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951410 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 43: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-52a. 







































































NAME         out22krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131022
Time              16.27
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH           10302.198 Hz
FIDRES         0.314398 Hz
AQ            1.5903403 sec
RG                  101
DW               48.533 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0














































7 Current Data Parameters
NAME         out22krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20131022
Time              16.29
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  868
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922185 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






Spectra 45: 13C-NMR (CD3OD, 125 MHz) of compound MKR-19a. 













































































































































NAME         out22krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131022
Time              17.11
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           10302.198 Hz
FIDRES         0.314398 Hz
AQ            1.5903403 sec
RG                  101
DW               48.533 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700086 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0











































































NAME         out22krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20131022
Time              17.38
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                  596
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924674 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 47: 13C-NMR (DMSO-d6, 125 MHz) of compound MKR-33a. 












































NAME         jan07krmH9
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               8.23
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                   32
DW               50.000 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700096 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




















































































3 Current Data Parameters
NAME         jan07krmH9
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               8.45
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 1024
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924414 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 49: 13C-NMR (DMSO-d6, 125 MHz) of compound MKR-54a. 













































































NAME         jan20krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150120
Time              17.46
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 90.5
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



























































































NAME     jan17_MKR-42aC13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150117
Time              18.29
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                456.1
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951417 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 51: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-42a. 











































































































NAME     fev19MKR-38aH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150219
Time              10.39
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   32
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                    4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299998 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







































































































NAME     fev13MKR-38aH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150212
Time              12.01
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 2822
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                287.4
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951412 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 53: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-38a. 










































































NAME         jan07krmH8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               8.11
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 80.6
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700093 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



























































































NAME         jan07krmH8
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               8.14
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                  159
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924632 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 55: 13C-NMR (DMS0-d6, 125 MHz) of compound MKR-50a. 












































































































































NAME         fev11mrkH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.48
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                   32
DW               62.400 usec
DE                 7.00 usec
TE                298.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800077 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0












































































































NAME         fev11mrkH3
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              17.41
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  512
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.6 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        89.69999695 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        11.30000019 W
PLW12        0.08928400 W
PLW13        0.07232000 W
F2 - Processing parameters
SI                65536
SF          100.6251918 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 57: 13C-NMR (CD3OD, 100 MHz) of compound MKR-41a. 




















































































































NAME         fev11mrkH4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.51
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 71.8
DW               62.400 usec
DE                 7.00 usec
TE                298.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800077 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0












































































































NAME         fev11mrkH4
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              17.54
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  256
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.5 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        89.69999695 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        11.30000019 W
PLW12        0.08928400 W
PLW13        0.07232000 W
F2 - Processing parameters
SI                65536
SF          100.6251886 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 59: 13C-NMR (CD3OD, 100 MHz) of compound MKR-44a. 





















































































































































NAME     fev05MKR-27aH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150205
Time              16.23
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                812.7
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299997 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
































































































NAME         set25mkrC2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              10.29
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG               2580.3
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952390 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 61: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-27a. 






































































































































NAME     mai29MKR-37a-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.51
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                  512
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1295946 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

































































































NAME         mai30krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              15.25
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  320
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251929 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0









Spectra 63: 13C-NMR (CD3OD, 100 MHz) of compound MKR-37a. 































































































NAME         jul21krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140722
Time               0.33
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  101
DW               50.000 usec
DE                 7.00 usec
TE                297.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800124 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
































































































NAME         jul21krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140722
Time               7.36
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 4396
DS                    1
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  144
DW               20.800 usec
DE                 6.50 usec
TE                297.6 K
D1           5.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251874 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 65: 13C-NMR (CD3OD, 100 MHz) of compound MKR-36a. 



































































































































NAME          set18mkH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130918
Time              11.00
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                228.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299994 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

















































































































NAME         set25mkrC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              10.00
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG               2896.3
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951434 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 67: 13C-NMR (CD3OD, 62.5 MHz) of compound MKR-20a. 




























































































NAME         mai13krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150513
Time              10.19
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                298.3 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.50 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800031 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






































































NAME         mai13krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150513
Time              10.35
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        89.69999695 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        11.30000019 W
PLW12        0.10079000 W
PLW13        0.08164300 W
F2 - Processing parameters
SI                65536
SF          100.6253884 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




Spectra 69: 13C-NMR (DMSO-d6, 100 MHz) of compound KSR-3. 





















































NAME         fev24ksrH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20160224
Time               8.15
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8223.685 Hz
FIDRES         0.250967 Hz
AQ            1.9922944 sec
RG                 80.6
DW               60.800 usec
DE                10.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824710 MHz
NUC1                 1H
P1                 8.50 usec
PLW1        14.99699974 W
F2 - Processing parameters
SI                32768
SF          400.1799601 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




















































NAME         fev24ksrH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20160224
Time               9.03
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354026 MHz
NUC1                13C
P1                15.45 usec
PLW1        82.79399872 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.64299965 W
PLW12        0.09493300 W
PLW13        0.07689600 W
F2 - Processing parameters
SI                32768
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




Spectra 71: 13C-NMR (D2O, 100 MHz) of compound KSR-1. 





























































































NAME        fev11KS-0H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time               9.22
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299952 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

































































































3 Current Data Parameters
NAME       fev19KS-0C13
EXPNO                 5
PROCNO                1
F2 - Acquisition Parameters
Date_          20150219
Time              11.03
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            DMSO
NS                  575
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952654 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




Spectra 73: 13C-NMR (DMSO-d6, 62.5 MHz) of compound KS-0. 





































































NAME      mar25-KS-0bH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150325
Time               9.00
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                456.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                14.20 usec
PL1               -6.00 dB
SFO1        250.1315447 MHz
F2 - Processing parameters
SI                32768
SF          250.1299955 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0























































































NAME     mar25-KS-0b-C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150325
Time               9.24
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                  104
DS                    0
SWH           15060.241 Hz
FIDRES         0.459602 Hz
AQ            1.0878977 sec
RG                645.1
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                11.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952634 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




Spectra 75: 13C-NMR (DMSO-d6, 62.5 MHz) of compound KS-0b. 




















































































NAME         abr13mkrH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150413
Time               8.53
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 80.6
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700091 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








































































































5 Current Data Parameters
NAME         abr13mkrH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150413
Time               9.05
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                  285
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924626 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





Spectra 77: 13C-NMR (DMSO-d6, 125 MHz) of compound KS-0c. 



















































































































































NAME         mar11mkrH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150311
Time              16.12
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                   64
DW               62.400 usec
DE                 7.00 usec
TE                298.3 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.50 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800030 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0





















































































































































0 Current Data Parameters
NAME         mar11mkrH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150311
Time              16.22
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 3200
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        89.69999695 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        11.30000019 W
PLW12        0.10079000 W
PLW13        0.08164300 W
F2 - Processing parameters
SI                65536
SF          100.6256867 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0










Spectra 79: 13C-NMR (DMSO-d6, 100 MHz) of compound KS-1. 


















































































































































































































NAME         abr13mkrH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150413
Time               7.39
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  114
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700089 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




























































































































































NAME         abr13mkrH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150413
Time               7.59
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 1560
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924721 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0










Spectra 81: 13C-NMR (DMSO-d6, 125 MHz) of compound KS-2. 
















































































































































NAME         dez03krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20151203
Time              19.16
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           12335.526 Hz
FIDRES         0.376450 Hz
AQ            1.3281963 sec
RG                  114
DW               40.533 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                13.15 usec
PLW1        15.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1700050 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



















































































































8 Current Data Parameters
NAME         dez03krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20151203
Time              21.26
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 3072
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9129345 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0










Spectra 83: 13C-NMR (DMSO-d6, 150 MHz) of compound KS-3. 




































































































































































































































NAME         abr09mkrH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              12.25
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           12335.526 Hz
FIDRES         0.376450 Hz
AQ            1.3281963 sec
RG                  181
DW               40.533 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                13.15 usec
PLW1        15.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1700064 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0









































































































NAME         abr09mkrH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              12.45
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                  512
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9128670 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0










Spectra 85: 13C-NMR (DMSO-d6, 150 MHz) of compound KS-4. 













































































































































































































































NAME         abr09mkrH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              12.51
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           12335.526 Hz
FIDRES         0.376450 Hz
AQ            1.3281963 sec
RG                  203
DW               40.533 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                13.15 usec
PLW1        15.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1700065 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



























































































































NAME         abr09mkrH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              12.53
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 1024
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.3 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9129389 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0










Spectra 87: 13C-NMR (DMSO-d6, 150 MHz) of compound KS-5. 
























































































































NAME         abr09mkrH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              13.37
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH           12335.526 Hz
FIDRES         0.376450 Hz
AQ            1.3281963 sec
RG                  114
DW               40.533 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                13.15 usec
PLW1        15.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1700065 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



































































































































NAME         abr09mkrH3
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              13.38
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 1355
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.3 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9129377 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0











Spectra 89: 13C-NMR (DMSO-d6, 150 MHz) of compound KS-6. 






























































NAME         mar13rapH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130313
Time              10.05
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   10
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1448.2
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299957 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0











































































































NAME          mar13rapC
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130313
Time              11.12
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            DMSO
NS                  828
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952624 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 91: 13C-NMR (DMSO-d6, 62.5 MHz) of compound MK-0. 





2 Current Data Parameters
NAME         mar13rapp1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130313
Time              10.13
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                65536
SOLVENT            DMSO
NS                   21
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               1824.6
DW               12.300 usec
DE                 6.00 usec
TE                298.4 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0

































































NAME         mar27rapH4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130327
Time              11.05
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 2048
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300321 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 93: 1H-NMR (CD3OD, 250 MHz) of compound MK-0a. 

























































































NAME         mar27rapH7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130327
Time              11.59
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT           CDCl3
NS                  220
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                32768
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951398 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




















NAME         mar27rapP4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130327
Time              11.09
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                65536
SOLVENT            MeOD
NS                   33
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                645.1
DW               12.300 usec
DE                 6.00 usec
TE                298.3 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 95: 31P-NMR (CD3OD, 101 MHz) of compound MK-0a. 









































NAME         set17rapH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130917
Time              15.11
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8223.685 Hz
FIDRES         0.250967 Hz
AQ            1.9922944 sec
RG                  203
DW               60.800 usec
DE                10.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824710 MHz
NUC1                 1H
P1                 8.40 usec
PLW1        14.99699974 W
F2 - Processing parameters
SI                32768
SF          400.1800910 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




































































































NAME         set17rapH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20130917
Time              15.58
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                15360
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354026 MHz
NUC1                13C
P1                18.25 usec
PLW1        85.50700378 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.64299965 W
PLW12        0.13139001 W
PLW13        0.10643000 W
F2 - Processing parameters
SI               131072
SF          100.6251881 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 97: 13C-NMR (CD3OD, 100 MHz) of compound MK-9. 





3 Current Data Parameters
NAME         set18rapP1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130918
Time               7.34
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                65536
SOLVENT            MeOD
NS                  311
DS                    4
SWH           81521.742 Hz
FIDRES         1.243923 Hz
AQ            0.4019541 sec
RG                 2050
DW                6.133 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        202.3409675 MHz
NUC1                31P
P1                12.00 usec
PLW1        89.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          202.3510850 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0

























































































































































NAME     jul31MK-11a-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140731
Time              12.31
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299995 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 99: 1H-NMR (CD3OD, 250 MHz) of compound MK-11a. 
























































































































































































NAME     jan12_MK-11aC13_TMSBr
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              22.18
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                645.1
DW               33.200 usec
DE                 6.00 usec
TE                298.5 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951412 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





























NAME     jan13_MK-11a(TMSBr)F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              17.41
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   15
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2580.3
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 101: 19F-NMR (CD3OD, 235 MHz) of compound MK-11a. 







NAME     jan13_MK-11a(TMSBr)P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              17.50
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    7
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               2298.8
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




































































































































NAME         jan20krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150120
Time              17.43
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 71.8
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700145 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 103: 1H-NMR (CD3OD, 500 MHz) of compound MK-11b. 

























































































































































































NAME     jan17_MK-11b(1)C31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150117
Time              16.40
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951408 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0



























2 Current Data Parameters
NAME     jan17_MK-11b(1)F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150117
Time              16.20
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   17
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2298.8
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 105: 19F-NMR (CD3OD, 235 MHz) of compound MK-11b. 







NAME     jan17_MK-11b(1)P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150117
Time              16.11
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    7
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                912.3
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


























































































NAME       fev05MK-11H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150205
Time              17.38
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 2048
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299998 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 107: 1H-NMR (CD3OD, 250 MHz) of compound MK-11. 





































































































NAME         mai27krmH4
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140527
Time              18.03
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0



























2 Current Data Parameters
NAME       fev05MK-11F1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150205
Time              17.49
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   11
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2580.3
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 109: 19F-NMR (CD3OD, 235 MHz) of compound MK-11. 







NAME     mai22MK-11(2)P31
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140522
Time              17.32
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    5
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 2048
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0















































































































NAME        jun12krmH10
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              20.03
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 90.5
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 111: 1H-NMR (CD3OD, 400 MHz) of compound MK-29. 



















































































































































































NAME        jun12krmH10
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              22.34
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251871 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0





















NAME         jun17krmF3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              10.41
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT            MeOD
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  114
DW                4.400 usec
DE                 6.50 usec
TE                293.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 113: 19F-NMR (CD3OD, 470 MHz) of compound MK-29. 







NAME     jun05MK-31-P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140605
Time              11.02
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                   11
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               2580.3
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




































































































































NAME         jun12krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time               9.46
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                   57
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800122 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 115: 1H-NMR (CD3OD, 400 MHz) of compound MK-30. 































































































































































































NAME         jun12krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time               9.53
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1387
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251884 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0





















NAME         jun17krmF2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              10.37
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT            MeOD
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                 90.5
DW                4.400 usec
DE                 6.50 usec
TE                293.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 117: 19F-NMR (CD3OD, 470 MHz) of compound MK-30. 





4 Current Data Parameters
NAME     jun05MK-30-P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140605
Time              10.48
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    7
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 4096
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




















































































NAME          set25mkH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130925
Time              11.13
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                645.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299995 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 119: 1H-NMR (CD3OD, 250 MHz) of compound MK-7a. 




























































































































5 Current Data Parameters
NAME         out02rapC4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131003
Time               7.07
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                16001
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922190 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0



























NAME     jul23-MK-7a_19F
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150723
Time              10.45
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   19
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                812.7
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 121: 19F-NMR (CD3OD, 235 MHz) of compound MK-7a. 







NAME         out02rapP4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131002
Time              19.10
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                  512
DS                    4
SWH           81521.742 Hz
FIDRES         2.487846 Hz
AQ            0.2009771 sec
RG                 2050
DW                6.133 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        202.3409675 MHz
NUC1                31P
P1                12.00 usec
PLW1        89.00000000 W
F2 - Processing parameters
SI                32768
SF          202.3510850 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


































































NAME         jun12krmH9
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              17.30
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                300.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800122 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0











Spectra 123: 1H-NMR (CD3OD, 400 MHz) of compound MK-31. 























































































6 Current Data Parameters
NAME         jun12krmH9
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              18.02
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251853 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0














































































































































5 Current Data Parameters
NAME         jun17krmF1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              10.33
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT            MeOD
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  114
DW                4.400 usec
DE                 6.50 usec
TE                293.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0











Spectra 125: 19F-NMR (CD3OD, 470 MHz) of compound MK-31. 





2 Current Data Parameters
NAME     jun05MK-29-P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140605
Time              11.14
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    4
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 4096
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0














































































NAME       fev05MK-1aH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150205
Time              16.28
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1290.2
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299997 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 127: 1H-NMR (CD3OD, 250 MHz) of compound MK-1. 































































































NAME        mai15krmC13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140516
Time               4.53
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1024
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924110 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


















9 Current Data Parameters
NAME      abr24MK-1-31P
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140424
Time              12.16
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    6
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 8192
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 129: 31P-NMR (CD3OD, 101 MHz) of compound MK-1. 













































































































































































NAME         jan20krmH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150120
Time              17.49
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  114
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700147 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




































































































































NAME     jan13_MK-47C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              12.54
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                 1087
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                  362
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951402 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 131: 13C-NMR (CD3OD, 62.5 MHz) of compound MK-47. 







NAME     jan13_MK-47P31
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              13.53
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    4
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               1824.6
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


























































































NAME        fev05MK-2H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150205
Time              16.33
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 2048
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299996 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 133: 1H-NMR (CD3OD, 250 MHz) of compound MK-2. 

















































































0 Current Data Parameters
NAME         out02rapC2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131002
Time              13.15
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922252 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




















NAME         out02rapP2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131002
Time              12.58
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                  512
DS                    4
SWH           81521.742 Hz
FIDRES         2.487846 Hz
AQ            0.2009771 sec
RG                 2050
DW                6.133 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        202.3409675 MHz
NUC1                31P
P1                12.00 usec
PLW1        89.00000000 W
F2 - Processing parameters
SI                32768
SF          202.3510850 MHz
WDW                  EM
SSB      0
LB                 3.00 Hz
GB       0








Spectra 135: 31P-NMR (CD3OD, 202 MHz) of compound MK-2. 







































































NAME            Desktop
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130524
Time              19.07
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                724.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299995 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0















































































































1 Current Data Parameters
NAME     mai22Fab_monoacidC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130524
Time              19.09
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  256
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                406.4
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951420 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 137: 13C-NMR (CD3OD, 62.5 MHz) of compound MK-9a. 







NAME     mai24Fab_monoacidP1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20130524
Time              19.43
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                65536
SOLVENT            MeOD
NS                   41
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 2048
DW               12.300 usec
DE                 6.00 usec
TE                298.3 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0























































































NAME         jan07krmH7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               7.39
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  128
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700148 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0










Spectra 139: 1H-NMR (CD3OD, 500 MHz) of compound MK-48. 































































































































2 Current Data Parameters
NAME         jan07krmH7
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150108
Time               7.44
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  512
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6922194 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




















9 Current Data Parameters
NAME     jan13_MK-48P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              14.51
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    7
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                645.1
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0










Spectra 141: 31P-NMR (CD3OD, 101 MHz) of compound MK-48. 









































































































































NAME         fev11mrkH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150211
Time              15.54
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 71.8
DW               62.400 usec
DE                 7.00 usec
TE                298.5 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800076 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








































































































































3 Current Data Parameters
NAME     jan31_MK-49C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150131
Time              13.51
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT            MeOD
NS                  782
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                  256
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8951412 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0









Spectra 143: 13C-NMR (CD3OD, 62.5 MHz) of compound MK-49. 







NAME     jan31_MK-49P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150131
Time              13.36
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                   13
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               1625.5
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




















































































































































NAME         jul03kmrH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.36
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 90.5
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 145: 1H-NMR (CD3OD, 400 MHz) of compound MK-35. 


































































































3 Current Data Parameters
NAME         jul03kmrH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              15.17
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 2048
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                297.6 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0
















NAME     jun26-MK-35-31P
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140626
Time              10.52
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                   10
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                724.1
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0




Spectra 147: 31P-NMR (CD3OD, 101 MHz) of compound MK-35. 














































































































NAME        jul03kmrH14
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.30
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  101
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
















































































































NAME        jul03kmrH14
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               9.05
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1202
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.6 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0









Spectra 149: 13C-NMR (CD3OD, 100 MHz) of compound MK-6. 







NAME      jul02MK-6-P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140702
Time              10.41
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    5
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                 6502
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0













































































































NAME         jun12krmH7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              13.52
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800122 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 151: 1H-NMR (CD3OD, 400 MHz) of compound MK-13. 






























































































0 Current Data Parameters
NAME         jun12krmH7
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              14.51
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 2048
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6251865 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




















NAME         jun17krmF8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              11.10
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                  128
DS                    4
SWH           81521.742 Hz
FIDRES         2.487846 Hz
AQ            0.2009771 sec
RG                 2050
DW                6.133 usec
DE                 6.50 usec
TE                293.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        202.3409675 MHz
NUC1                31P
P1                12.00 usec
PLW1        89.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          202.3510850 MHz
WDW                  EM
SSB      0
LB                 3.00 Hz
GB       0








Spectra 153: 31P-NMR (CD3OD, 202 MHz) of compound MK-13. 





















































NAME      abr11MK-15-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150411
Time              11.58
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   32
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                724.1
DW               96.600 usec
DE                 6.00 usec
TE                296.4 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                14.20 usec
PL1               -6.00 dB
SFO1        250.1315447 MHz
F2 - Processing parameters
SI                32768
SF          250.1299671 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








































































NAME     abr11MK-15-C31
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150411
Time              14.16
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 2048
DS                    0
SWH           15060.241 Hz
FIDRES         0.459602 Hz
AQ            1.0878977 sec
RG                912.3
DW               33.200 usec
DE                 6.00 usec
TE                297.5 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                11.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952390 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







Spectra 155: 13C-NMR (D2O, 62.5 MHz) of compound MK-15. 







NAME     abr11MK-15-31P
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150411
Time              11.49
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT             D2O
NS                   13
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               2580.3
DW               12.300 usec
DE                 6.00 usec
TE                296.4 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
















































































































































































NAME         jul03kmrH8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.54
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 90.5
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800126 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 157: 1H-NMR (CD3OD, 400 MHz) of compound MK-27. 


























































































































8 Current Data Parameters
NAME         jul03kmrH8
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               1.22
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.6 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




















NAME     jun26-MK-27(1)P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140626
Time              10.30
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    8
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               1824.6
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 159: 31P-NMR (CD3OD, 101 MHz) of compound MK-27. 























































































































NAME         jul03kmrH9
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.15
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 80.6
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800125 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0









































































































































NAME         jul03kmrH9
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140704
Time               2.54
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                 90.5
DW               20.800 usec
DE                 6.50 usec
TE                297.5 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 161: 13C-NMR (CD3OD, 100 MHz) of compound MK-28. 







NAME     jun26-MK-28(1)P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140626
Time              10.36
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                   11
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                724.1
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0



























































































































NAME         mai27krmH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140527
Time              20.18
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                    8
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  101
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800121 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








Spectra 163: 1H-NMR (CD3OD, 400 MHz) of compound MK-12. 


































































































5 Current Data Parameters
NAME         mai27krmH5
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140527
Time              21.19
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 2048
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




















NAME     mai26MK-12-P31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140526
Time              20.34
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    6
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               1625.5
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0








Spectra 165: 31P-NMR (CD3OD, 101 MHz) of compound MK-12. 































































































NAME     jul22-MK-41_1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150722
Time              11.49
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                14.20 usec
PL1               -6.00 dB
SFO1        250.1315447 MHz
F2 - Processing parameters
SI                32768
SF          250.1299994 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
















































































































8 Current Data Parameters
NAME         jul23krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150723
Time              10.44
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT            MeOD
NS                 1400
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9126342 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0








Spectra 167: 13C-NMR (CD3OD, 150 MHz) of compound MK-41. 







NAME     jul22-MK-41_31P
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150722
Time              11.58
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            MeOD
NS                    4
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG               4597.6
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





































































NAME         jul29krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150729
Time              14.19
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            DMSO
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.50 usec
PLW1        11.30000019 W
F2 - Processing parameters
SI                65536
SF          400.1800000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0









Spectra 169: 1H-NMR (DMSO-d6, 400 MHz) of compound MK-16. 

























































5 Current Data Parameters
NAME         jul29krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150729
Time              16.21
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT            DMSO
NS                 6144
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  203
DW               20.800 usec
DE                10.00 usec
TE                298.4 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        89.69999695 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        11.30000019 W
PLW12        0.10079000 W
PLW13        0.08164300 W
F2 - Processing parameters
SI                65536
SF          100.6253896 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





















NAME     jul29-MK-16_31P
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150729
Time              10.58
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG           zg0ig
TD                65536
SOLVENT            DMSO
NS                    6
DS                    0
SWH           40650.406 Hz
FIDRES         0.620276 Hz
AQ            0.8060928 sec
RG                16384
DW               12.300 usec
DE                 6.00 usec
TE                298.2 K
D1          30.00000000 sec
d11          0.03000000 sec
TD0                   1
SFO1        101.2494172 MHz
NUC1                31P
P0                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310000 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                32768
SF          101.2544800 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0









Spectra 171: 31P-NMR (CD3OD, 101 MHz) of compound MK-16. 























































































































































































































NAME         jul22krmH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140722
Time              15.23
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT            MeOD
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.0 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1800122 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

















































































































































































4 Current Data Parameters
NAME         jul29krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140729
Time              16.27
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6923968 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





Spectra 173: 13C-NMR (CD3OD, 125 MHz) of compound MK-24a. 









NAME         jul23mkrF2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140723
Time              10.30
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT            MeOD
NS                   17
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2580.3
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0

























































































































































NAME         jul29krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140729
Time              17.12
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  101
DW               50.000 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8699568 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 175: 1H-NMR (D2O, 500 MHz) of compound MK-24b. 




















































































NAME         jul29krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140729
Time              17.16
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                  512
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924110 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0


















NAME         jul23mkrF4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140723
Time              11.44
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT             D2O
NS                   14
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                  512
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




Spectra 177: 19F-NMR (D2O, 235 MHz) of compound MK-24b. 

















































































































NAME      mai29MK-24-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.11
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299683 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
































































NAME         mai30krmC7
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              18.01
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                10240
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253458 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




Spectra 179: 13C-NMR (D2O, 100 MHz) of compound MK-24. 









NAME      fev04MK-24F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150204
Time               9.28
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT             D2O
NS                   13
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               3649.1
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0


































































































NAME         abr09mkrH5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              14.48
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH           12335.526 Hz
FIDRES         0.376450 Hz
AQ            1.3281963 sec
RG                  114
DW               40.533 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                13.15 usec
PLW1        15.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1699426 MHz
WDW                  EM
SSB      0
LB                 0.50 Hz
GB       0





Spectra 181: 1H-NMR (D2O, 600 MHz) of compound MK-32. 





































































































1 Current Data Parameters
NAME         abr09mkrH5
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150409
Time              14.51
INSTRUM           spect
PROBHD   5 mm PATBO BB-
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                  788
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                 9.10 usec
PLW1        90.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        15.00000000 W
PLW12        0.40529001 W
PLW13        0.25938001 W
F2 - Processing parameters
SI                32768
SF          150.9128670 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0
























NAME      abr10MK-32F19
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20150410
Time               9.14
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT             D2O
NS                   32
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                645.1
DW                7.100 usec
DE                 6.00 usec
TE                296.3 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0





Spectra 183: 19F-NMR (D2O, 235 MHz) of compound MK-32. 













































































NAME        jun12krmH11
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              22.37
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1799655 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



































































































4 Current Data Parameters
NAME        jun12krmH11
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140614
Time               1.08
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 5120
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0




Spectra 185: 13C-NMR (D2O, 100 MHz) of compound MK-33. 






1 Current Data Parameters
NAME         jun17krmF6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140617
Time              10.54
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT             D2O
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  144
DW                4.400 usec
DE                 6.50 usec
TE                293.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
























































NAME         out02rapH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20131002
Time              10.45
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG            zg30
TD                65536
SOLVENT             D2O
NS                   64
DS                    0
SWH           12335.526 Hz
FIDRES         0.188225 Hz
AQ            2.6563926 sec
RG                  161
DW               40.533 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        600.1737063 MHz
NUC1                 1H
P1                 7.38 usec
PLW1         9.00000000 W
F2 - Processing parameters
SI                65536
SF          600.1699416 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0

















































Spectra 187: 1H-NMR (D2O, 600 MHz) of compound MK-8. 

























































































NAME         out02rapH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20131002
Time              11.10
INSTRUM           spect
PROBHD   5 mm TBI 1H/13
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 5120
DS                    0
SWH           36057.691 Hz
FIDRES         1.100393 Hz
AQ            0.4543829 sec
RG                  203
DW               13.867 usec
DE                10.00 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        150.9279571 MHz
NUC1                13C
P1                16.50 usec
PLW1        95.00000000 W
======== CHANNEL f2 ========
SFO2        600.1724007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             70.00 usec
PLW2         9.00000000 W
PLW12        0.09990100 W
PLW13        0.04895200 W
F2 - Processing parameters
SI               131072
SF          150.9128670 MHz
WDW                  EM
SSB      0
LB                 1.50 Hz
GB       0

















NAME      jan31_MK-8F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150131
Time              17.08
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT             D2O
NS                   25
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                 4096
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 189: 19F-NMR (D2O, 235 MHz) of compound MK-8. 

















NAME         jul03kmrH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.33
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1799674 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0



















































































































































NAME         jul07krmF2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140707
Time              16.51
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 5120
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924110 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





































































































3 Current Data Parameters
NAME         jul07krmF2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140707
Time              16.32
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG      zgfhigqn.2
TD               131072
SOLVENT             D2O
NS                   32
DS                    4
SWH          113636.367 Hz
FIDRES         0.866977 Hz
AQ            0.5767168 sec
RG                  203
DW                4.400 usec
DE                 6.50 usec
TE                298.2 K
D1           1.00000000 sec
D11          0.03000000 sec
D12          0.00002000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        470.3006980 MHz
NUC1                19F
P1                16.50 usec
PLW1        54.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
F2 - Processing parameters
SI                65536
SF          470.3477330 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0








































NAME       mai29MK-3-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.29
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299646 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 193: 1H-NMR (D2O, 250 MHz) of compound MK-3. 































NAME         mai30krmC6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              13.13
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0


































































































NAME       mai29MK-4-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.32
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299667 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 195: 1H-NMR (D2O, 250 MHz) of compound MK-4. 











































NAME         mai30krmC5
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              13.08
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0


































































































NAME       mai29MK-4-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.32
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299667 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 197: 1H-NMR (D2O, 250 MHz) of compound MK-10. 































NAME         mai30krmC2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              11.29
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0



























































NAME      fev04MK-46aH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150204
Time               9.32
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1290.2
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299680 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 199: 1H-NMR (D2O, 250 MHz) of compound MK-46a. 

















































NAME     fev06MK-46aC13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150206
Time              23.19
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT             D2O
NS                 5240
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                645.1
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952390 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0






























































































NAME      jan12_MK-46H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              20.41
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                645.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299680 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 201: 1H-NMR (D2O, 250 MHz) of compound MK-46. 
















































NAME     jan12_MK-46C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              21.15
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT             D2O
NS                 1024
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                574.7
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952390 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0



















































































































NAME         jul03kmrH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              14.39
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  203
DW               62.400 usec
DE                 7.00 usec
TE                297.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1799675 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 203: 1H-NMR (D2O, 400 MHz) of compound MK-36. 




































NAME         jul07krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140708
Time               0.03
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 5120
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924110 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0







































































NAME         jun12krmH3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              10.31
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                 80.6
DW               62.400 usec
DE                 7.00 usec
TE                300.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1799652 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 205: 1H-NMR (D2O, 400 MHz) of compound MK-37. 









































NAME         jun12krmH3
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              10.34
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                  512
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.3 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0


























































NAME       mai29MK-5-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.20
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299685 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 207: 1H-NMR (D2O, 250 MHz) of compound MK-5. 































NAME         mai30krmC9
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              14.57
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0
























































NAME         jun12krmH6
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              12.28
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            8012.820 Hz
FIDRES         0.244532 Hz
AQ            2.0447233 sec
RG                  114
DW               62.400 usec
DE                 7.00 usec
TE                300.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        400.1824713 MHz
NUC1                 1H
P1                 8.00 usec
PLW1        12.00000000 W
F2 - Processing parameters
SI                65536
SF          400.1799653 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 209: 1H-NMR (D2O, 400 MHz) of compound MK-42. 





































NAME         jun12krmH6
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140613
Time              13.17
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 2057
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0
























































NAME         dez19krmH1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20141219
Time               8.54
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                  144
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8699561 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 211: 1H-NMR (D2O, 500 MHz) of compound MK-40. 





































NAME         dez19krmH1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20141219
Time               8.33
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                  512
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.2 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6924110 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0












































NAME      jul02MK-45-H1
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140702
Time              10.56
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1290.2
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299678 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 213: 1H-NMR (D2O, 250 MHz) of compound MK-45. 




































NAME         jul03kmrH6
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20140703
Time              22.18
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                297.9 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0



































NAME      mai29MK-38-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.42
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1625.5
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299686 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 215: 1H-NMR (D2O, 250 MHz) of compound MK-38. 



















NAME         mai30krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              10.43
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0
























































NAME      mai29MK-25-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.35
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299685 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 217: 1H-NMR (D2O, 250 MHz) of compound MK-25. 
















































NAME         mai30krmC3
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              16.31
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 3072
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0






























































NAME      mai29MK-26-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.38
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1290.2
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299685 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 219: 1H-NMR (D2O, 250 MHz) of compound MK-26. 










































NAME         mai30krmC4
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              17.11
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 2048
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.3 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0






























































NAME      mai29MK-21-1H
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140529
Time              10.23
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT             D2O
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG               1149.4
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1299658 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0




Spectra 221: 1H-NMR (D2O, 250 MHz) of compound MK-21. 




































NAME         mai30krmC8
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140530
Time              14.46
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT             D2O
NS                 1024
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.2 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0



























































NAME     jan12_KA-0(1)H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              19.10
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                  362
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0






Spectra 223: 1H-NMR (CDCl3, 250 MHz) of compound KA-0. 














































NAME     jan14_KA-0(1)C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time              11.05
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT           CDCl3
NS                  131
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                 1024
DW               33.200 usec
DE                 6.00 usec
TE                298.3 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952295 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0



























































































NAME     jan12_KA-2(1)H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              18.53
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                456.1
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 225: 1H-NMR (CDCl3, 250 MHz) of compound KA-2. 






























































































NAME     jan14_KA-2(1)C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time               9.53
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT           CDCl3
NS                  511
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                812.7
DW               33.200 usec
DE                 6.00 usec
TE                298.4 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952263 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0





















NAME     jan14_KA-2(1)F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time               9.50
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT           CDCl3
NS                   17
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG                645.1
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 227: 19F-NMR (CDCl3, 235 MHz) of compound KA-2. 





































































































NAME       jul31KA-1-H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140731
Time               9.59
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                 1024
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300000 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0
















































































8 Current Data Parameters
NAME         ago08krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20140808
Time              17.42
INSTRUM           spect
PROBHD   5 mm PABBI 1H/
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                20480
DS                    4
SWH           24038.461 Hz
FIDRES         0.733596 Hz
AQ            0.6815744 sec
RG                  114
DW               20.800 usec
DE                 6.50 usec
TE                300.3 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        100.6354031 MHz
NUC1                13C
P1                14.10 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        400.1816007 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             90.00 usec
PLW2        10.00000000 W
PLW12        0.10000000 W
PLW13        0.08100000 W
F2 - Processing parameters
SI                65536
SF          100.6253410 MHz
WDW                  EM
SSB      0
LB                 2.00 Hz
GB       0







Spectra 229: 13C-NMR (CDCl3, 100 MHz) of compound KA-1. 









NAME      jan13_KA-1F19
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150113
Time              14.03
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG        zgfhigqn
TD               131072
SOLVENT           CDCl3
NS                   21
DS                    0
SWH           70422.539 Hz
FIDRES         0.537281 Hz
AQ            0.9306112 sec
RG               2580.3
DW                7.100 usec
DE                 6.00 usec
TE                298.2 K
D1          10.00000000 sec
d11          0.03000000 sec
d12          0.00002000 sec
TD0                   1
SFO1        235.3220464 MHz
NUC1                19F
P1                12.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
F2 - Processing parameters
SI                65536
SF          235.3573500 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0














































































































NAME        dez15KA-8H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20141215
Time              11.15
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                912.3
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300053 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 231: 1H-NMR (CDCl3, 250 MHz) of compound KA-8. 


























































NAME         dez23krmC1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20141223
Time              10.22
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                  512
DS                    0
SWH           32894.738 Hz
FIDRES         1.003868 Hz
AQ            0.4980736 sec
RG                 2050
DW               15.200 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7062372 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6923895 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0










































































NAME      jan12_KA-12H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              19.14
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                912.3
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300054 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 233: 1H-NMR (CDCl3, 250 MHz) of compound KA-12. 



















































NAME     jan14_KA-12C13
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time              10.39
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT           CDCl3
NS                  723
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                912.3
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952258 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0











































































































NAME         dez19krmH2
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20141219
Time               9.01
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    2
SWH           10000.000 Hz
FIDRES         0.305176 Hz
AQ            1.6384000 sec
RG                 80.6
DW               50.000 usec
DE                 6.50 usec
TE                298.1 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        499.8730869 MHz
NUC1                 1H
P1                11.75 usec
PLW1        25.00000000 W
F2 - Processing parameters
SI                65536
SF          499.8700268 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 235: 1H-NMR (CDCl3, 500 MHz) of compound KA-5. 





























































7 Current Data Parameters
NAME         dez19krmH2
EXPNO                 2
PROCNO                1
F2 - Acquisition Parameters
Date_          20141219
Time               9.47
INSTRUM           spect
PROBHD   5 mm PABBO BB/
PULPROG          zgpg30
TD                32768
SOLVENT           CDCl3
NS                 1024
DS                    4
SWH           29761.904 Hz
FIDRES         0.908261 Hz
AQ            0.5505024 sec
RG                 2050
DW               16.800 usec
DE                 6.50 usec
TE                298.1 K
D1           2.00000000 sec
D11          0.03000000 sec
TD0                   1
======== CHANNEL f1 ========
SFO1        125.7049801 MHz
NUC1                13C
P1                10.00 usec
PLW1        91.00000000 W
======== CHANNEL f2 ========
SFO2        499.8719995 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2             80.00 usec
PLW2        26.85300064 W
PLW12        0.57928002 W
PLW13        0.37074000 W
F2 - Processing parameters
SI                32768
SF          125.6923930 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0















































NAME     jan12_KA-12 or 9 or 5H1
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150112
Time              19.25
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG            zg30
TD                32768
SOLVENT           CDCl3
NS                   16
DS                    0
SWH            5175.983 Hz
FIDRES         0.157958 Hz
AQ            3.1653888 sec
RG                812.7
DW               96.600 usec
DE                 6.00 usec
TE                298.2 K
D1           1.00000000 sec
TD0                   1
======== CHANNEL f1 ========
NUC1                 1H
P1                13.25 usec
PL1               -6.00 dB
SFO1        250.1317509 MHz
F2 - Processing parameters
SI                32768
SF          250.1300054 MHz
WDW                  EM
SSB      0
LB                 0.30 Hz
GB       0







Spectra 237: 1H-NMR (CDCl3, 250 MHz) of compound KA-7. 



















































NAME     jan14_KA-12ou9ou5C31
EXPNO                 1
PROCNO                1
F2 - Acquisition Parameters
Date_          20150114
Time              15.02
INSTRUM           spect
PROBHD   5 mm QNP 1H/13
PULPROG          zgpg30
TD                16384
SOLVENT           CDCl3
NS                  549
DS                    0
SWH           15060.241 Hz
FIDRES         0.919204 Hz
AQ            0.5439488 sec
RG                724.1
DW               33.200 usec
DE                 6.00 usec
TE                298.2 K
D1           2.00000000 sec
d11          0.03000000 sec
DELTA        1.89999998 sec
TD0                   1
SFO1         62.9015280 MHz
NUC1                13C
P1                10.00 usec
PLW1        -1.00000000 W
SFO2        250.1310005 MHz
NUC2                 1H
CPDPRG[2        waltz16
PCPD2            100.00 usec
PLW2        -1.00000000 W
PLW12       -1.00000000 W
PLW13       -1.00000000 W
F2 - Processing parameters
SI                32768
SF           62.8952255 MHz
WDW                  EM
SSB      0
LB                 1.00 Hz
GB       0













Appendix III – Structures of synthesised compounds used in biological assays 







Appendix III (continuition) – Structures of synthesised compounds used in biological 








Appendix III (continuition) – Structures of synthesised compounds used in biological 























Appendix IV – Residual activity (%) of the compounds assayed against PTP1B and 
LMW-PTP are shown in below table. 
 
Residual activity (%) 
Compound PTP1B LMW-PTP 
DMSO & H2O control 
(without inhibitor) 
100 ± 2.72 100 ± 2.85 
MKR-24a 42.95 ± 1.88 87.81 ± 10.01 
MKR-28a 35.71 ± 7.57 62.54 ± 9.88 
MKR-25a 111.16 ± 9.13 75.82 ± 1.65 
MKR-17a 1.13 ± 0.13 10.74 ± 0.77 
MKR-18a 1.48 ± 0.56 30.17 ± 6.38 
MKR-9a 0.66 ± 0.31 30.91 ± 1.32 
MKR-10a 9.82 ± 1.71 36.87 ± 0.58 
MKR-23a 4.96 ± 0.32 35.49 ± 4.17 
MKR-7a -0.58 ± 0.30 31.64 ± 2.29 
MKR-8a 19.34 ± 1.37 29.01 ± 1.25 
MKR-26a -0.12 ± 0.50 77.13 ± 2.47 
MKR-5a 15.31 ± 1.56 31.83 ± 2.70 
MKR-40a 1.40 ± 0.25 11.64 ± 0.68 
MKR-12a 43.36 ± 2.90 70.61 ± 0.52 
MKR-13a 26.64 ± 1.46 20.87 ± 3.22 
MKR-11a 91.61 ± 6.64 97.79 ± 7.45 
MKR-31a 32.75 ± 1.49 44.75 ± 3.74 
MKR-51a 28.44 ± 2.25 37.37 ± 4.02 
MKR-55a 27.46 ± 4.32 92.23 ± 8.90 
MKR-52a 25.04 ± 3.75 54.08 ± 1.11 
MKR-19a 92.07 ± 1.49 44.12 ± 1.13 
MKR-33a 83.72 ± 2.65 Precipitated 
MKR-54a 35.99 ± 2.60 87.11 ± 2.36 
MKR-42a 17.16 ± 0.87 11.41 ± 0.59 
MKR-38a 18.53 ± 1.70 34.67 ± 1.75 
MKR-50a 17.44 ± 4.44 23.54 ± 0.90 
MKR-41a 16.56 ± 0.70 22.18 ± 1.23 
MKR-44a 14.73 ± 0.41 26.05 ± 1.24 
MKR-27a 31.92 ± 9.44 85.20 ± 3.02 
MKR-37a -0.11 ± 0.20 1.21 ± 0.14 
MKR-36a 0.89 ± 0.14 3.30 ± 2.29 
MKR-20a 2.01 ± 0.20 42.44 ± 1.20 
MK-11a 22.25 ± 2.44 97.13 ± 1.58 
MK-11b 21.38 ± 2.09 97.07 ± 1.42 
MK-11 10.72 ± 0.63 60.61 ± 1.66 
MK-29 0.92 ± 0.07 69.15 ± 2.91 
MK-30 26.45 ± 8.10 83.63 ± 3.13 
MK-7a 2.78 ± 0.36 70.23 ± 2.31 
MK-31 47.44 ± 8.13 89.15 ± 3.06 





MK-47 19.05 ± 0.63 103.76 ± 1.84 
MK-2 16.04 ± 1.05 58.54 ± 3.0 
MK-9a 34.25 ± 1.36 53.88 ± 1.40 
MK-48 17.52 ± 2.31 0.03 ± 0.04 
MK-49 21.74 ± 2.15 2.64 ± 0.51 
MK-35 -0.16 ± 0.30 1.04 ± 0.14 
MK-6 1.61 ± 0.25 5.91 ± 0.46 
MK-13 22.45 ± 2.83 84.59 ± 0.59 
MK-15 20.46 ± 0.48 13.68 ± 2.11 
MK-27 2.58 ± 0.42 72.92 ± 2.72 
MK-28 35.13 ± 1.31 87.70 ± 3.09 
MK-12 15.37 ± 2.43 65.14 ± 1.0 
MK-24a 64.57 ± 5.29 63.22 ± 4.28 
MK-24b 60.77 ± 10.11 83.90 ± 4.16 
MK-24 66.51 ± 2.65 68.02 ± 3.56 
MK-32 31.40 ± 6.54 92.69 ± 2.97 
MK-33 69.88 ± 6.02 81.55 ± 5.82 
MK-8 11.81 ± 2.43 81.01 ± 2.85 
MK-34 65.05 ± 10.40 120.02 ± 1.51 
MK-3 18.73 ± 2.67 30.68 ± 8.83 
MK-4 58.77 ± 4.04 101.16 ± 0.49 
MK-10 1.92 ± 0.79 18.22 ± 2.45 
MK-46a 22.38 ± 2.23 Precipitated 
MK-46 20.10 ± 2.01 85.11 ± 1.37 
MK-36 29.44 ± 1.16 97.33 ± 5.36 
MK-37 0.52 ± 0.49 68.20 ± 2.61 
MK-5 -0.47 ± 1.09 -1.66 ± 0.50 
MK-42 81.93 ± 1.90 79.18 ± 3.89 
MK-40 13.61 ± 1.92 4.84 ± 4.20 
MK-45 6.0 ± 1.39 58.45 ± 1.95 
MK-38 1.11 ± 0.29 26.11 ± 1.04 
MK-25 -2.31 ± 0.46 -3.17 ± 1.30 
MK-26 -2.67 ± 0.28 10.48 ± 2.32 
MK-21 3.07 ± 0.57 37.76 ± 6.03 
KSR-6aa 18.19 ± 0.54 92.60 ± 7.07 
KSR-6ab -0.68 ± 0.32 47.61 ± 4.08 
KSR-6a 34.55 ± 1.30 118.26 ± 2.83 
KSR-6 13.08 ± 2.38 Precipitated 
KM-1 12.45 ± 0.35 93.71 ± 1.44 
KSR-6e -0.75 ± 0.30 40.11 ± 0.97 
KSR-6f 22.58 ± 4.37 45.59 ± 1.08 
KSR-6d -0.58 ± 0.39 65.35 ± 5.39 
KSR-6c 13.0 ± 1.88 89.63 ± 3.35 
KSR-6b 4.37 ± 0.39 55.17 ± 1.99 
KSR-6g 0.52 ± 0.65 68.08 ± 5.20 
KSR-6h 0.25 ± 0.24 5.87 ± 1.05 
KSR-6i 0.59 ± 0.51 13.97 ± 2.85 





KM-2 18.46 1.42 114.81 ± 0.85 
KM-15 15.76 ± 0.84 108.62 ± 4.79 
KM-7 13.82 ± 1.40 226.53 ± 11.10 
KM-5 19.68 ± 1.0 89.73 ± 0.85 
KM-11 21.47 ± 2.37 102.22 ± 3.74 
KM-13 31.03 ± 11.43 94.82 ± 6.55 
KM-4 30.97 ± 2.63 106.74 ± 5.32 
KM-14 16.91 ± 5.13 76.06 ± 4.13 
KM-8 26.98 ± 5.28 98.54 ± 7.01 
KM-9 16.44 ± 1.36 97.60 ± 2.30 
KM-10 26.95 ± 1.72 111.72 ± 8.44 
KM-18 25.59 ± 2.04 64.56 ± 2.26 
KM-19 18.47 ± 1.15 30.61 ± 4.29 
KM-21 15.70 ± 2.09 96.50 ± 2.83 
KM-23 24.61 ± 1.15 92.06 ± 2.42 
KM-25 38.26 ± 5.21 128.07 ± 2.48 
KM-27 17.57 ± 1.43 102.34 ± 4.47 
KM-29 33.92 ± 2.09 96.51 ± 0.37 
KS-0 19.62 ± 0.82 90.73 ± 1.31 
KSR-0 13.98 ± 1.39 53.84 ± 1.98 
KSR-0a 13.09 ± 0.63 82.94 ± 11.29 
KSR-0b 26.07 ± 3.88 84.16 ± 6.44 
KSR-0c 35.99 ± 4.98 96.16 ± 7.04 
KSR-0d 13.35 ± 1.05 98.55 ± 2.59 
KSR-0e 32.11 ± 3.75 118.64 ± 5.13 
KSR-0f 13.10 ± 5.11 7.07 ± 0.67 
KSR-3 15.01 ± 5.67 4.39 ± 3.80 
KSR-1 14.77 ± 6.40 100.23 ± 5.73 
KAM 75.26 ± 1.91 96.98 ± 2.46 
KAM-12 0.69 ± 0.78 0.27 ± 0.61 
KAM-1 91.43 ± 3.41 112.55 ± 3.94 
KAM-11 52.66 ± 2.67 101.46 ± 1.20 
KAM-8 2.58 ± 0.17 15.37 ± 2.13 
KAM-9 76.76 ± 0.79 110.19 ± 4.62 
KAM-10 34.19 ± 2.61 85.87 ± 4.63 
KAM-6 51.94 ± 2.33 85.10 ± 3.92 
KAM-2 31.75 ± 4.64 98.64 ± 5.63 
KAM-3 1.11 ± 0.23 2.93 ± 0.29 
KAM-4 32.41 ± 9.32 4.66 ± 0.42 
KAM-5 41.03 ± 12.0 71.17 ± 4.43 












Appendix V – Residual activity (%) of the compounds assayed against CDC25B are 
shown in below. 
 
CDC25B residual activity (%) 
Compound Activity  Compound Activity 
DMSO & H2O 
(Control) 
100%  
DMSO & H2O 
(Control) 
100% 
MKR-24a 113%  KM-3 94% 
MKR-28a 92%  KM-2 90% 
MKR-25a 100%  KM-15 96% 
MKR-17a 95%  KM-7 99% 
MKR-18a 91%  KM-5 75% 
MKR-9a 94%  KM-11 88% 
MKR-10a 99%  KM-13 93% 
MKR-23a 95%  KM-4 101% 
MKR-7a 94%  KM-14 92% 
MKR-8a 89%  KM-8 86% 
MKR-26a 106%  KM-9 94% 
MKR-5a 109%  KM-10 89% 
MKR-40a 104%  KM-6 78% 
MKR-12a 105%  KM-18 83% 
MKR-13a 105%  KM-19 61% 
MKR-11a 101%  KM-21 100% 
MKR-31a 98%  KM-22 110% 
MKR-51a 105%  KM-24 115% 
MKR-55a 105%  KM-23 96% 
MKR-52a 97%  KM-25 93% 
MKR-19a 95%  KM-26 94% 
MKR-33a 104%  KM-28 113% 
MKR-54a 111%  KM-27 79% 
MKR-42a 105%  KM-29 96% 
MKR-38a 112%  KM-30 103% 
MKR-50a 103%  KM-31 118% 
MKR-41a 101%  KM-32 110% 
MKR-44a 102%  KSR-0 92% 
MKR-27a 104%  KSR-0a 93% 
MKR-37a 79%  KSR-0b 72% 
MKR-36a 100%  KSR-0c 104% 
MKR-20a 94%  KSR-0d 71% 
MK-43 106%  KSR-0e 121% 
MK-0 111%  KSR-0f 66% 
MK-0a 95%  KSR-3 92% 
MK-11a 110%  KSR-1 112% 
MK-11b 89%  KS-0 87% 
MK-11 98%  KS-0b 90% 
MK-29 98%  KS-0c 81% 





MK-7a 98%  KS-2 101% 
MK-31 93%  KS-4 56% 
MK-1 105%  KS-5 83% 
MK-47 77%  KS-5 84% 
MK-2 112%  KAM 119% 
MK-48 97%  KAM-12 78% 
MK-49 106%  KAM-18 85% 
MK-35 89%  KAM-1 100% 
MK-6 102%  KAM-11 95% 
MK-41 104%  KAM-16 107% 
MK-13 104%  KAM-15 115% 
MK-15 106%  KAM-8 112% 
MK-9 a 110%  KAM-19 111% 
MK-27 88%  KAM-9 139% 
MK-28 105%  KAM-10 98% 
MK-12 111%  KAM-2 92% 
MK-16 92%  KAM-17 77% 
MK-24a 113%  KAM-21 96% 
MK-24b 105%  KAM-22 101% 
MK-24 119%  KAM-3 97% 
MK-32 113%  KAM-4 139% 
MK-33 102%  KAM-5 89% 
MK-8 83%  KAM-6 68% 
MK-34 92%  KAM-13 86% 
MK-3 92%  KAM-14 83% 
MK-4 120%  KAM-7 71% 
MK-10 116%  KA-0 88% 
MK-46a 88%  KA-2 93% 
MK-46 119%  KA-1 92% 
MK-36 71%  KA-8 90% 
MK-37 73%  KA-12 59% 
MK-5 91%  KA-5 96% 
MK-42 121%  KA-7 99% 
MK-40 111%  KM-1 81% 
MK-45 103%  KSR-6e 90% 
MK-38 86%  KSR-6f 101% 
MK-25 118%  KSR-6d 102% 
MK-26 102%  KSR-6c 95% 
MK-21 41%  KSR-6b 95% 
KSR-6aa 76%  KSR-6g 122% 
KSR-6ab 101%  KSR-6h 85% 












Appendix VI – IC50 curves of the selected inhibitors for PTP1B. 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix VII – IC50 curves of the selected inhibitors for LMW-PTP. 
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